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1. Introduction 
1.1 The origins of gliomas 
Gliomas are primary tumors of the central nervous system (CNS), which are derived from 
neural stem cells and/or more differentiated glial progenitor cells (see Fig. 1). 
Different glioma entities are recognized in the CNS, according to their histological and 
biochemical similarity to the different possible cell types of origin. Gliomas are therefore 
subdivided in oligodendrogliomas, astrocytomas and ependymomas [2,3]. The most 
common form, the glioblastoma multiforme (GBM), belongs to the astrocytic tumors. 
Studies examining genetic mouse models of gliomas in p53 and NF1 deficient mice have 
collected evidence that gliomas arise from stem cells in the subventricular zone [4]. 
However, it has been shown recently that virally mediated tumor suppressor knockdown is 
able to induce gliomas from differentiated neuronal and glial cells [5].  
Gliomas are classified into four different grades, according to the World Health Organization 
(WHO). Grade I comprises the most benign tumors, and grade IV the most malignant 
entities. The most common type of gliomas, the glioblastoma multiforme (GBM), belongs to 
the grade IV tumors and comprises more than 50 % of the gliomas in adulthood [6].  
Due to the diffuse infiltration of the healthy brain parenchyma by the tumor cells and the 
tendency of the low grade lesions to progress to more malignant entities, already grade II 
tumors have a dismal prognosis [7]. The GBM is subdivided into primary and secondary 
GBMs. Secondary GBMs arise from lower grade gliomas, whereas primary GBMs arise de 
novo. These tumor types, although not distinguishable by histology, are characterized by 
different alterations on the molecular level, e.g. mutations of the isocitrate dehydrogenase 
genes, IDH1 and 2, which are nearly exclusively found in secondary GBMs. Except for ionizing 
radiation, no environmental risk factors for glioma development are known [8].  
A genetic predisposition for glioma is present in individuals affected by the Li-Fraumeni 
syndrome, where the tumor suppressor protein p53 is frequently mutated, in patients 
suffering from neurofibromatosis, where NF1 or 2 are affected, and other rare genetic 
syndromes [8]. Besides these severe genetic syndromes, single nucleotide polymorphisms 
(SNPs) in the cyclin-dependent kinase inhibitor 2B  (CDKN2B) and regulator of telomere 
elongation helicase 1 (RTEL1) genes have been linked to glioma susceptibility [9], as well as 
different SNPs in DNA repair genes [10]. 
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1.2 Diagnosis and therapeutic options 
Most patients suffering from gliomas present themselves in the clinic with symptoms caused 
by elevated intracranial pressure. The pressure is increased by the tumor mass and by the 
edema accompanying it. Symptoms include seizures, headache and psychopathological 
symptoms [11]. Diagnosis of the tumor itself is performed with magnetic resonance 
tomography (MRT). The grading of the lesion is based on histological analysis. GBMs are 
characterized by a striking heterogeneity of the tissue. Necrotic areas, proliferating 
endothelial cells and pseudopalisading cells are typical features of a GBM (see Fig. 2) [6]. 
Other grading criteria include nuclear pleomorphisms, enhanced cellularity and mitotic 
activity [2]. Depending on the tumor localization, therapy includes, if possible, surgical 
Figure 1: Cells of origin of different subtypes of gliomas. 
Glial progenitors, astrocyte progenitors and differentiated glial cells can serve as cells of origin in the 
development of glioblastomas.  Astrocytomas are thought to be derived from glial progenitors, astrocyte 
progenitors and/or mature astrocytes, modified after [4]. 
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resection, chemotherapy with temozolomide and radiotherapy. If resection is impossible, 
the tissue is at least biopsied, to enable a grading of the tumor. Due to the massive 
infiltration of healthy brain parenchyma complete resection is impossible [12]. 
Unfortunately, gliomas are quite resistant to radiotherapy and treatment with the alkylating 
agent temozolomide. Resistance against temozolomide is conferred by the O-6-
methylguanine-DNA methyltransferase (MGMT) that repairs O6-methylguanine DNA-
adducts. 
Therefore, the methylation status of the MGMT promoter is nowadays analyzed very often, 
as methylation of the promoter is a prognostic factor as well as predictive for a patient’s 
benefit from chemotherapy. However, other events, such as defects in DNA mismatch 
repair, contribute to temozolomide resistance, too [13]. 
Finally, increased intracranial pressure and invasion of vital brain regions lead to death. 
Besides temozolomide, many other drugs are currently under investigation in clinical trials. 
In addition, approaches consisting of immunotherapy and viral therapy are in development 
[14,15]. Identified tumor drivers, like the receptor tyrosine kinase (RTK) epidermal growth 
factor receptor (EGFR), are used for targeted therapies, e.g. the EGFR inhibitor Erlotinib. 
GBMs acquire resistance towards Erlotinib fast, the reason being among others parallel 
activation of different RTKs [16]. Anti-angiogenic therapy with bevacizumab, a monoclonal 
antibody targeting VEGF, has a significant impact on progression free survival [17]. However,  
there is evidence for increased invasion of glioma cells into the brain parenchyma after 
inhibition of the VEGF pathway [18]. Therefore, anti-angiogenic therapy combined with anti-
invasive therapy would be a promising therapeutical approach, as it has been shown that 
inhibition of SRC family kinases with dasatinib blocks the increased invasion after 
bevacizumab application in an orthotopic xenograft mouse model [19].  
 
Figure 2: Hematoxylin and eosin staining of glioma sections.  
Different grades of tumor lesions including a low grade astrocytoma, an anaplastic astrocytoma 
and a glioblastoma. The glioblastoma shows typical pseudopalisading cells (arrows) [7]. 
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Moreover, anti-invasive therapy with imaprimine blue combined with doxorubicin 
chemotherapy has shown very promising effects on overall survival in a mouse model of 
glioma [20]. 
However, despite of aggressive therapy, GBMs have a dismal prognosis and a median 
survival time of about one year after diagnosis [8].  
 
1.3 Molecular alterations in GBM 
In the last decades, numerous expression and sequencing studies were performed, to 
establish a genome wide overview of aberrant expression patterns, mutations and gene 
copy number alterations in gliomas. The Cancer Genome Project (TCGA) has analyzed copy 
number alterations and mRNA expression patterns and in addition sequencing of the protein 
encoding genes of 22 GBM genomes was performed [21,22]. These studies have contributed 
significantly to our understanding of glioma initiation, progression and classification [23].  
Frequently altered pathways include the p53, retinoblastoma and the RTK/Ras/PI3K signaling 
pathways [21]. GBMs can be classified into different, molecularly distinct, categories that are 
defined by the underlying genetic lesions. Classical categorization only distinguished primary 
and secondary GBMs, which cannot be separated based on histology. However, p53 
mutations occur more frequently, and IDH mutations nearly exclusively, in secondary GBMs. 
Secondary GBMs are much less frequent than primary GBMs, and affect mostly younger 
patients. 
Molecular analysis of primary and secondary GBMs revealed that there are three to four 
main categories of GBMs, the proneural, classical, mesenchymal and neural subtype [24]. As 
the neural subtype is less well defined than the other subtypes, it is not further discussed 
here. The classical subtype is characterized by epidermal growth factor receptor (EGFR) 
amplification, EGFR mutation or expression of a tumor specific EGFR variant, the EGFRvIII.  
EGFRvIII contains an in-frame deletion that comprises the ligand binding domain. The 
EGFRvIII is a constitutively active receptor variant [25], and EGFR and EGFRvIII cooperate to 
drive cell transformation and tumor progression [26]. This subtype normally does not 
contain p53 mutations. The retinoblastoma pathway is nearly exclusively disrupted by cyclin-
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dependent kinase inhibitor 2A (CDKN2A) deletion in this subtype, and astrocytic markers are 
expressed [27]. 
 
The proneural subtype, which comprises most secondary GBMs, is characterized by p53 and 
IDH mutations, and tumors of this subtype frequently contain PDGFRA amplifications. 
Oligodendrocyte markers such as platelet-derived growth factor receptor, alpha polypeptide 
(PDGFRA), NK2 homeobox (NKX-2) and oligodendrocyte lineage transcription factor 2 (OLIG-
2) are strongly expressed in this subtype [27]. In addition, further subtypes in the proneural 
subgroup have been identified that are characterized by H3F3A mutations, which are 
restricted to younger patients [28]. Moreover, a subgroup exists that shows global 
hypermethylation [29]. A trend towards overall prolonged survival is present in the 
proneural subtype, however, the more favourable prognosis in restricted to the tumors 
showing global hypermethylation [30].  
 
Furthermore, the mesenchymal subtype, which contains NF1 deletions and mutations, and 
that shows expression of mesenchymal markers Met and CHI3L1, exists [27]. It has been 
shown that CEBPß and STAT3 activity are crucial for the establishment of the mesenchymal 
subtype [31].  
 
The three mentioned subtypes, classical, proneural and mesenchymal have been identified 
(albeit named differently) by several groups and different approaches, including proteomic 
and mRNA expression analysis [24,27,32,33]. 
 
RTKs, like epidermal growth factor receptor (EGFR) and platelet-derived growth factor 
receptor A (PDGFRA), which are frequently overexpressed or mutated in GBMs, are not only 
drivers for glioma initiation, but also important signaling inputs for migration and invasion 
[34]. Stimulation of RTKs leads to signaling events that finally converge on reorganization of 
the tubulin and actin cytoskeleton. 
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1.4 The actin cytoskeleton in cell migration and invasion 
The eukaryotic cytoskeleton consists of tubulin, actin and intermediary filaments. 
These different structural components of the cell provide mechanical stability and enable 
cell locomotion [35]. Actin as well as tubulin are important for cell migration and are 
regulated in a coordinated fashion. Since this work focuses on the process of actin 
reorganization, only the actin cytoskeleton and the proteins involved in its reorganization 
are discussed in the following section. Actin is present in the cell in an equilibrium between 
G- and F-actin, and actin filaments can nucleate spontaneously, provided the G-actin 
concentration is sufficiently high. F-actin is a double helical, intrinsically polar filament. The 
more dynamic filament end, where actin subunits are rapidly added or removed, depending 
on the concentration of G-actin available for polymerization, is called barbed end. The less 
dynamic end of the actin filament is referred to as the pointed end. At the barbed end, actin 
is normally present in the ATP-bound state, whereas it is ADP-bound at the pointed end. 
Inside cells, actin is bound by variety of actin binding proteins [35]. 
The isolated proteins that are necessary for assembly of actin filaments and for the 
propulsion of beads in an in vitro motility assay are called minimal reconstituted motility 
machinery. It consists of actin, cofilin, capping protein, Wiskott-Aldrich syndrome-like  
(N-WASP), the Arp 2/3 complex and profilin [35]. N-WASP is an Arp 2/3 activator, whereas 
Arp 2/3 itself initiates branching from already existing filaments. 
Cofilin´s most important cell biological functions are actin filament severing and 
enhancement of depolymerization at the pointed end [35,36]. 
The family of mammalian cofilin proteins consists of actin depolymerizing factor/ destrin 
(ADF), cofilin-2 (CFL2) and cofilin-1 (CFL1). These genes differ in tissue expression and 
function. CFL1 is ubiquitously expressed, whereas CFL2 is primarily found in muscle and ADF 
in epithelia [37]. The CFL1 gene is referred to as cofilin in the following sections. 
Actin is part of a number of diverse cellular structures, and in cells at least 15 actin based 
structures are recognized [38]. 
Especially important for migration and invasion are lamellipodia, the lamellum, invadopodia, 
blebs and the different forms of stress fibers that are involved in the formation of these 
structures [1,39]. Stress fibers are subdivided into distinct entities, depending on type and 
localization (see Fig. 3). There are ventral stress fibers, dorsal stress fibers and transverse 
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arcs. Stress fibers are induced e.g. after RhoA stimulation, and exist in vivo in highly motile 
cells like myofibroblasts, or where cells are exposed to mechanical stress [1]. 
The lamellipodium is located at the leading edge, where a meshwork of growing actin 
filaments pushes the membrane forward [40].  
 
 
 
1.5 Signaling towards cofilin 
The signaling towards cofilin is initiated at the plasma membrane by RTKs, G-protein coupled 
receptors or integrins. 
Via PI3-Kinase and small GTPases of the Rho-family the signal is propagated, and finally 
cofilin phosphorylation is performed by LIMKs or TESKs. The F-actin binding of cofilin is 
regulated by phosphorylation of a single serine residue, serine 3 [41]. The phosphorylation 
on serine 3 abrogates the binding of cofilin to F-actin. Due to their sequence similarity and 
Figure 3: Stress fiber structures in eukaryotic cells. 
Shown are dorsal and ventral stress fibers that are connected to the extracellular matrix via focal 
adhesions and integrins. Also shown is a transverse arc, modified after [1]. 
8 
 
conservation of the serine residue, it is at least possible that LIMKs, TESKs and the cofilin 
phosphatases regulate the phosphorylation of all three cofilin proteins. Phosphoregulation 
of cofilin-1 plays an important role in a variety of physiological and pathological situations 
[41], but also for the other two family members phosphorylation is an important regulatory 
mechanism. A critical role for phosphoregulation of cofilin-2 has been shown in the 
differentiation of smooth muscle cells [42] and ROCK dependent phosphoregulation of ADF 
has been shown to be implicated in the amoeboid type of migration of cancer cells [43].  
LIMK1 and LIMK2 themselves are activated by kinases of the PAK or ROCK-family by 
phosphorylation on threonine residues 508 or 505, respectively (see Fig. 4) [44,45]. In 
contrast to the alterations and role of RTKs and PI3K in cell migration and invasion, which are 
well characterized, much less is known about their effector proteins Rho/ROCK and Rac/PAK 
in glioma. However, these are crucial for signal transmission and reorganization of the actin 
cytoskeleton [46].  
The cellular role of the LIMK mediated phosphorylation of cofilin is explained by the Local 
Excitation Global Inhibition (LEGI) model. This model postulates that cofilin is only activated 
focally where actin remodeling is taking place, and inhibited by phosphorylation on serine 3 
in the rest of the cell [47]. LIMK mediated cofilin phosphorylation abolishes its severing 
activity. On the other hand, phosphorylation of cofilin also leads to cofilin recycling, and 
might play an important role in maintaining a very high local concentration of active cofilin in 
structures important for invasion, e.g. invadopodia [41]. In the process of cofilin recycling 
phosphorylation of actin bound cofilin leads to the dissociation of actin and cofilin. The 
phosphoralyted cofilin can then be reactivated by dephosphorylation by cofilin 
phosphatases, e.g. SSHs and CIN.  
Previous work in our laboratory has revealed that LIMKs are highly upregulated in astrocytic 
tumors on protein level, whereas the cofilin phosphatase CIN is downregulated on protein 
level [48]. Importantly, ROCK has already been shown to contribute to tumor formation in 
the skin [49] and the importance of LIMKs for cancer cell invasion has been shown in a 
variety of experimental model systems [50-52]. 
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Figure 4: The regulatory pathway of cofilin phosphorylation.  
Actin turnover is initiated by receptor tyrosine kinase signaling. Subsequently, PI3K and the small 
GTPases Rho/Rac are activated. These in turn activate ROCK and Pak proteins, respectively, which 
in turn phosphorylate the LIMKs. The LIMKs phosphorylate cofilin on serine 3, and abolish its actin 
binding. CIN, SSH1-3 and other phosphatases can dephosphorylate cofilin, modified after [41,53]. 
 
 
 
The role of CIN and LIMKs has until now not been examined in glioma. This is however 
important, due to the fact that ROCK proteins have a variety of substrates besides LIMKs 
[54], and the ROCK inhibitor induced phenotypes do not need to be necessarily induced by a 
change in cofilin phosphorylation. In this study, cell migration and invasion are examined 
after deregulation of CIN. CIN, a cofilin phosphatase, is strongly downregulated in glioma 
specimens. Therefore, the pathophysiological changes in the phosphoregulation of cofilin 
are mimicked more closely here than by overexpression of a constitutively active mutant of 
cofilin, which has been performed by others. 
Besides phosphorylation, cellular cofilin activity is furthermore controlled by PIP2-binding 
and intracellular pH [55]. In metastatic breast cancer cells, PIP2 hydrolysis is especially 
important for the initial cofilin activation during chemotaxis at the leading edge [56]. PH 
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dependent cofilin regulation has been shown to influence invadopodium turnover [57]. 
Invadopodia are invasive, matrix resolving, F-actin rich structures specifically induced by 
cancer cells [58]. 
 
1.6 Cofilin in cell migration and invasion 
Cofilin activity is needed for invasion and metastasis, which was shown in a study on 
metastatic mammary carcinoma cells [46]. In these cells, cofilin activation is coupled to cell 
polarization and stimulus induced induction of lamellipodia [59]. Mechanistically, cofilin 
creates barbed ends together with the Arp 2/3 complex at the leading edge of these cells, 
driving cell locomotion [47]. However, the significance and importance of barbed end 
initiation by cofilin in cells is discussed controversially [35,60], and there are also studies 
pointing out the importance of cofilin in cellular actin recycling and regulation  of the G-actin 
level [61].  
Cofilin overexpression could be a mechanism that leads to an increase in cofilin activity and 
drives cancer invasion. There are some reports on cofilin protein overexpression in cancer 
[62-64]. However, none of the studies cited above [62-64] has examined the cofilin 
regulatory pathways. It is therefore unclear if cofilin activity is indeed higher in the examined 
cancers and if one of the other above mentioned regulatory mechanisms is deregulated as 
well. Whereas at least some cofilin activity is crucial for invasion in mammary carcinoma 
cells [46], the studies examining LIMKs have found that an increase in cofilin 
phosphorylation, and therefore global inactivation, is accompanied by enhanced invasion 
[52].  
 
There are also conceptual controversies if enhanced or diminished cofilin phosphorylation 
drives invasion. On the one hand, an increase in actin dynamics through an increase in active 
cofilin could speed up actin remodeling, and therefore enhance invasion [46]. On the other 
hand, inactivation of cofilin might lead to an increased build up of cellular force [65]. 
 
In glioma, only few studies have been conducted that address the question if higher or lower 
cofilin activity drives invasion, again yielding controversial results. A recent report links 
ROCK1 expression and activity and glioma invasion [66]. The ROCK-inhibitors fasudil and  
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Y-27632 have been shown to induce apoptosis and to decrease invasiveness of glioma cells 
in vitro, and to enhance survival of mice in a glioma xenograft model in vivo [67]. Others 
have shown that treatment of glioma cells with Y-27632 increases invasion in an in vitro 
transwell setup [68] and that a knockdown of cofilin leads to a reduction of motility in vitro, 
whereas overexpression of a constitutively active cofilin mutant GFP chimera enhances cell 
migration in vitro and invasiveness in vivo [69].  
These differences could be partly explained by the fact that cofilin has a concentration 
dependent influence on cell motility, with highest motility occurring at intermediate 
expression levels [70]. Given that the expression differences measured are well correlated 
with overall cofilin activity in the experimental system used in this study, an intermediate 
level of cofilin activity would be optimal for cell migration. Therefore, activating cofilin in an 
experimental system where cofilin activity is low as well as inactivating cofilin in a system 
where cofilin activity is already high could both lead to an increase in motility. 
There is only one study available on the regulation of the cofilin pathway in gliomas, which 
has reported evidence for an upregulation of cofilin with increasing grade of malignancy 
[69]. 
 
 
1.7 Cellular functions of chronophin (CIN/PDXP) 
Chronophin (CIN/PDXP) belongs to the haloacid dehalogenase superfamily (HAD) of 
phosphatases. The catalytic core consists of a modified Rossmann fold [71], and it contains 
the typical catalytic motif DxDx(V⁄ T), with the catalytic aspartate residue in position 25 in 
the human enzyme. 
It has been identified initially as pyridoxal phosphate phosphatase, as a phosphatase for 
activated vitamin B6 [72,73]. After that, CIN was identified as cofilin specific phosphatase 
[74].  
Moreover, CIN was found in a screen for phosphatases that regulate NCOA3. NCOA3 is an 
important factor for the regulation of the transcriptional response to estrogen in the cell. 
Alterations in estrogen signaling are well known to be involved in breast cancer. CIN 
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knockdown leads to an enhanced transcriptional response after estrogen stimulation, 
including an increase in c-myc expression [75]. 
On the cellular level, CIN depletion in HeLa cells leads to an increase in p-cofilin and an 
increase of F-actin, which is most prominent in mitotic cells [74]. Other studies emphasize 
the importance of CIN at the leading edge, where it is functioning downstream of PAR2 [76] 
and has an influence on the number of cofilin induced barbed ends in neutrophils [60]. 
CIN is highly expressed in the brain on mRNA level as well as on protein level [74]. Here, 
however, expression in nearly all examined regions is very strong [77].  
In rat brains, astrocytes and neurons are positive for CIN, but in human samples the staining 
is predominantly found in astrocytes and microglia [78]. In clinical samples of human glioma 
specimens and normal brain tissue, a staining of astrocytes and neurons could be detected 
with an extensively characterized antibody (Sondergeld, unpublished). As mentioned above, 
there are reports on CIN function in both neuronal cells and astrocytes. CIN has been 
implicated in astroglial apoptosis [79], and acts as an HSP90 interacting ATP sensor in 
neuronal cells [80]. 
Interestingly, CIN maps to a genomic locus that is lost in more than 40 % of primary GBMs, 
on which the affected tumor suppressor is unknown [81]. tween 
 
1.8 C-myc in glioma 
The transcription factor c-myc plays a role in cell proliferation, induction of apoptosis and 
tumorigenesis. Due to the fact that many c-myc target genes are involved in biosynthetic 
processes, an important and cell type independent function of c-myc is biomass 
accumulation [82]. 
On a mechanistic level, c-myc can act as a general transcriptional amplifier of already 
transcriptionally active genes in lymphocytes and embryonic stem cells [83,84]. However, c-
myc mediated gene repression, e.g. for CDKN2B, is also important [85] and studies on c-myc 
promoter binding and transcriptional regulation have found a significant role for c-myc in 
gene repression in cancer cells [86]. The coactivator max is an obligate partner for c-myc, 
with which it forms a heterodimer. This heterodimer can bind canonical E-Boxes, which have 
the consensus-sequence CANNTG [87]. A heterodimer consisting of the constitutively 
expressed proteins max and MNT is thought to establish a basal transcriptional activity at 
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the promoters that are also recognized by the myc/max and MXD/max heterodimers (see 
Fig. 5). The MXD proteins can also form heterodimers with max and can replace c-myc, and 
are therefore considered as negative regulators of myc/max dependent transcription. 
Max and the myc-family members c-myc, N-myc and L-myc are expressed in glioma, and 
expression correlates with malignancy grade [88]. Furthermore, a high percentage of glioma 
overexpresses at least one myc protein [89]. 
C-myc is essential for tumor propagating cell renewal in a genetic mouse glioma model [90], 
and can transform differentiated astrocytes [91]. Especially interesting is that MXI1, a MXD 
family member, has been described as tumor suppressor in glioma cells [92]. The MXI1 gene 
maps to a genomic locus that is lost in ~65 % of GBMs [3]. In addition, there is crosstalk 
between RhoA signaling and myc dependent transcription. Increasing c-myc expression 
reduces the RhoA induced actin structures in NIH3T3 fibroblasts [93]. There is also a link 
between myc expression and LIMK1 activity. On a mechanistic level, increased cofilin 
phosphorylation after LIMK1 overexpression leads to a decrease in STAT3- tyrosine 
phosphorylation and c-myc repression [94].  
 
Figure 5: Transcriptional regulation of c-myc by MXD proteins. 
MXD proteins like MXI1 are thought to be negative regulators of c-myc induced transcription by 
competing with c-myc for the obligate cofactor max, modified after [87]. 
14 
 
2. Aims of the study: 
Cofilin is a crucial regulator of actin cytoskeletal dynamics and upregulation of the kinases 
controlling cofilin phosphorylation has been linked to increased invasiveness in breast and 
prostate cancer. 
Proteins controlling the phosphorylation of cofilin are deregulated in human astrocytic 
tumors. Whereas the LIMK2 that phosphorylates cofilin, is strongly upregulated, the cofilin 
phosphatase chronophin is downregulated.  
In this work, we focused on the consequences of loss of chronophin expression in glioma 
cells, due to the fact that its role for cell migration and glioma progression has not been 
examined so far.  
 
The aim of the study was therefore 
-to characterize the motile behavior of glioma cells after chronophin deregulation in 2D 
migration assays  
-to determine the changes in invasive behavior after chronophin deregulation in transwell 
invasion assays 
-to analyze the effects of manipulating cofilin phosphorylation levels in invasion and 
migration assays with cofilin-phoshorylation mutants and/or ROCK-inhibitors 
-to perform orthotopic implantation experiments to model cell growth and invasion in vivo 
-to analyze the transcriptome of glioma cells after chronophin depletion in high throughput 
transcriptomic assays  
 
Therefore, this study should contribute substantially to the understanding of chronophin´s 
role in glioma pathogenesis and to the understanding of the regulation of cofilin 
phosphorylation in gliomas. Further, the kinases upstream of cofilin might emerge as 
promising therapeutic targets for anti-invasive therapy in gliomas. 
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3. Materials 
3.1 List of manufacturers and distributors 
Number Company
1 5 Prime GmbH, Gaithersburgh, MD, USA
2 Abcam, Cambridge, UK
3 Adolf Kuehne AG, Schindellegi, Switzerland
4 Agilent, Böblingen, Germany
5 Alpha Innotech, Santa Clara, CA, USA
6 American Type Culture Collection ATCC, Manassas, VA, USA
7 Applichem, Darmstadt, Germany
8 B. Braun, Melsungen, Germany
9 Chemicon, Temecula, CA, USA
10 BD Becton Dickinson GmbH, Heidelberg, Germany
11 BDK Luft- und Reinraumtechnik GmbH, Sonnenbühl, Germany
12 Beckman Coulter, Krefeld, Germany
13 Biochrom AG, Berlin, Germany
14 Biometra, Goettingen, Germany
15 Bio-Rad, Munich, Germany
16 Braun, Tuttlingen, Germany
17 Calbiochem, Darmstadt, Germany
18 Cell Signalling Technologies, Danvers, CO, USA
19 Clontech, Palo Alto, CA, USA
20 Cytoskeleton Inc., Denver, CO, USA
21 Dharmacon RNAi Technologies, Schwerte, Germany
22 Eppendorf, Hamburg, Germany
23 Fermenta, St. Leon-Roth, Germany
24 Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany
25 Fujifilm, Tokyo, Japan
26 GE Healthcare, Munich, Germany
27 Greiner bio-one, Frickenhausen, Germany
28 Hartenstein, Würzburg, Germany
29 Heraeus, Hanau, Germany
30 Hettich, Tuttlingen, Germany
31 Ibidi, Martinsried, Germany
32 Idea Scientific, Minneapolis, MN, USA
33 Invitrogen, Karlsruhe, Germany
34 Leibniz institute DSMZ, German Collection of microorganisms and cell cultures
35 Leica microsystems, Wetzlar, Germany
36 Lonza, Cologne, Germany
37 Merck, Darmstadt, Germany
38 Millipore, Billerica, MA, USA
39 MWG Biotech, Ebersberg, Germany
40 Nalgene, Rochester, NY, USA
41 NEB, New England, USA  
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Number Company
42 Nikon, Tokyo, Japan
43 Openbiosystems, Huntsville, AL, USA
44 PAN Biotech GmbH, Aidenbach, Germany
45 peqlab, Erlangen, Germany
46 Perkin Elmer, Waltham, MA, USA
47 Prior Scientific GmbH, Jena, Germany
48 Promega, Heidelberg, Germany
49 Qiagen, Hilden, Germany
50 R and D, Minneapolis, MN, USA
51 Roth, Karlsruhe, Germany
52 Sarstedt, Nuembrecht, Germany
53 Seton Scientific, Petaluma, CA, USA
54 Sigma Aldrich, Munich, Germany
55 Southern-Biotech, Birmingham, AL, USA
56 Starlab GmbH, Hamburg, Germany
57 Thermo-Fisher Scientific - Germany GmbH, Schwerte, Germany
58 Tocris Bioscience, Wiesbaden-Nordenstadt, Germany
59 Vector, Burlingame, CA, USA
60 Wako Chemicals GmbH, Neuss, Germany
61 DAKO, Hamburg, Germany
62 Okolab, Ottaviano, NA, Italy
63 Leitz, Grand Rapids, MI , USA  
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3.2 Chemicals 
Chemical Manufacturer
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 7
4',6-diamidino-2-phenylindole (DAPI) 54
Acetic acid 36
Acrylamide 30 % / Bisacrylamide 0.8 % 51
Adenosine triphosphate (ATP) 54
Agarose 51
Ammonium persulfate (APS) 36
Ampicillin sodium salt 51
Aprotinin 54
Aqua ad injectibila 24
Bovine serum albumin fraction V 7
Bromophenol blue 54
Calcium chloride (CaCl2) 7
Carbenicillin 54
Deoxyribonucleotide triphosphate (dNTP) 41
Di-sodium hydrogen phosphate dihydrate (Na2HPO4) 7
Ethanol 100 % 51
Ethanol 70 % 54
Ethanol Rotipuran p.a. 51
Ethidium bromide 54
Ethylenediaminetetraacetic acid (EDTA) 54
Ethylene glycol tetraacetic acid (EGTA) 54
Fluorescence mounting medium 55
Glucose 7
Glycerol anhydrous 7
Glycin 51
Hexadimethrine bromide 54
Hydrochloric acid 54
Hydrogen peroxide 51
Igepal 54
Isopropanol 54
Kanamycin sulfate 51
LB agar 7
LB medium 51
Leupeptin 54
Magnesium chloride (MgCl2) 7
Manganese (II) chloride (MnCl2) 7
Methanol 54
Mayer´s hemalaun 51
Sodium pyrophosphate 7
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Chemical Manufacturer
Sodium hydroxide (NaOH) 7
Nonfat dry milk powder 7
Nonylphenol ethoxylates (NP-40) 54
Normal goat serum 44
Orange G 51
Paraformaldehyde (PFA) 51
Peptone 7
Phenylmethanesulfonylfluoride (PMSF) 54
Phosphatase inhibitor cocktail 1 54
Phosphatase inhibitor cocktail 3 54
PhosTag 60
Piperazine-N,N′-bis(2-ethanesulfonic acid) (PIPES) 7
Potassium acetate 7
Potassium chloride (KCl) 36
Potassium dihydrogen phosphate (KH2PO4) 36
RNAse free water 51
RNAse A 54
RNAse-exitus plus
TM
28
Roti-Histol 7
siRNA resuspension buffer 21
Sodium azide (NaN3) 36
Sodium chloride (NaCl) 51
Sodium dodecyl sulfate (SDS) 51
ß-Glycerophosphate 36
ß-Mercaptoethanol 54
SYBR Green 36
Tetramethylethylenediamine (TEMED) 51
Tris base 51
Tris-HCl 7
Triton X-100 36
Tween 20 54
Urea 7
Yeast extract 7  
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3.3 Primers 
Custom Primers 39  
3.4 DNA and Protein ladders 
100 bp DNA Ladder Plus 41
1 kb DNA Ladder 41
Precision Plus ProteinTM Standards Dual Color 15  
3.5 Plasmids 
pCDNA3 33
peGFPN1 19
pIRESNeo2 19
hCIN//pCMVSport6 43
hCFL1//pCMVSport6 43
SHC 002 54
TCN0000050046 54  
3.6 Immunocytochemistry reagents 
Chronophin antibody, rabbit, monoclonal 18
Alexa Fluor 546 Phalloidin 33
Alexa Flour 488 conjugated goat anti-rabbit, highly cross  absorbed 33
Vinculin antibody, mouse, monoclonal 54  
3.7 Immunohistochemistry reagents 
Biotynilated goat anti-rabbit HRP conjugate 59
ABC complex 59
DAB substrate 59
Cytochrom C-Oxidase IV antibody, rabbit, monoclonal 18
Tissue-Tek® O.C.T. compound 28
Mounting medium 57  
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3.8 Antibodies for immunoblotting 
Target Manufacturer Dilution Source
GAPDH 18 1:1000 rabbit, monoclonal, clone 14C10
ß-Actin 38 1:10000 mouse, monoclonal, clone MAB1501
α-Tubulin 54 1:10000 mouse, monoclonal, clone DM1A
Chronophin 18 1:1000 rabbit, monoclonal, clone C85E3
Rac 1/2/3 18 1:1000 rabbit, polyclonal, clone
RhoA 18 1:1000 rabbit, monoclonal, clone 67B9
P-Ser3-Cofilin 18 1:1000 rabbit, monoclonal, clone 77G2
Cofilin-1 18 1:1000 rabbit, polyclonal
MMP9 8 1:1000 rabbit, polyclonal
MMP14 2 1:1000 rabbit, polyclonal
MMP2 8 1:1000 mouse, monoclonal, clone VB3
uPA 54 1:1000 mouse, monoclonal, clone 3B8
uPAR 50 1:500 mouse, monoclonal, clone 62022
GFP 33 1:1000 rabbit, polyclonal
c-myc 18 1:1000 rabbit, monoclonal
secondary anti-rabbit HRP conjugated 57 1:10000 goat, polyclonal
secondary anti-mouse HRP conjugated 57 1:10000 goat, polyclonal
 
 
3.9 Bacterial strains and cell lines 
DBTRG-05-MG 34
U87 6
GBM6840 Dr. S.S. Tony To, Departement of Health 
Technology and Informatics, 
The Hong Kong Polytechnic University, Hongkong, China
E. Coli  DH5α 33
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3.10 Tissue culture reagents  
Dulbecco´s phosphate buffered saline 44
Dulbecco´s modified Eagle´s medium w/o phenolred 4.5 g/l glucose 44
Dulbecco´s modified Eagle´s medium 4.5 g/l glucose 44
HAM´s F10 4.5 g/l glucose 44
Fetal calf serum 13
L-glutamine 44
Penicillin / streptomycin 44
Geneticindisulfate (G418) 51
Lipofectamine 2000 33
Opti-MEM 33
Puromycin 17
Trypsin / EDTA 44
Dimethyl sulfoxide 7
Latrunculin A 54
Oleoyl-L-α-lysophosphatidic acid sodium salt (LPA) 54
Bradykinin 54
Epidermal growth factor, human (EGF) 54
Platelet-derived growth factor BB, human (PDGFBB) 54
Y-27632 54
Fasudil 58
Fibronectin, human 17
Collagen I, rat tail 54
Collagen IV,  human 54
Vitronectin,  human 54
Poly-L-lysine 54
Soybean trypsin inhibitor 54  
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3.11 Tissue culture materials 
Bovine serum albumin 7
Calcein AM 33
Cell culture flasks 75 cm2 57
Cellulose acetate filter 0.45 µm  FiltropurS 0.45 52
Cryo 1°C freezing container 40
Falcon tube 15 ml 10
Falcon tube 50 ml 10
Hoechst 33342 33
Kryo vials 40
Matrigel coated 24-well plate inserts, pore size 8 µm 10
Plastic pipettes 5 ml, 10 ml, 25 ml, 50 ml 27
Polystyrene round-bottom tube 5 ml 10
Sterile filter 0.2 µm FiltropurS 0.2 52
Surgical disposable scalpel 8
Tissue culture dishes Ø 15, 30 and 100 mm 57
White 96-well plate with lid 46
 
 
3.12 Other materials 
 
Cell scraper 28
Cotton swabs 28
Cover slips 51
Glass slides 28
Glass slides superfrost 28
Hard Shell® 384-well PCR plates 15
Hematocytometer 28
Hydrophobic barrier pen 61
Hybond C nitrocellulose membrane 26
Omnifix®-F syringes and needles 8
Open top tubes thickwall polyallomer 53
PCR Sealers
TM
 Microseal® ´B´ film 15
PCR tubes, 0.2 ml 28
Pipette tips 10, 200 and 1000 µl 22
Reaction tubes 0.5, 1.5 and 2.0 ml 22
Reaction tubes 1.5 ml, Biopur® 22
Whatman paper 28  
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3.13 Enzymes and reaction buffers 
 
 
3.14 Kits 
Cignal FinderTM10-Pathway Reporter Array Cancer 49
Cignal
TM
 Reporter Assay c-myc 49
CignalTM Reporter Assay SRE 49
Dual-Glo® Luciferase Assay System 48
G-LISA Rac1,2,3 Activation Assay Biochem Kit (colorimetric format) 20
G-LISA RhoA Activation Assay Biochem Kit (colorimetric format) 20
pGEM®-T Easy Vector System 48
Plasmid plus Midi Kit 49
QIAquick Gel Extraction Kit 49
RevertAidTM H Minus First Strand cDNA Synthesis Kit 23
SuperSignal® West Pico Chemiluminescent Substrate 49
SV Total RNA Isolation System 48  
 
 
 
DNA-Polymerases
Dream Taq DNA polymerase 23
Hot Taq DNA polymerase 1
Platinum Pfx polymerase 33
10 x Hot Taq buffer 1
10 x Dream Taq buffer 23
10 x Pfx buffer 33
MgSO4 33
Restriction Enzymes
BamHI 41
EcoRI 41
XhoI 41
EcoRV 41
NotI 41
StuI 41
DPNI 41
T4 DNA Ligase 41
Ligases
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3.15 Solutions and buffers 
3.15.1 Bacterial culture  
 
SOC medium 
In dH2O 
Peptone        20.0 g 
Yeast extract       5.0 g 
NaCl       0.5 g 
KCl           (0.25 M)                10.0 ml 
MgCl2            (2 M)            5.0 ml 
Glucose        (1 M)             20.0 ml 
Adjust pH = 7.0, add dH2O to 1 L, autoclave 
  
LB medium  
In dH2O 
25 g LB medium powder per 1 L dH2O, autoclave 
 
LB agar 
In dH2O 
40 g LB agar powder per 1 L dH2O, autoclave 
 
Kanamycin stock solution 
50 mg/ml in dH2O  
 
Ampicillin stock solution 
50 mg/ml in dH2O 
 
Carbenicillin stock solution 
50 mg/ml in 50 % ethanol 
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3.15.2 Mini-Plasmid preparation 
 
S1-solution  
in dH2O 
EDTA (pH = 8.0)               10 mM 
RNAse A                100 µg/ml 
Tris-HCl (pH = 8.0)               50 mM 
 
S2-solution  
in dH2O 
NaOH                             200 mM 
SDS                             1 % (w/v) 
 
S3-solution (pH = 5.2)  
in dH2O 
Potassium acetate               3 M 
Acetic acid                            pH adjustment 
 
 
3.15.3 SDS-PAGE 
 
10 x Running buffer SDS gels 
in dH2O 
Tris base                 150 mM 
Glycine                            2 M 
SDS                 1 % (w/v) 
 
4 x Stacking gel buffer  
in dH2O 
Tris base                             0.5 M 
Adjust pH = 6.8 
SDS                             0.4 % (w/v) 
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4 x Running gel buffer  
in dH2O 
Tris base                                     1.5 M 
Adjust pH = 8.8 
SDS                                     0.4 % (w/v) 
 
4 x Laemmli buffer (lysis buffer) 
Bromophenol blue                       2.0 mg 
ß-Mercaptoethanol                       1.6 ml 
SDS                         3.2 g 
Glycerol                         16.0 ml 
Tris-HCl pH 6.8                       20.0 ml 
 
Phostag lysis buffer  
Aprotinin            5.0 µg/ml 
Glycerol            10.0 % (v/v) 
Igepal             1.0 % (v/v) 
Leupeptin             1.0 µg/ml 
Sodium pyrophosphate          1.5 mM 
Phosphatase inhibitor cocktail 1         1:1000 
Phosphatase inhibitor cocktail 3               1:1000 
PMSF             1.0 mM 
ß-Glycerophosphate           1.0 mM 
Tris-HCl (pH = 8.0)             20.0 mM 
 
Phostag solution D 
in dH2O containing 3 % methanol (v/v) 
Phostag                                    5 mM  
 
Phostag solution E 
in dH2O  
MnCl2                                                      10 mM 
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3.15.4 Immunoblotting 
 
Blotto buffer 
In dH2O 
Nonfat dry milk                        5.0 % (w/v)     
Tris-HCl, pH=8.0                       50.0 mM    
NaCl                          80.0 mM   
CaCl2                         2.0 mM     
NP-40                         0.2 % (v/v) 
 
Antibody dilution buffer 
In dH2O 
BSA                         1.0 % (w/v)   
HEPES                         10.0 mM 
NaCl                         0.5 M 
NaN3                                   0.02 % (w/v)   
Tween 20                        0.2 % (v/v) 
 
Towbin buffer 
In dH2O 
Tris base                         3.0 g 
Glycine                        14.4 g 
dH2O                          800 ml 
Methanol                         200 ml 
 
Anode 1 buffer, for low molecular weight proteins 
In dH2O 
Tris base        0.3 M 
Methanol  40.0 % (v/v) 
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Anode 2 buffer, for low molecular weight proteins 
In dH2O  
Tris base  25.0 mM 
Methanol  40.0 % (v/v) 
 
Cathode buffer, for low molecular weight proteins 
In dH2O 
Tris base  25.0 mM 
Glycine  40.0 mM 
Methanol  10.0 % (v/v) 
 
Anode 1 buffer, for high molecular weight proteins 
In dH2O 
Tris base  0.3 M 
Methanol              20.0 % (v/v) 
 
Anode 2 buffer, for high molecular weight proteins 
In dH2O 
Tris base        25.0 mM 
Methanol                20.0 % (v/v) 
 
Cathode buffer, for high molecular weight proteins 
In dH2O 
Tris base  25 mM 
Glycine  40 mM 
Methanol  10 % (v/v) 
SDS   0.005 % (w/v)   
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3.15.5 Immunocytochemistry and immunohistochemistry 
 
1 x PBS 
In dH2O 
KCl                0.2 g 
KH2PO4                       0.2 g 
Na2HPO4                     1.15 g 
NaCl                8.0 g 
Adjust pH = 7.4, add dH2O to 1 L. 
 
10 x TBS 
In dH2O 
Tris-HCl               24.0 g 
Tris base              5.6 g 
NaCl               88.0 g 
Adjust pH to 7.6, add dH2O to 1 L. 
 
Paraformaldehyde for ICC 
In 1 x PBS 
Paraformaldehyde             4 % (w/v) 
Adjust pH to 7.2 
 
ICC blocking buffer 
In 1 x PBS 
Normal goat serum               10.0 % (v/v) 
Saponin               0.3 % (w/v) 
 
ICC antibody dilution buffer 
In 1 x PBS 
Normal goat serum             1.0 % (v/v) 
Saponin               0.3 % (w/v) 
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IHC blocking buffer 
In 1 x PBS 
Normal goat serum             10.0 % (v/v) 
Triton X-100               0.3 % (v/v) 
 
IHC antibody dilution buffer 
In 1 x PBS 
Normal goat serum                1.0 % (v/v) 
Triton X-100               0.3 % (v/v) 
 
 
3.15.6 Agarose gel electrophoresis 
 
10 x TAE-buffer 
In dH2O 
Tris base              242.0 g 
Acetic acid              57.1 ml 
EDTA 0.5 M, pH=8.0               100.0 ml 
Adjust volume to 5L 
 
5 x Orange G loading dye 
In dH2O 
EDTA               10 µM 
Glycerol              65 % (v/v) 
Orange G              0.2 % (w/v) 
Tris base              50 µM 
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3.15.7 Actin spin down assay 
 
Spin down buffer 1 
PIPES, pH=6.9     50.0 mM 
NaCl      50.0 mM 
EGTA      5.0 mM 
Glycerol     5.0 % 
MgCl2      5.0 mM 
Igepal      0.1% (v/v) 
Triton X-100     0.1% (v/v) 
Tween 20      0.1% (v/v) 
ß-Mercaptoethanol    0.1% (v/v) 
 
Spin down buffer 2 
In spin down buffer 1 
ATP     1 mM 
Aprotinin    5 µg/ml 
Leupeptin    1 µg/ml 
PMSF    1 mM 
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3.15.8 Cell culture 
 
Puromycin 
10 mg/ml in cell culture grade dH2O  
 
Hexadimethrine bromide 
8 mg/ml in cell culture grade dH2O 
 
Complete medium GBM6840 
In DMEM 4.5 g/l glucose 
Fetal calf serum   10 % (v/v) 
L-glutamine    2 mM 
Penicillin    100 U/ml 
Streptomycin    100 µg/ml 
(Puromycin     1.0 µg/ml, for transduced cells only) 
 
Complete medium U87 
In DMEM 4.5 g/l glucose 
Fetal calf serum   10 % (v/v) 
L-glutamine    2 mM 
Penicillin    100 U/ml 
Streptomycin    100 µg/ml 
 
Complete medium DBTRG-05-MG 
In HAM´s F10 4.5 g/l glucose 
Fetal calf serum   10 % (v/v) 
L-glutamine    2 mM 
Penicillin    100 U/ml 
Streptomycin    100 µg/ml 
(Puromycin     0.5 µg/ml, for transduced cells only) 
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Starving medium: 
Medium w/o FCS 
 
Starving medium + BSA 
Medium w/o FCS + 0.1 % BSA (w/v) 
 
Freezing medium 
In complete medium 
FCS  20 % (v/v) 
DMSO  10 % (v/v) 
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3.16 List of devices used 
Device Application
Leica SP5 microscope 35 Confocal microscopy
Leica DM 4000 B 35 Microscopy for histology
NikonTi eclipse 42 Epifluorescence microscopy/live imaging
Prior Stage Pro Scan 47 Epifluorescence microscopy/live imaging
FACS Calibur
TM
9 Flow cytometry
Envision 2104 multilabel reader 46 Fluorescence/luminescence measurements
BDK S-1200 11 S1 cell culture
BDK SK-1500 11 S2 cell culture
LAS-1000 25 Western blot
Fluor Chem Q imaging system 4 Western blot, DNA gel visualization
Incubator BD6220 57 Cell culture
BD6220 29 Bacterial culture
Shaker ISF-1-V 3 Bacterial culture
C1000
TM
 thermal cycler 15 Polymerase chain reaction
CFX384
TM
 real time system 15 Real-time PCR
Trans Blot® semi-dry transfer cell 15 Semi-dry western blot
GENIE® blotter 32 Wet-tank blotting
DNA gel electrophoresis system 15 DNA gel electrophoresis
Lumen 200 Pro 47 Epifluorescence microscopy/live imaging
Mini-Protean SDS gel electrophoresis 15 SDS gel electrophoresis
NanoDrop 2000c spectrophotometer 45 RNA and DNA measurement
Hera Cell 240 29 S2 incubator
Centrifuge 5702 R 22 S2 centrifuge
TFX-35 M 14 Cloning
Hettich Universal 16 R 30 DNA preparation
Hettich Universal 16 R 30 S1 cell culture
Cryostat CM 3050S 35 Cryo sections
Ultracentrifuge Optima
TM
 TLX 12 Spin down assay
Cell culture microscope 63 Cell counting
Temperature and CO2 controlled 
humidified microscope stage
62 Live cell imaging
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4. Experimental procedures 
 
4.1 RNA specific methods 
 
4.1.1 Isolation of total RNA 
 
Total RNA was isolated from GBM6840 cells with the SV Total RNA Isolation System Kit from 
(48). Isolation of total RNA is necessary for gene expression analysis of mRNAs by microarray 
and PCR based technologies. All steps were performed with special RNAse free materials and 
all pipettes and equipment were cleaned with 70 % ethanol and RNAse-Exitus plus before 
performing the experiment.  
Cells were grown in Ø 10 cm cell culture dishes, and 600,000 cells were seeded per dish 48 h 
before harvest in complete DMEM. Then, the supernatant was aspirated and cells were 
washed with ice cold PBS. The cells were lysed immediately in 175 µl prechilled RNA-lysis 
buffer on ice, and collected with a cell scraper. Then, the lysate was passed three times 
through a 20 gauge and three times through a 25 gauge needle with a syringe to shear 
genomic DNA, and the lysate was then transferred in a 1.5 ml tube. Then, 350 µl RNA 
dilution buffer were added and the solution was mixed by inverting the tube three times. 
The solution was heated at 70 °C for 3´ to denature RNA secondary structures. Afterwards, 
the solution was centrifuged at 18,000 x g for 10´ and the supernatant was transferred into a 
fresh 1.5 ml tube. 200 µl 95 % ethanol were added and the solution was mixed by pipetting. 
Then the solution was pipetted into the spin basket assembly provided in the kit, and 
centrifuged for 1´ at 18,000 x g to bind the RNA to the column. The column was washed with 
600 µl RNA wash buffer, and centrifuged for 1´ at 18,000 x g. Then, the DNAse-mix was 
added that digests the genomic DNA in the sample. 
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The following DNase-mix was prepared per column: 
 
Yellow core buffer:    40.0 µl 
MnCl2 0.09 M      5.0 µl 
DNase I      5.0 µl 
     50.0 µl 
 
The 50.0 µl DNAse-mix were applied to the column, and incubated for 15´ at RT. 
Then, 200 µl DNAse stop solution were added, and the columns were centrifuged for 1´ at 
18,000 x g. After that, the column was washed as before with 600 µl and 250 µl RNA wash 
buffer again. Then, the RNA was eluted from the column with 100 µl RNAse free water and 
the liquid was collected by centrifugation for 1´ at 18,000 x g. The RNA was immediately 
frozen in liquid nitrogen, and stored at -80°C.  
 
4.1.2 Labeling and microarray 
 
Total RNA was measured with an Experion Bio-analyzer system to assure quality of the RNA, 
hybridization to Agilent microarrays was performed by Dr. Michael Krause (Institut für 
Molekularbiologie und Tumorforschung, Marburg) and analysis of the raw data was 
performed by Lukas Rycak at the Microarray Core facility at the University of Marburg.  
The platform used was a Human GE  4 x 44k Microarray Kit (Agilent G4845A), labeling and 
hybridization were performed with the Quick-Amp Labeling Kit (2 color) (Agilent 5190-0444) 
The microarray scanner and software used were the Agilent Microarray Scanner G2505C and 
Feature Extraction v10.5.1.1 (4). 
 
4.1.3 cDNA synthesis 
 
cDNA synthesis is needed for converting the RNA template as generated in 4.1.1 into a DNA 
template suitable for PCR applications. All steps were performed with special RNAse free 
materials and all pipettes and equipment were cleaned with 70 % ethanol and RNAse-Exitus 
plus before performing the experiment.  
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The cDNA synthesis was performed with the RevertAid H Minus First Strand cDNA Synthesis 
Kit from (23). 
 
From each RNA sample 
 
500 ng Total-RNA       x  µl 
Random hexamer primer     1.0 µl 
dH2O, RNAse free                    add  11.0 µl  
Total volume     11.0 µl 
were gently mixed and centrifuged briefly. Then, the samples were incubated at 65° C for 5´ 
to denature RNA secondary structures and then the tubes were chilled on ice. 
 
For every sample 
5 x Reaction buffer    4.0  µl 
RiboBlock RNAse inhibitor (20U/µl)  1.0  µl 
10 mM dNTPs     2.0  µl 
Reverse Transcriptase   2.0  µl  
Total volume               20.0  µl 
were added, gently mixed and centrifuged briefly. 
The samples were then incubated for 5´ at RT and incubated for 1 h at 42°C to synthesize the 
cDNA. Afterwards, the samples were incubated at 70°C for 5´ to stop the reaction and 
subsequently the cDNA was stored at -20°C. 
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4.2 DNA specific methods 
4.2.1 Transformation of competent E. coli 
 
Chemically competent E. coli DH5α were thawn for 10´ on ice, and then the DNA to be 
transformed, 500 ng plasmid DNA or 8.0 µl from a ligation reaction, was added to 200 µl 
bacteria solution. The cells were incubated with the DNA for 45´ on ice, and then a heat 
shock was performed for 45´´ at 42°C in a water bath. Then, the bacteria were again 
incubated for 5´ on ice, and afterwards 600 µl RT SOC medium were added. The cells were 
allowed to grow for 1.5 h at 700 rpm and 37°C, to allow for the expression of the plasmid 
encoded resistance gene. Then, the bacteria were collected by centrifugation for 5´ at 1,844 
x g. The supernatant was discarded, the pellet was resuspended in the back flow of medium 
left, and plated on LB agar plates containing the selection antibiotics kanamycin or 
ampicillin.  
 
4.2.2 Gateway cloning 
 
First, a PCR product was generated as described in 4.2.3 in a total volume of 150 µl PCR 
reaction. It was purified as described in 4.2.5.  Then, A-overhangs were added to the blunt 
end PCR product by a standard Taq-polymerase. Per PCR-product 
Purified PCR product    44.0  µl 
Taq       0.5  µl 
10 x Taq- buffer     5.0  µl 
10 mM dNTPs      0.5 µl  
Total volume                50.0 µl 
were mixed in a PCR tube, and incubated for 20´ at 72°C in a thermocycler. Then, the PCR-
product was run on a 1 % agarose gel, excised from it and purified with the QIAquick gel 
extraction kit as described in 4.2.5. Afterwards, the ligation reaction was performed at 4°C 
O/N. 
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Per reaction 
T4 DNA Ligase    1.0 µl 
2 x Rapid ligation buffer  5.0 µl 
PCR product    3.0 µl 
pGEMT Easy vector   1.0 µl 
Total volume               10.0 µl 
were mixed in a 0.5 ml reaction tube. The ligated DNA was transformed as described in 
4.2.1. 
 
4.2.3 Cloning-PCR 
 
Amplification of specific DNA sequences by polymerase chain reaction is needed for cloning 
reactions. To ensure the sequence integrity of the amplified fragments, a proof reading DNA 
polymerase, Platinum Pfx, from (33) was used for this application. Primers used and 
annealing temperatures (TA) are listed in table 1.  
Per reaction 
10 x Pfx buffer    2.5 µl 
Pfx-polymerase    0.5 µl 
MgSO4     0.5 µl 
dNTPs     0.5 µl 
Enhancer     2.5 µl 
Primer mix (10 µM each)  2.5 µl 
Template    1.0 µl (25 ng Plasmid DNA) 
dH2O       add 25.0 µl 
Total volume    25.0 µl 
were mixed. 
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Table 1: Primers used for cloning PCR reactions. 
Target Forward Cutting site TA Elongation time
hCFL1 ATATACTCGAGGCCACCATGGCCTCCGGTGTGGCTGTCT
hCFL1 Reverse
ATATAGGATCCCCTCCCAAAGGCTTGCCCTCCAGGGAG
56°C 2´
XhoI
BamHI
 
 
The reactions were cycled in a thermocycler under the following conditions: 
Denaturation   95°C  5´ 
Denaturation   95°C  1´ 
Annealing   TA  1´ 
Elongation   68°C  x 
Final     68°C  10´ 
Hold    12°C  
 
 
4.2.4 Preparation of agarose gels for DNA electrophoresis 
 
1 % w/v agarose was mixed with 150 ml 1 x TAE buffer, and heated until boiling in a 
microwave. Then, the solution was cooked three times for 10´´, and subsequently cooled 
down to 60°C. Then, the solution was poured into a gel casting frame.  
 
 
4.2.5 Purification of DNA from agarose gels and PCR reactions 
 
PCR products or digested DNA fragments were generated as described in 4.2.3 or 4.2.6 and 
the DNA was extracted from agarose gels with the QIAquick Gel extraction Kit. The DNA was 
mixed with Orange G loading dye and run on 1 % agarose gels at constant voltage (85 V) for 
50´. Then, the gels were stained in ethidium bromide and the bands at the expected length 
35 x 
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were cut out. Then, the gel slices were weighed, and three volumes of buffer QG were 
added. The gel slice was dissolved for 10´ at 50°C and mixed vigorously several times during 
the incubation time. For PCR products that were purified without separation on a gel, five 
volumes of buffer QG were added to the PCR reaction directly.  
Then, one volume of isopropanol was added to the solution. Afterwards, the solution was 
applied to a spin column that was provided in the kit, and centrifuged at 14,000 x g for 1´. 
The column was washed with 750 µl buffer PE, and the flow through was discarded. Then, 
the column was dried by centrifugation at 14,000 x g for 1´. Afterwards, the DNA was eluted 
with 50 µl dH2O. 
 
4.2.6 Restriction digestion and cloning 
 
hCIN//pCMVSport6 and pCDNA3 were digested with EcoRI and XhoI.  
For this reaction 
Plasmid DNA    4.0 µl = 4.0 µg 
BSA 100 x    0.5 µl 
EcoRI-buffer     5.0 µl 
dH2O               38.5 µl 
EcoRI     1.0 µl 
XhoI      1.0 µl 
Total volume               50.0 µl 
 
were mixed and the reaction mixtures were incubated 4 h at 37°C. 
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hCIN//pCMVSport6 and pIRESNeo2 were digested with EcoRV and NotI. 
For this reaction 
Plasmid DNA    4.0 µl = 4.0 µg 
BSA 100 x    0.5 µl 
Buffer 3    5.0 µl 
dH2O               38.5 µl 
EcoRV     1.0 µl 
NotI      1.0 µl 
Total volume               50.0 µl 
were mixed and the reactions were incubated 4 h at 37°C. 
 
hCFL1//pGEMTeasy and pEGFP-N1 were digested with BamHI and XhoI. 
For this reaction 
pEGFP-N1/CFL1//pGEMTeasy   6.0 µg ( = 6.0 µl/10 µl) 
BamHI     1.0 µl  
XhoI     1.0 µl 
Buffer 3    5.0 µl 
dH2O     37.0 / 33.0 µl 
Total volume    50.0 µl 
were mixed and the reactions were incubated 4 h at 37°C. 
 
 
 
 
43 
 
4.2.7 Ligation 
 
For each ligation reaction  
Ligation buffer   2.0 µl 
Insert DNA   5.0 µl 
Plasmid DNA  1.0 µl 
T4 DNA Ligase  1.0 µl 
dH2O   11.0 µl  
Total volume   20.0 µl 
were mixed and incubated in a thermocycler for 48 h at 16°C. Afterwards, the DNA was 
transformed as described in 4.2.1. 
 
4.2.8 Preparation of agar plates 
 
Autoclaved LB agar was heated until cooking in a microwave and subsequently cooled down 
to 50°C. Then, ampicillin or kanamycin stock solution was diluted 1:1000 in the agar solution 
and the agar containing antibiotics was poured into petri dishes.  
 
 
4.2.9 Plasmid isolation from E. coli, Mini-Prep format 
 
The Mini-Prep is suitable for isolation of DNA for cloning and sequencing applications. A 
single colony of E. Coli DH5α was grown in 5 ml LB-medium O/N at 37°C and 180 rpm. Then,  
2 ml of the solution were centrifuged for 5´ at 1,844 x g. The supernatant was discarded, and 
the pellet was resuspended in 300 µl prechilled buffer S1. Then, 300 µl buffer S2 were 
added, the solution was mixed by inverting eight times, and the bacteria were lysed for 5´ at 
RT. Then, 300 µl S3 were added, the solution was mixed by inverting eight times, and 
incubated for 30´ on ice. Afterwards, the solution was centrifuged for 10´ at 18,407 x g, and 
the pellet was discarded. DNA was precipitated from the supernatant with 700 µl 
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isopropanol, and was collected by centrifugation for 20´ at 18,407 x g and 4°C. The pellet 
was washed in 500 µl 70 % ethanol, centrifuged for 10´ at 18,407 x g and dissolved in 50 µl 
dH2O. 
 
4.2.10 Plasmid isolation from E. coli, Midi-prep format 
 
The DNA Midi-prep is used for generation of large amounts of plasmid DNA suitable for cell 
culture applications. It was performed with the Plasmid Plus Midi Kit from (49). E. coli DH5α 
transformed as described in 4.2.1 were grown in 50 ml LB medium O/N at 37°C at 180 rpm. 
Then, the cells were collected by centrifugation for 15´ at 4°C and 2,325 x g. Afterwards, the 
supernatant was discarded and the pellet resuspended in 4 ml buffer P1. Then 4 ml buffer P2 
were added, and the solution was incubated at RT for 5´. Then, 4 ml buffer P3 were added, 
and the solution was incubated on ice for 15´. The solution was centrifuged again for 30´ at 
4°C and 2,325 x g and the pellet was discarded. The supernatant was recentrifuged for 15´ at 
4°C and 2,325 x g. Then, a QIAGEN Tip 100 was equilibrated with 5 ml buffer QBT. The 
supernatant was applied to the column, and the column was allowed to empty by gravity 
flow. Afterwards, the column was washed three times with 10 ml buffer QC. The DNA was 
eluted with 5 ml buffer QF, and precipitated with 3.5 ml isopropanol. The DNA was collected 
by centrifugation at 2,325 x g for 30´ and 4°C. Then, the pellet was washed in 70 % ethanol 
and dried. Finally, the DNA was dissolved in 100 µl cell culture grade dH2O and the 
concentration was determined with the NanoDrop 2000c spectrophotometer.  
 
4.2.11 Site directed mutagenesis 
 
To study the impact of amino acid exchanges mimicking a non-phosphorylatable cofilin 
(S3A), a phosphorylated cofilin (S3E), or for creation of a chronophin construct lacking the 
shRNA target site (named hereafter ΔshRNA), the sequences of the plasmids that were 
cloned as described in 4.2.6 and 4.2.7 had to be mutated. The approach used was PCR 
based, and the mutations to be inserted were included in the synthesized primer pairs that 
were used for a PCR with the non-mutated construct as a template. 
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The PCR-setup was as described in 4.2.3, the primers used are given in table 2. For hCIN, two 
overlapping PCR products had to be generated, which are named hCINΔshRNA left and 
hCINΔshRNA right hereafter. 
Table 2: Primers used for mutagenesis PCRs. 
Construct Primer Sequence
CFL1-S3A forward primer GCCACCATGGCCGCCGGTGTGGCTG
CFL1-S3E forward primer GAGGCCACCATGGCCGAGGGTGTGGCTGTCTCT
hCINΔshRNA left forward primer AGCTCGGATCGATATCGTCGA
hCINΔshRNA right forward primer GCCCCTACATGTTTGAATGTATCACGGAGAACTTCAGC
CFL1-S3A reverse primer CGGTGGTACCGGCGGCCACACCGAC
CFL1-S3E reverse primer CTCCGGTGGTACCGGCTCCCACACCGACAGAGA
hCINΔshRNA left reverse primer GCTGAAGTTCTCCGTGATACATTCAAACATGTAGGGGC
hCINΔshRNA right reverse primer AATCCATAGGGGACCAGCTT
 
 
4.2.11.1 Mutagenesis of hCIN//pIRESNeo2 to hCINΔshRNA//pIRESNeo2 
 
For hCIN, a mutagenesis and cloning protocol was performed with the primer pairs given in 
table 2. The PCR reactions were mixed according to the protocol in 4.2.3. 
First, two PCR-products were created, that contained 3 silent mutations in the shRNA target 
site and a sequence overlap. Counted from the translational start site, in position 657 a 
cytosine was exchanged to thymine, in position 660 a guanine was exchanged to adenine 
and in position 663 a cytosine was exchanged to thymine (see Fig. 6). 
 
Mutated Sequence  GCCCCTACATGTTTGAATGTATCACGGAGAACTTCAGC  
                  ||||||||||||| || || |||||||||||||||||| 
PDXP human 644    GCCCCTACATGTTCGAGTGCATCACGGAGAACTTCAGC    681 
 
Figure 6: Alignment of human CIN and the mutated primer sequence. 
 
The hCINΔshRNA left product was 760 bp, and the hCINΔshRNA right product was 476 bp 
long. Then a fill up PCR was performed with the overlapping fragments, to create one insert 
of 1220 bp suitable for cloning into the hCIN//pIRESNeo2 construct. In the fill up PCR, both 
products were combined to create a single long product. Then, purification, digestion and 
ligation of the product were performed as described in 4.2.5, 4.2.6 and 4.2.7, respectively. 
The restriction sites used were EcoRV and StuI. 
46 
 
Cycling conditions hCINΔshRNA left PCR product: 
Denaturation   95°C  5´ 
Denaturation   95°C  1´ 
Annealing   57°C  1´ 
Elongation   68°C  2´30´´ 
Final     68°C  7´ 
Hold    12°C  
 
Cycling conditions hCINΔshRNA right PCR product: 
Denaturation   95°C  5´ 
Denaturation   95°C  1´ 
Annealing   57°C  30´´ 
Elongation   68°C  1´ 
Final     68°C  7´ 
Hold    12°C  
 
Cycling conditions fill up PCR: 
Denaturation   95°C  5´ 
Denaturation   95°C  1´ 
Elongation   68°C  2´30´´ 
Final     68°C  10´ 
Hold    12°C 
 
 
 
35 x 
35 x 
12 x 
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4.2.11.2 CFL1-S3A-GFP and CFL1-S3E-GFP 
 
For the CFL1-S3A and CFL1-S3E mutants, a standard PCR reaction of the CFL1//pEGFP-N1 
construct was performed. 
 
Per reaction 
10 x Pfx buffer    5.0 µl 
Pfx-polymerase    1.0 µl 
MgSO4     1.0 µl 
dNTPs     1.0 µl 
Enhancer     5.0 µl 
Primer mix (10 µM each)  1.25 µl 
Template    1.0 µl (25 ng – 500 ng plasmid DNA) 
dH2O         add  50.0 µl 
Total volume     50.0 µl 
were mixed and the reactions were cycled in a C1000 thermal cycler under the following 
conditions: 
Denaturation   95°C  5´ 
Denaturation   95°C  1´ 
Annealing   55°C  1´ 
Elongation   68°C  10´ 
Final     68°C  7´ 
Hold    12°C  
Afterwards, 1 µl DPNI was added to digest methylated parental plasmids, and the reaction 
was incubated for 3 h at 37°C. Then, another 0.5 µl DPNI were added, and the reaction was 
again incubated for 2 h at 37°C. Then, the DNA was transformed as described in 4.2.1. 
18 x 
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4.2.12 Semiquantitative PCR 
 
The semiquantitative PCR is used to measure relative transcript abundances in different 
biological samples. 1:5 diluted cDNA as prepared in 4.1.3 was used as a template for this 
reaction. Annealing temperatures (TA) and primer sequences for all templates are shown in 
table 3. For target amplification, the DreamTaq DNA-polymerase from (23) was used. 
Table 3: Primer sequences and conditions for semiquantitative PCR. 
Length 
in bp
GAPDH CCCTTCATTGACCTCAACTA CCAAAGTTGTCATGGATGAC 401 57.0 25
CIN TGCAACCCCCTCCCAGCAGT TCCACTCGGGCTCCAGGACG 397 59.0 28
CFL1 ATGCCCTCTATGATGCAACC GCTTGATCCCTGTCAGCTTC 152 54.3 25
CFL2 TGGTTATATGCCTCCCTTGC GCCTCACAGAACTGCAATCA 177 54.3 25
ADF CGTAAATGCTCCACACCAGA AGCATTCCCACAAAATGCTT 164 54.3 25
MMP2 CACTTTCCTGGGCAACAAAT CTGAGCGATGCCATCAAATA 382 58.0 30
MMP9 CACTGTCCACCCCTCAGAGC GCCACTTGTCGGCGATAAGG 263 58.0 33
MMP14 CATTGGAGGAGACACCCACT GGTGTCAAAGTTCCCGTCAC 352 58.0 32
uPAR CATGCAGTGTAAGACCAACGGGGA AATAGGTGACAGCCCGGCCAGAGT 254 58.5 33
uPA TGAGGTGGAAAACCTCATCC GCAGCACACAGCATTTTGGTG 321 58.5 30
CathepsinB AGAATGGCACACCCTACTGG AACCACAGGCTGGGATGTAG 333 59.0 30
c-myc CCTACCCTCTCAACGACAGC CTCTGACCTTTTGCCAGGAG 228 59.0 30
c-JUN CCCCAAGATCCTGAAACAGA CCGTTGCTGGACTGGATTAT 168 54.3 25
STAT3 CAGTCAGTGACCAGGCAGAA GCTGCAACTCCTCCAGTTTC 289 54.3 25
p53 GTGGAAGGAAATTTGCGTGT AGCTGTTCCGTCCCAGTAGA 220 52.3 25
SP1 CTTCTTACCCCAGCCTACCC AGGCTCAGCCATAGGGAAAT 279 54.3 25
Target Forward Primer Reverse Primer TA Cycles
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For each PCR reaction per cDNA sample:    
10 x buffer   2.5 µl 
cDNA    1.0 µl 
DreamTaq   0.3 µl 
dNTPs 10mM   0.5      µl  
dH2O    18.2   µl 
Total volume   22.5 µl 
were mixed and 2.5 µl primer mix (10 µM each) was added. 
Then the PCR reactions were cycled in a C1000 thermal cycler. 
95°C   5´ 
95°C   30´´ 
TA           30´´ 
72°C   1´ 
72°C   10´ 
 
After cycling, the reactions were mixed with Orange G loading dye and separated on a 1 or 3 
% TAE-agarose gel depending on the size of the PCR product. The agarose gel was stained for 
15´ in dH2O containing 0.5 µg/ml ethidium bromide, 5´ destained in dH2O and then a picture 
was taken. Then, the band intensities were measured with ImageJ ver. 1.45i and normalized 
to the GAPDH level. 
 
 
x X cycles, TA and the number of cycles are given in table 3 
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4.2.13 Real-time quantitative PCR 
 
Real-time quantitative PCR is performed to accurately measure the relative amount of 
template in a PCR reaction. The primers used are given in table 4. The measurement of 
double stranded DNA was performed with a CFX384 real-time system that monitors the 
increase in fluorescence of the dsDNA binding dye SYBR Green. 
Table 4: Primers used for real-time PCR. 
Target Forward Primer Reverse Primer
MXI1 ATGGAGCGGGTGAAGATG ATGAAGAGGCGTAGCCATGT
VEGFA GGATTTTGGAAACCAGCAGA GTCACTCACTTTGCCCCTGT
THBS1 TGCTATCACAACGGAGTTCAGT GCAGGACACCTTTTTGCAGATG
CIN CTGGAGACCGACATCCTCTTT TTCTAGGCGGGAGACTCCTG
GAPDH CATGAGAAGTATGACAACAGCCT AGTCCTTCCACGATACCAAAGT
EDIL3 TCGAAGACATTGCACTTTGC GTCCATGTTGAGCGTTCTGA  
 
The following reagents were mixed in Hard Shell 384-well PCR plates: 
cDNA     2.0     µl 
10 x HotTaq buffer   1.25   µl 
10 x SYBR Green    0.25   µl 
dH2O     7.775 µl 
dNTPs (10 mM)   0.25   µl 
HotTaq____    0.075 µl_____ 
Total volume                12.1   µl 
Afterwards, 0.4 µl primer mix were added per well (10 µM each). 
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Cycling conditions in the CFX-Cycler: 
94°C 2´ 
94°C 20´´ 
56°C 20´´ 
65°C 40´´ 
65°C 1´ 
+ melt curve 
The cycler determines the threshold cycle CT for every sample. Afterwards, the relative 
expression in the different goups compared to the Ctl shRNA cells was calculated by the  
2-ΔΔCT method [95]. To calculate the ΔCT, the CT of the housekeeping gene, GAPDH, is 
substracted from the CT of the target gene, e.g. CIN for every sample. Then, from this ΔCT 
value the ΔCT value of the means of the control group are substracted, yielding the  ΔΔCT 
[95]. 
 
 
 
 
 
 
 
 
 
40 x 
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4.3 Protein biochemistry 
 
4.3.1 SDS-PAGE 
 
SDS-Polyacrylamide gel electrophoresis is used for separation of proteins by their molecular 
mass. All protein lysates were prepared in 1 x Laemmli-buffer and run on 12 % SDS-gels. The 
gel casting was performed with equipment from the Mini-Protean SDS gel system. First, the 
short plates and spacer plates (1 mm gel thickness) were assembled with the casting frame 
on the casting stand. Then, for the separating gel the following reagents were mixed for two 
gels: 
H2O       3.5 ml 
Acrylamide 30 % / Bisacrylamide 0.8 %  4.0 ml 
4 x Tris-HCl/SDS pH = 8.8    2.5 ml 
Then, 75 µl 10 % APS and 7.5 µl TEMED were added, and the gels were covered with 
isopropanol. After polymerization of the separating gel was completed, the isopropanol was 
discarded and the gels were covered with a stacking gel.  For the stacking gel, the following 
reagents were mixed for two gels: 
H2O       2.48 ml 
Acrylamide 30 % / Bisacrylamide 0.8 %  0.52 ml 
4 x Tris-HCl/SDS pH = 6.8    1.0  ml 
20 µl 10 % APS and 5 µl TEMED were added to induce polymerization. 
The electrophoresis equipment used was a Mini-Protean SDS gel electrophoresis system. 
Electrophoresis was performed at a constant voltage for 30´ at 80 V (stacking gel) and for 1 h 
20´ at 120 V (separating gel).  
Then the protein was transferred on nitrocellulose using a semi-dry blotting device as 
described in 4.3.2. 
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4.3.2 Semi-dry western blotting 
 
Western blotting describes the transfer of protein from a SDS gel to a membrane suitable for 
immunoblotting. 
For proteins of up to 40 kDa molecular weight, the low molecular weight buffers were used, 
for proteins > 40 kDa, high molecular weight buffers were used. 
The gel was washed in cathode buffer for 10´, and the blotting sandwich was assembled as 
shown in figure 7. Two whatman papers were equilibrated in anode buffer 1. Another was 
incubated in anode buffer 2 and three in cathode buffer. Transfer was performed at 70 mA 
for 30´ for low molecular weight proteins, and for 1 h for high molecular weight proteins.  
  
     
 
3 x whatman paper cathode 
    
SDS gel 
1 x nitrocellulose membrane anode II 
1 x whatman paper anode II 
2 x whatman paper anode I 
 
               Anode 
        Figure 7: Sandwich for semi-dry western blotting. 
 
 
 
 
 
 
                  Cathode 
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4.3.3 Phostag SDS-PAGE 
 
The analysis of phosphocofilin was performed with standard SDS-PAGE gels containing 1 µM 
Phostag, which allows for separation of phosphorylated and unphosphorylated proteins [96]. 
The gel was washed in 10 mM EDTA in Towbin buffer after electrophoresis and washed 
three times for 5´ in Towbin blotting buffer afterwards. For two separating gels, 
 
H2O 3.5 ml 
Acrylamide 30 % / Bisacrylamide 0.8 % 4.0 ml 
Phostag solution D 50.0 µl 
Phostag solution E 50.0 µl 
4 x Tris-HCl/SDS pH = 8.8 2.5 ml 
 
were mixed. Then, 75 µl 10 % APS and 7.5 µl TEMED were added to start polymerization of 
the acrylamide, and the gels were covered with isopropanol. After polymerization of the 
separating gel was completed, the isopropanol was discarded and the gels were covered 
with a stacking gel.  For the stacking gel the following reagents were mixed for two gels: 
H2O  2.48 ml 
Acrylamide 30 % / Bisacrylamide 0.8 %  0.52 ml 
4 x Tris-HCl/SDS pH = 6.8  1.0  ml 
 
20 µl 10 % APS and 5 µl TEMED were added to induce polymerization of the acrylamide. 
Electrophoresis was performed at a constant current for 70´ at 30 mA.  
Then, the proteins were transferred on a nitrocellulose membrane using a wet-tank transfer 
as described in 4.3.4. 
 
4.3.4 Wet-tank transfer  
 
The Phostag gels were blotted on a nitrocellulose membrane in a wet-tank blotting device, 
the GENIE blotter. The whatman paper and the nitrocellulose membrane were equilibrated 
in Towbin buffer prior to assembly of the blotting sandwich. The sandwich was assembled as 
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shown in figure 8. The protein was transferred on a nitrocellulose membrane at constant 
voltage of 12 V for 1 h. 
 
                     Anode    
1 x whatman paper 
1 x nitrocellulose membrane 
SDS gel 
1 x whatman paper  
 
                    Cathode 
      Figure 8: Sandwich for wet-tank protein transfer. 
 
4.3.5 Detection of proteins after western blotting 
 
The membranes were blocked in blotto buffer for 30´. Then, the membranes were rinsed in 
dH2O, and incubated in primary antibody diluted in antibody diluent O/N. All antibodies used 
and dilutions are given in 3.8 in material and methods. The next day, the membranes were 
rinsed three times in dH2O and incubated with secondary antibody diluted 1:10,000 in blotto 
buffer. After 1.5 h incubation at RT, the membranes were rinsed three times in dH2O and 
incubated with picoluminescence substrate for exactly 2´. Then, the luminescence signal was 
recorded in a LAS1000 or Fluor Chem Q Imaging system. Band intensities were quantified 
with ImageJ ver. 1.45i or AlphaView ver. 2.0.1.1 and normalized to the respective GAPDH, ß-
actin or α-tubulin level. The cofilin antibody used recognizes cofilin-1 but crossreacts with 
cofilin-2. The ratio of p-cofilin/total cofilin was calculated by 
% 𝑃 − 𝐶𝑜𝑓𝑖𝑙𝑖𝑛 =  
𝑃−𝐶𝑜𝑓𝑖𝑙𝑖𝑛
(𝑃−𝐶𝑜𝑓𝑖𝑙𝑖𝑛+𝐶𝑜𝑓𝑖𝑙𝑖𝑛)
. 
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4.4 Cell culture techniques 
 
4.4.1 Cell lines and cell culture 
 
Eukaryotic cells were cultured with sterile equipment and all working steps were performed 
under a BDK-S 1200 laminar flow hood. The cell lines HEK293T, GBM6840 and U87 were 
cultured in complete DMEM medium and DBTRG-05-MG cells were cultured in complete 
HAM´s F10. Origin and marker positivity are important characteristics for the cell lines used 
and can be important for their reactivity to stimuli and their behavior in cell culture 
experiments. DBTRG-05-MG are glioma cells, established from a secondary GBM that 
occurred in a 59 year old female individual and stain for Vimentin but not GFAP [97]. 
GBM6840 cells were established from a GBM from a 17 year old female individual, and are 
strongly positive for both Vimentin and GFAP [98]. U87 are established from a grade IV 
astrocytoma that occurred in a 44 year old male individual [99]. 
Both media, HAM´s F10 and DMEM, were supplemented with L-glutamine, 100 u/ml 
penicillin and 100 µg/ml streptomycin. The cells were incubated in a humidified incubator at 
37°C and 7 % CO2. Cells were checked on a regular basis for mycoplasma, and contaminated 
cultures were discarded immediately. Cells were cultured to 80 – 90 % confluency, and then 
splitted 1:10 (GBM6840, HEK293T) or 1:4 (DBTRG-05-MG and U87). For this purpose, the 
medium was aspirated from the adherent cells. Then, the cells were washed with 5 ml of 
sterile DPBS. After that, 3 ml trypsin/EDTA were added to the culture dish, and then a 
volume was aspirated leaving the cells covered with trypsin/EDTA. The cells were allowed to 
detach for 3´ at 37 °C, and were subsequently resuspended in 10 ml complete medium. For a 
1:10 dilution, 1 ml cell suspension was plated onto a new cell culture dish. The total volume 
in the 75 cm2 cell culture flasks or Ø 10 cm cell culture dishes was 12.5 ml. 
Cultures of primary mouse astrocytes were kindly provided by Alexandra Bohl (Institut für 
Pharmakologie, Universität Würzburg). 
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4.4.2 Freezing cells 
 
For long term storage, cells need to be cryoconserved. For that purpose, cells grown to 80 % 
confluency on 75 cm2 cell culture flasks or Ø 10 cm cell culture dishes were harvested by 
trypsinization as described in 4.4.1. Then, the cells were resuspended in 5 ml complete 
medium and collected by centrifugation for 5´ at 99 x g. The cell pellet was resuspended in 
freezing medium and immediately transferred into a cryo vial and put on ice. Then, the vials 
were transferred in a cryo box, and stored at -80°C O/N. On the next day, the vials were 
transferred into liquid nitrogen. 
 
 
4.4.3 Thawing cells 
 
For rethawing, the cells were first thawn in a waterbath at 37°C, until only a small ice crystal 
was left in the cryo vial. Then, the content of the cryo vial was mixed with 5 ml prewarmed 
complete medium in a 15 ml falcon tube, and then the cells were collected by centrifugation 
for 5´ at 99 x g. The cell pellet was resuspended in 3 ml complete medium, and then the cells 
were plated on 75 cm2 cell culture flasks or Ø 10 cm cell culture dishes in a total volume of 
12.5 ml medium. 
 
 
4.4.4 RNA interference (RNAi) 
 
RNA interference can be used to downregulate gene expression by targeting specific mRNAs. 
It is a conserved mechanism in eukaryotes for gene-silencing and anti-viral defense. Double 
stranded RNA molecules, siRNAs or miRNAs, mediate in general a silencing mechanism for 
homologous sequences [100]. However, the mechanisms can be diverse and silencing can be 
performed by mRNA degradation, translational silencing, and other mechanisms [101]. The 
most relevant mechanism by which the transfected RNAs in the experiments target mRNAs 
is the cleavage dependent mechanism. 
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Here, after entry into the cells, an RNA induced silencing complex (RISC) is formed, 
processed, and mRNAs complementary to the guide strand are degraded [101], as shown in 
figure 9. 
For silencing mRNAs in cell culture, double stranded small interfering RNAs are transfected 
into cells, or short hairpin RNA encoding plasmids are stably transduced into target cells 
[100]. The sequences used for hCIN or the respective control sequences are given in table 5. 
 
 
 
Figure 9: Mechanism of RNAi induced gene silencing.  
The guide strand (blue) is loaded onto the RISC whereas the passenger strand (red) is degraded. A 
mRNA molecule (black) that is complementary to the guide strand is degraded. Modified after 
[100]. 
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4.4.5 Transfection 
 
Transfection is used for transfer of DNA or RNA into eukaryotic cells. The transfection 
reagent used was Lipofectamine 2000. Ø 6 cm plates with adherent cells were washed with 
1 ml prewarmed Opti-MEM, and 3 ml Opti-MEM were added to the plate. For a Ø 6 cm dish, 
250 µl Opti-MEM were mixed with the indicated RNA or DNA concentration and in parallel, 
250 µl Opti-MEM were mixed with 3 µl Lipofectamine 2000, and incubated for 5´ at RT in 
polystyrene tubes. 
Then, the solutions were mixed and incubated for another 20´ at RT to allow transfection 
complex formation.  Afterwards, the solution was added to the cell culture plates in a 
dropwise fashion. The cells were incubated in the Opti-MEM medium containing 
transfection complexes for 4 h, and then the medium was exchanged to complete medium. 
The expression plasmid for human c-myc was kindly provided by the group of Prof. Dr. 
Martin Eilers (Lehrstuhl für Biochemie und Molekularbiologie, Biozentrum Universität 
Würzburg). 
 
4.4.6 Establishment of virally transduced cell lines 
 
Cells can be genetically modified at high efficiency with virally mediated DNA transfer.  First, 
the DNA that is supposed to be transferred into the target cells needs to be packaged into 
viral particles. All steps were performed under aseptic conditions in a S2 cell culture 
laboratory. 
HEK293T cells were transfected at 70 % confluency as described in 4.4.5 to produce lentiviral 
particles carrying vectors with a non targeting control shRNA and a chronophin targeting 
shRNA. These plasmids SHC002 and TCN0000050046 were purchased from (54), and the 
target sequences are shown in table 5. 
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The plasmids for the packaging, pVSVG, pMDL, pAdvantage and pRSV were kindly provided 
by Dr. Stefan Kissler (Rudolf Virchow Center for experimental Biomedicine, Würzburg).  
Per plate, 30 µl Lipofectamine 2000 and 
pVSVG      2.0 µg 
pMDL       1.5 µg 
pAdvantage      2.0 µg 
pRSV      1.5 µg 
shRNA coding plasmid   5.0 µg 
 
were used. Supernatants were collected three and four days after transfection, sterile 
filtered with 0.45 µm filters and viral particles were collected by ultracentrifugation. After 
collection of the particles, they were stored at -80°C. DBTRG-05-MG cells were infected at 70 
% confluency and afterwards the infected clones were selected with 0.5 µg/ml puromycin.  
 
Table 5: siRNA and shRNA sequences. 
Target Type Sense Antisense
hCIN siRNA UCGAGUGCAUCACGGAGAAUU UUCUCCGUGAUGCACUCGAUU
Target Type Sequence 5´-3´
none (control) shRNA CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTTGTTTTT
hCIN shRNA CCGGCCTACATGTTCGAGTGCATCACTCGAGTGATGCACTCGAACATGTAGGTTTTTG
 
 
4.4.7 Establishment of stably transfected cell lines 
 
For the establishment of stably transfected cell lines, cells were transfected as described in 
4.4.5 with 1.0 µg pIRESNeo2 or pEGFP-N1 vector. After 24 h, the medium was exchanged, 
and 400 µg/ml G418 were added to the complete culture medium. The cells were cultured 
for another two weeks until G418 resistant clones had been selected.  
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4.4.8 Preparation of paraformaldehyde 
 
First, the PFA was weighed in. Here, the amount needed to get 4 % (w/v) of the final volume 
of PFA solution to be prepared was used. Then, dH2O equal to 2/3 of the total volume of PFA 
solution to be prepared was heated to 60°C. 
The PFA was added to the water under the fume hood, and then 2N NaOH was added until 
the solution became clear. Afterwards, 3 x PBS equal to 1/3 of the total volume of PFA 
solution to be prepared was added and the pH was adjusted to 7.2 with HCl. 
 
 
4.4.9 Plate coating 
 
The plates to be coated were first washed with sterile dH2O, and then coated for 1.5 h at 
37°C, 7 % CO2 with 10 µg/ml collagen I in 0.05 M HCl, 10 µg/ml collagen IV in 0.05 M HCl, 100 
µg/ml poly-L-lysine in PBS, 0.5 µg/ml vitronectin in dH2O or 10 µg/ml fibronectin in PBS. 
Afterwards, the plates were washed with sterile dH2O, and the water was removed by 
flicking. Then, the plates were blocked with 0.5 % BSA in DMEM for 30´ at 37°C and 7 % CO2. 
Afterwards, the plates were washed with sterile dH2O and dried O/N. 
 
4.4.10 Immunocytochemistry and phalloidin staining 
 
Cells were seeded at a density of 9,300 cells/cm2 on collagen IV coated coverslips. Growth 
was allowed O/N and afterwards cells were starved for 4 h in starving medium. For the 
inhibitor treatment, cells were incubated with 10 µM Y-27632 or 0.1 % (v/v) DMSO as 
control for 2 h. Cells were immediately fixed in 4 % PFA at RT for 15´.  Cells were washed 
with PBS, and permeabilized and blocked with ICC blocking buffer. Afterwards, cells were 
washed in PBS + 0.3 % saponin and stained in ICC antibody dilution buffer O/N at 4°C with 
vinculin primary antibody. On the next day, the slides were washed three times in PBS + 0.3 
% saponin and incubated with Alexa Fluor 488 anti-rabbit IgG or anti-mouse IgG (diluted 
1:200 in antibody dilution buffer) and Alexa Fluor 546 phalloidin (diluted 1:50 in antibody 
dilution buffer) for 2 h at RT. The slides were washed again three times in PBS + 0.3 % 
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saponin. Then, the slides were counterstained with DAPI, at a concentration of 1 µg/ml for 
10´. Afterwards, the coverslips were washed twice in PBS, mounted in fluorescence 
mounting medium and the cells were visualized with confocal microscopy using a Leica SP5. 
At least 30 sections in the z-axis of slice thickness 0.695 µm were imaged, and from the 
acquired stacks maximum projections of these z-stacks were calculated with the Leica 
Application Suite Advanced Fluorescence Software for three independent experiments. 
 
 
4.4.11 Immunocytochemistry CIN staining 
 
Cells were seeded at a density of 9,300 cells/cm2 on glass coverslips. Growth was allowed for 
48 h. Then the cells were fixed in 4 % PFA at RT for 15´.  Cells were washed with PBS, and 
permeabilized and blocked with ICC blocking buffer. Afterwards, cells were washed in PBS + 
0.3 % Saponin and stained in antibody dilution buffer O/N at 4°C with α-CIN antibody diluted 
1:50. On the next day, the coverslips were washed in PBS + 0.3 % saponin and incubated 
with Alexa Fluor 488 anti-rabbit IgG (diluted 1:200) and Alexa Fluor 546 phalloidin (diluted 
1:50) for 2 h at RT. The coverslips were washed again three times in PBS + 0.3 % saponin. 
Then, the coverslips were counterstained with DAPI, at a concentration of 1 µg/ml for 10´. 
Afterwards, the coverslips were washed twice in PBS, mounted in fluorescence mounting 
medium and the cells were visualized with confocal microscopy using a Leica SP5. 
 
 
4.4.12 Immunocytochemistry and F-actin staining of stimulated cells 
 
Cells were seeded at a density of 9,300 cells/cm2 on glass coverslips. Growth was allowed for 
24 h and afterwards the cells were starved O/N in DMEM w/o FCS. The cells were stimulated 
with LPA at a concentration of 1 µM, 50 ng/ml PDGFBB, 100 ng/ml EGF or 1 µM Bradykinin 
diluted in starving medium or pure starving medium (unstimulated) for 10´. 
Afterwards, the cells were immediately fixed in 4 % PFA at RT for 15´.  The coverslips were 
washed with PBS, and permeabilized and blocked with ICC blocking buffer. Afterwards the 
coverslips were washed in PBS + 0.3 % saponin and incubated with Alexa Fluor 546 
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phalloidin diluted 1:50 in ICC antibody dilution buffer for 2 h at RT. Then, the coverslips were 
counterstained with DAPI, at a concentration of 1 µg/ml for 10´. Afterwards, the coverslips 
were washed twice in PBS, mounted in fluorescence mounting medium and the cells were 
visualized with confocal microscopy using a Leica SP5. At least 30 sections in the z-axis of 
slice thickness 0.695 µm were imaged, and from the acquired stacks maximum projections of 
these z-stacks were calculated with the Leica Application Suite Advanced Fluorescence 
Software for three independent experiments. 
 
 
4.4.13 Actin spin down assay  
 
Cells were seeded at a density of ~20,000 cells/cm2, growth was allowed for 24 h and the 
cells were then starved O/N in starving medium. Afterwards, lysis was performed in 500 µl 
37°C prewarmed spin down buffer 2. All other equipment and the centrifuge were 
prewarmed to 37°C before the experiment, too. 
The lysates were homogenized by aspirating them five times through a syringe with a 30 
gauge needle and were then incubated at 37°C for 10´.   
Afterwards, the F-actin and G-actin containing fractions were separated by 
ultracentrifugation. 350 µl lysate were centrifuged in an Optima TLX ultracentrifuge at 
100,000 x g at 37°C. The supernatant containing G-actin was collected immediately after 
centrifugation, and the pellet containing F-actin was resuspended in 350 µl 8 M urea. The 
actin in the pellet was depolymerized by incubation for 1 h on ice. 
Afterwards, the fractions were mixed with Laemmli-buffer, and processed for standard SDS-
PAGE. F/G-actin levels were estimated via western blot. The ß-Actin antibody was used for 
detection of actin in the fractions.  
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4.4.14 Chemotaxis-assay on collagen IV 
 
For chemotaxis-assays, GBM6840 control shRNA and CIN shRNA cells were seeded at a 
concentration of 3 x 106 cells/ml on collagen IV coated µ-slide chemotaxis chambers in a 
total volume of 7 µl per chemotaxis chamber. Cells were allowed to adhere O/N, and starved 
in medium w/o FCS for 6 h on the next day. Then, 8 µl DMEM containing 100 ng/ml EGF or 
10 % FCS were added on one reservoir side. Build up of the chemoattractant gradient was 
allowed for 2 h, and afterwards a time lapse DIC movie was recorded in a humidified, 
temperature and CO2 controlled microscope stage incubator. A picture per position was 
recorded every 20´ for 24 h. At least 30 cells per condition were tracked and analyzed. 
The forward migration index for each cell was then calculated by dividing the displacement 
on the chemoattractant gradient axis through the accumulated distance of each cell. 
 
 
4.4.15 2D-Migration 8-well setup 
 
For the assays with the ROCK-inhibitors, CFL1-S3A mutant and U87 cells, 8-well µ-slides were 
coated with 10 µg/ml collagen IV as described in 4.4.17.  
GBM6840 and U87 cells were seeded at a density of 6,000 cells/cm2 in starving medium with 
BSA and allowed to adhere for 6 h. Afterwards, cells were preincubated with 10 µM fasudil, 
10 µM Y27632, or 0.2 % DMSO as a control for 30´. All inhibitors used were dissolved in 
sterile DMSO, stored at -20°C and thawed maximally three times. The GFP expressing cells 
used here had been sorted for GFP-expression by C. Linden (Institut für Virologie und 
Immunbiologie, Würzburg) as described in 4.5.2. 
DIC-movies were recorded for 12 h in a humidified, temperature and CO2 controlled 
microscope stage incubator. At least 50 cells per condition were tracked and analyzed with 
ImageProPlus, ver. 7.0. Two parameters were calculated from the measurements, the 
accumulated distance as well as the distance from origin for each object/tracked cell. The 
accumulated distance is the sum of the travelled distances (d1, d2,…di) between the 
timepoints t0 and the last timepoint ti and is thus expressed as ∑ 𝑑𝑖. The distance from origin 
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(D) is measured by the software as the distance between the starting point of an object at t0 
and its position at the last timepoint ti (see Fig. 10).  
The directionality of each object is then calculated by  𝐷𝑖𝑟𝑒𝑐𝑡𝑖𝑜𝑛𝑎𝑙𝑖𝑡𝑦 =  
𝐷
𝑎𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑑𝑖𝑠𝑡𝑎𝑛𝑐𝑒
 
. 
 
 
 
 
4.4.16 Transwell assay 
 
Cells were grown to 90 % confluency, trypsinized, resuspended in complete medium and 
counted in a hematocytometer. Afterwards, the cells were centrifuged and resuspended in 
starving medium and resuspended to a density of 5.0 x 104 cells/ml. 2.5 x 104 cells from the 
lines GBM6840, U87 or DBTRG-05-MG were seeded per upper compartment of a growth 
factor reduced matrigel-coated transwell chamber with 8 µm pore size in a 24-well plate 
format. The effective growth area of the transwell membrane used was 0.3 cm2. EGF at a 
concentration of 100 ng/ml was added to the lower compartment of the chamber to 
stimulate the migration of the glioma cells. Cells were allowed to migrate for 24 h, and 
afterwards non-invading cells were removed with a cotton swab from the upper side of the 
insert, and the cells on the lower side of the membrane were fixed with methanol. 
Afterwards, cells were stained with 1 µg/ml DAPI in PBS for 10´, washed twice in PBS, the 
membranes were cut out from the culture inserts and transferred on microscopy glass slides. 
After cutting out the membrane, a circle of d = ~ 3,400 µm was left from it. Therefore, the 
area of the membrane was ~ 9.08 mm2, and the area on which counting was performed was 
Figure 10: Parameters used for the calculation of accumulated distance and distance from 
origin. 
 The travelled distances between the timepoints t0 and the last timepoint t3 are denoted as d1, 
d2 and d3. The distance from origin (D) is the distance between the position of the object at 
first and the last time point timepoint.   
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 ~ 3.45 mm2, or ~ 38 % of the total membrane area. Fluorescent micrographs were taken 
with a 4 x objective on an inverted microscope in the DAPI channel, one micrograph was 
taken per membrane and analyzed afterwards. Automated object counting of the nuclei on 
the membrane was performed with ImageProPlus, ver. 7.0. 
 
4.4.17 Proliferation assay 
 
For the analysis of cell proliferation, 1,000 (U87 and GBM6840) or 2,000 (DBTRG-05-MG) 
cells were seeded per well on 96-well plates, and a separate well was prepared for every 
time point. 6 h after seeding, the medium was exchanged. Then, every 24 h for five days, 
one well from each condition was stained with 1 µM Hoechst 33342 for 1 h at 37°C and 7 % 
CO2. Then, one picture was taken from the center of the well on each day for each condition 
with a 10 x objective on a NikonTi eclipse microscope equipped with a DAPI filter, and 
automated image analysis was performed with ImageProPlus 7.0 to automatically count the 
number of nuclei per well. 
 
4.4.18 Cytokinesis assay  
 
Cells were seeded at a density of 5,000 cells/cm2 on 8-well Ibitreat slides. They were 
incubated at 37°C, 7 % CO2 in an humidified incubator for 16 h, afterwards media were 
exchanged to the respective starving medium and the cells were allowed to recover for 6 h. 
As the cells in the transwell assay as described in 4.4.16 were also seeded in starving 
medium, this was done to make the condition between the two assays comparable. 
Afterwards, DIC movies were taken on a NikonTi eclipse microscope, and the number of 
completed mitoses was determined. Only mitoses were counted, which started and whose 
cytokinesis was completed within the observation period, and at least 100 cells were 
followed over the time course. 
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4.4.19 Cell roundness and cell area scoring 
 
Cells were seeded at a density of 9,300 cells/cm2 on collagen IV coated coverslips. Growth 
was allowed O/N and afterwards cells were starved for 4 h in starving medium. Cells were 
fixed in 4 % PFA at RT for 15´. Then cells were stained with Alexa Fluor 546 phalloidin diluted 
1:50 in PBS supplemented with 0.3 % saponin and 0.1 % BSA. Fluorescent micrographs were 
taken employing a 20 x objective on a NikonTi eclipse microscope and automatically analyzed 
with ImageProPlus 7.0. At least 100 cells were scored for each condition. The perimeter is 
calculated as the chain code length of the outline. The area is determined by counting the 
number of pixels within the object including the outline.  The roundness R is then calculated 
by 𝑅 =
 𝑝𝑒𝑟𝑖𝑚𝑒𝑡𝑒𝑟2
4 × 𝜋 × 𝑎𝑟𝑒𝑎
. 
 
4.4.20 Adhesion Assay 
 
The plates for the adhesion assay were coated on the day before the assay as described in 
4.4.9. Tissue culture treated, 96-well plates with clear bottom and black walls were used. 
400,000 cells were seeded 48 h prior to the assay on a Ø 10 cm dish in complete medium. 
The cells were starved in starving medium with 0.1 % BSA. Then, the cells were labeled with 
1 µg/ml calcein AM in starving medium w/o phenol red for 15´ at 37°C and 7 % CO2. 
Afterwards, the cells were trypsinized, and the trypsin reaction was stopped in 5 ml starving 
medium w/o phenol red supplemented with 0.1 % BSA and 0.5 mg/ml soybean trypsin 
inhibitor. The cells were allowed to recover for 30´ at 37°C and 7 % CO2. The cells were 
counted and the cell number was adjusted to 100 cells/µl. Then, the cell suspension was 
incubated on the different substrates for 10´, 20´ or 40´. After incubation, the plates were 
washed twice with PBS, and then 100 µl of lysis buffer containing 50 mM Tris and 1 % Triton 
X-100 were added and the plate was incubated at RT for 15´. Then, the fluorescence 
intensity in every well was measured with an Envision 2104 multilabel reader. 
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4.4.20 Cignal Cancer Panel, c-myc luciferase assays and SRE-luciferase assay 
 
To analyze the effect of CIN deregulation on the activity of a variety of cancer relevant 
transcription factors, a luciferase based reporter assay was performed. In this assay, a 
tandem repeat transcriptional element (TRE) for a specific transcription factor is used that 
controls the expression of a firefly luciferase. As an internal control, a Renilla luciferase is 
cotransfected, which is expressed under the control of a constitutively active pCMV 
promoter (see Fig. 11). 5000 cells were seeded per well of white 96-well plate 48 h before 
the assay. Then, the cells were transfected with 50 ng reporter plasmid mix per well and 4 
pmol siRNA /well or 10 ng hCIN//pCDNA3 and 0.2 µl Lipofectamine 2000. The cells were 
grown for 24 h in medium w/o phenol red supplemented with 0.5 % (Cignal Cancer Panel, 
SRE) or 5 % FCS (c-myc, SRE) after transfection. The volume of medium used was 75 µl/well. 
Afterwards, the luciferase activity was measured with the Dual Glo luciferase assay system. 
75 µl Dual Glo Luciferase reagent were added, incubation was performed for exactly 15´ at 
RT, and the Firefly luminescence intensity was measured in an Envision 2104 multilabel 
reader. Afterwards, the Dual Glo Stop and Glo Reagent was added, incubation was 
performed for exactly 15´ at RT, and the Renilla luminescence intensity was measured in an 
Envision 2104 multilabel reader. 
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Figure 11: Principle of the luciferase based promoter activity assay.  
A tandem repeat transcriptional element (TRE) for a specific transcription factor is transfected into 
cells that controls the expression of a firefly luciferase. As an internal control, a Renilla luciferase is 
cotransfected, which is expressed under the control of a constitutively active pCMV promoter. A 
hCIN encoding plasmid or a human CIN targeting siRNA was cotransfected. Afterwards, Firefly and 
Renilla luminiscence were measured. Modified after [102]. 
 
4.4.21 Small GTPase activity assays 
 
The measurement of GTP-bound, active Rho- and Rac 1/2/3 was performed with 
commercially available ELISA based activity assays containing a RhoA-GTP or Rac 1/2/3-GTP 
binding 96-well plate. On these plates, a RhoA-GTP or Rac 1/2/3-GTP binding domain of a 
Rho effector is bound. 
Cells were seeded at a density of ~20,000 cells/cm2 and grown for 24 h. Afterwards the 
medium was exchanged to starving medium and the cells were starved O/N. Afterwards, 
cells were washed with ice-cold PBS, immediately lysed in lysis buffer, frozen in liquid 
nitrogen and stored at -80°C until measurement. Aliquots of the lysates were taken for 
western blot and RhoA and Rac 1/2/3 protein detection. The samples were incubated on a 
96-well plate coated with a Rho-GTP or Rac 1/2/3-GTP binding protein of a Rho effector 
binding specifically RhoA or Rac 1/2/3. Afterwards, the plate was washed with washing 
buffer, incubated with primary antibody and secondary antibody, and a HRP-based 
colorimetric detection of the bound RhoA-GTP and Rac1/2/3-GTP, respectively, was 
performed.  
The absorbance of each sample was measured in duplicate wells and measured in an 
Envision 2104 multilabel reader. 
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4.5 Flow cytometry based methods 
 
4.5.1 F-actin FACS 
 
Cells were seeded at a density of ~20,000 cells/cm2 and starved O/N in starving medium 
containing 0.1 % BSA. Afterwards, the cells were trypsinized briefly for 90´´, resuspended in 
starving medium and immediately fixed in 2 % PFA for 15´ at RT (see Fig. 12). Afterwards, 
cells were permeabilized with 0.5 % saponin for 15´, washed twice with PBS + 0.5 % saponin 
and stained with Alexa Fluor 546 Phalloidin diluted 1:25 in PBS, supplemented with 0.1 % 
BSA and 0.5 % saponin, for 1 h at RT. Then cells were washed again three times in PBS 
containing 0.5 % saponin, and analyzed in a FACS Calibur flow cytometer. 
 
Figure 12: Principle of the FACS based measurement of total F-actin levels. 
The cells were trypsinized, permeabilized and stained with Alexa Fluor 546 phalloidin. Afterwards, 
the cells were analyzed in a flow cytometer. 
 
 
4.5.2 Cell sorting 
 
Cells were sorted by Christian Linden (Institut für Virologie und Immunbiologie, Würzburg) in 
the Core Facility for Cell Sorting in Würzburg. The cells were sorted for GFP expression on a 
FACS Aria III Flow cytometer, and cells were gated as GFP+ that were more than 1.3 x above 
the highest background fluorescence level measured in control cells. 
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4.5.3 GFP-expression analysis 
 
The analysis of GFP expression was performed with a FACS Calibur flow cytometer. The cells 
were harvested by trypsinization, resuspended in complete medium and analyzed in the FL-1 
channel. 
 
 
 
 
4.6 In vivo assays 
 
4.6.1 GFP-Luciferase transduction 
 
For transduction of the FUGLW vector [103], lentiviral particles were created, and all steps 
were performed in a S2 laboratory under a laminar flow hood. The FUGLW vector encodes a 
luciferase-GFP fusion gene and was kindly provided by Dr. A. Beilhack (Medizinische Klinik 
und Poliklinik II, Universitätsklinikum Würzburg). 
2.5 x 106 HEK293T cells were seeded 24 h prior to transfection in DMEM complete medium 
on a Ø 10 cm dish. Then 1 ml Opti-MEM plus 30 µl Lipofectamine 2000 (1) and 1ml Opti-
MEM plus 
 
pVSVG      5.0 µg 
pPAX2       5.0 µg 
pAdvantage      2.0 µg 
FUGLW     5.0 µg 
(2) were mixed and incubated for 5´ at RT. Then, solution (1) and (2) were mixed, and 
incubated for another 20´ at RT. Then, the transfection mix was applied drop by drop to the 
HEK293T-cells, and after 3 h the medium was exchanged to complete medium. After 72 h 
and 96 h, the virus containing supernatant was harvested from the cells, and cellular debris 
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was removed by centrifugation at 800 x g and 4°C. The supernatant was filtered with a 0.45 
µm cellulose acetate filter. 60 % confluent GBM6840 cells were transduced in complete 
medium containing 8 µg/ml hexadimethrine bromide, and the cells were incubated for 24 h 
in the virus containing supernatant. The cell lines used for FUGLW transduction all originated 
from GBM6840 cells. These cells were first transduced with a control or CIN targeting shRNA 
[48], hereafter named Ctl shRNA and CIN shRNA. Then, the cells were transfected with the 
pIRESNeo2 empty vector or the hCINΔshRNA//pIRESNeo2 construct that was created as 
described in 4.2.11.1, and stably transfected cell lines were selected as described in 4.4.7 .  
Finally, Ctl shRNA transduced pIRESNeo2 transfected, CIN shRNA transduced pIRESNeo2 
transfected and CIN shRNA transduced hCINΔshRNA//pIRESNeo2 transfected cells were used 
for the FUGLW transduction. These cells are hereafter named control, CIN knockdown and 
rescue, respectively. 
 
4.6.2 Clone picking 
 
Clones were picked from GFP-Luciferase expressing cells, which were transduced as 
described in 4.6.1. The protocol used for single cell clone picking was based on the serial 
dilution of cells in a 96-well plate [104]. 200 µl of a cell suspension containing 5 x 104 cells/ml 
in complete DMEM were pipetted into the first well of a 96-well plate. Then, eight serial 1:2 
dilutions were prepared from that well in complete DMEM in a total volume of 200 µl in the 
wells. Then, from each of these eight wells another twelve 1:2 dilutions were prepared, 
again in a final volume of 200 µl. 24 h later, it was checked in which wells single cells were 
present, and those clones were grown for three weeks at 37°C and 7 % CO2 in a humidified 
incubator. Finally, GFP expression was examined as described in 4.5.3. Then, clones were 
selected that had a high GFP expression. These were then examined for their CIN expression. 
CIN knockdown clones were selected, in which the CIN protein levels were reduced to less 
than 20 % of the respective control cells. Rescue cells were selected, in which the CIN 
protein level was increased back to the level in control cells ± 20 %. 
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4.6.3 Orthotopic implantation 
 
The control, CIN knockdown and rescue cell clones generated as described in 4.6.2 were 
injected into NOD-SCID mice by Prof. Dr. Anna Leena Sirén. NOD-(Non obese diabetic) SCID 
(severe combined immunodeficeny) mice are genetically engineered immunocompromised 
mice that lack natural killer cells and in which T- and B-cell development is blocked [105].  
Immunocompromised mice are used to prevent rejection of the tumor xenograft by the 
immune system [106].  
Injection was performed according to the following protocol. 
Under aseptic conditions, mice were anesthetized by intraperitoneal injection of ketamine 
(0.1 mg/g) and xylazine (0.005 mg/g).  After removal of the periosteum the cranium was 
accessible. A 10 µl Hamilton microsyringe equipped with a 33 gauge needle was centered 
above the Bregma, and placed 1.0 mm posterior and 2.0 mm lateral over the midline. 
Through a hole in the cranium, the needle was inserted 3.0 mm under the dura mater. Then, 
10,000 cells in a total volume of 5 µl were injected into the brain. The needle was removed 
and the wound was closed with Etilon 3.0. 10 mice per group were injected. Due to the fact 
that some animals died during the experiment and others showed no luminescence signal in 
the cerebrum, three animals were lost per group. All mice were female and approximately 
10 weeks old. The animals were controlled daily for weight loss and behavioral deficits. 
 
 
4.6.4 In vivo luciferase imaging 
 
The luciferase imaging was performed by Dr. Sabrina Kraus (Medizinische Klinik und 
Poliklinik II, Universitätsklinikum Würzburg) and Prof. Dr. Anna Leena Sirén 
(Neurochirurgische Klinik und Poliklinik, Universitätsklinikum Würzburg) according to the 
following protocol. 
The animals were anesthetized with a mixture of ketamine (100 mg/kg) and xylazine  
(10 mg/kg) containing 150 mg/kg luciferin by intraperitoneal injection. After exactly 10´, the 
bioluminescence intensity of the whole animal was measured in a bioluminescence imager 
in dorsal position, and the images were analyzed with the Living image 4.0 Software. The 
first measurement was performed on day 1 after surgery for all mice, and repeated on day 3, 
74 
 
7, 11, 15 and 20 after surgery. The anesthetized animals were killed on day 20 directly after 
luminescence imaging by decapitation. Afterwards, the brain was removed from the skull, 
and an ex vivo imaging was performed in the bioluminescence imager. Then, the brains were 
conserved as described in 4.6.5. 
 
4.6.5 Cryo sections  
 
Cryo sections from the mice from the experiments described in 4.6.3 and 4.6.4 were 
prepared as follows. First, brains were removed from the mice and fixed in 4 % ice cold PFA 
for 24 h at 4°C. Then, the brains were transferred in 20 % sucrose in TBS. After incubation for 
24 h at 4°C the brains were frozen slowly in liquid nitrogen. For this purpose, the brains were 
glued to a piece of aluminum foil with Tissue-tek and only the edge of the foil was 
submerged in the liquid nitrogen until the tissue was frozen. When the tissue was frozen, the 
whole brain was submerged in liquid nitrogen and then stored at -80°C. 
For the preparation of the sections, the brains were glued to a stamp with Tissue-tek, and 18 
µm thick coronal sections (containing both hemispheres) were prepared with a Cryostat CM 
3050S. These were transferred on poly-L-lysine coated superfrost glass slides. The cerebral 
hemispheres were cut and preserved as completely as possible, and from the 21 brains at 
least 160 sections were cut per brain. The sections were stored at -80°C. 
 
 
4.6.6 Immunohistochemistry 
 
For Immunohistochemistry, frozen sections were prepared as described in 4.6.5. The slides 
were thawed for 20´ at RT prior to the staining procedure. The slides were rehydrated in 1 x 
TBS for 10´, and the brain sections on the slides were surrounded with a hydrophobic barrier 
pen. To quench endogenous peroxidase activity, the brain sections were incubated for 15´ at 
RT in 100 % methanol containing 3 % H2O2.Then, the slides were washed in 1 x TBS for 5´. 
The sections were blocked for 1 h in IHC blocking buffer. Then, the slides were incubated 
with primary antibody in IHC antibody dilution buffer O/N at 4°C. In order to specifically 
detect the implanted human glioblastoma cells, an antibody was used that only recognizes 
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the human Cytochrom C Oxidase IV, and not the murine antigen. This rabbit human 
Cytochrom C Oxidase IV antibody was diluted 1:1000, and every 20th section from every 
brain was stained and examined systematically for presence of tumor cells. To exclude 
staining artifacts the slides with control, knockdown and rescue cell injected brains were 
always stained in parallel and mixed. On the next day, the sections were washed three times 
in 1 x TBS + 0.3 % Triton X-100 for 5´. Then, a biotinylated goat anti-rabbit secondary 
antibody was applied to the sections in TBS + 1 % BSA for 1 h at RT. Afterwards, the slides 
were incubated with avidin coupled horse radish peroxidase (ABC complex) diluted in TBS for 
30´ at RT. Then, the slides were washed three times in TBS. After that, the DAB staining was 
developed with DAB substrate for 10´ at RT, and the reaction was stopped by rinsing the 
slides in running tap water for 5´. The slides were counterstained in Mayer´s hemalaun for 
2´, again rinsed in running tap water, and dehydrated in alcohol and Roti-Histol. The slides 
were mounted in mounting medium and covered with a coverslip. 
 
4.7 In silico analyses 
 
4.7.1 Rembrandt data mining 
 
The Rembrandt database from the National Cancer Institute (http://rembrandt.nci.nih.gov) 
was accessed on the 23.8.2013 [107], and the expression ratios of the indicated probesets in 
the individual samples compared to the geometric mean of the non tumor samples were 
downloaded. The specific _at and a_at probesets were analyzed for the genes indicated, and 
the more unspecific x_at, _s_at probesets were excluded from the analysis. Then, the 
relative gene expression in GBM compared to the normal brain tissue was calculated. In 
total, 28 normal brain samples and 221 GBM samples were analyzed. All available GBM and 
normal brain samples available were analyzed, with the exception that re-resection GBM 
samples were excluded. 
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4.7.2 GEO-Analysis 
 
The Gene Expression Omnibus (GEO) Database, http://www.ncbi.nlm.nih.gov/geo/, was 
accessed on 5.3.2012 and the MASS normalized raw data for the GEO Accession GSE 4290 
[108] and the raw data for GSE12657 (unpublished) were downloaded. All further analysis 
steps were performed with R ver. 13.2.1. The data from GSE12657 were normalized with the 
RMA algorithm. Lists were generated containing the symbols for all significantly deregulated 
genes at an adjusted p ≤ 0.05 and a logFC ≥ 0.5 in GEO Accession GSE 4290 and all 
significantly regulated genes (p ≤ 0.05) from GSE12657 from the comparison pilocytic 
astrocytoma versus GBM. Then, the symbols from the lists were compared to the list of 
deregulated genes contained in table 8, and all genes regulated in the same direction were 
extracted. 
 
 
4.7.3 DAVID-Analysis 
 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) [109,110], 
http://david.abcc.ncifcrf.gov/, was accessed on 9.10.2012. The transcripts from the list in 
table 8 were categorized according to the Gene Ontology (GO) database.  
 
 
4.7.4 Ingenuity Pathway Analysis 
 
The analysis of transcription factor networks was performed with Ingenuity Pathway 
analysis, Ingenuity®Systems, www.ingenuity.com.  
This software determines potentially affected transcriptions factors from a gene list as 
shown in table 8. All identified transcription factors were exported that fulfilled the following 
criteria: The hit had to be significant with a p-value ≤ 0.05 and the number of regulated 
target molecules had to be at least 10 % of the molecules within the given data set. The 
cutoff of 10 % of the initial data set size was chosen due to the following reasons: IPA 
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identifies many significantly regulated transcription factors with only very few regulated 
molecules. Due to the few molecules found in the data set, these hits do not seem to be 
biologically meaningful. On the other hand, due to the different sizes of the data sets used in 
this analysis, it would have been hard to define an absolut number of regulated molecules. 
The IPA software also automatically generates graphical networks of the results, as shown in 
figure 34. 
 
 
4.8 Data analysis 
All graphs shown in this thesis were created with the commercially available GraphPad Prism 
ver. 5.0. All statistical analyses were carried out with R ver. 13.2.1, a software that is freely 
available at http://www.r-project.org/. Parameters given for the statistical analyses include 
the p-value, standard error of the mean and the degrees of freedom. The p-value is the 
measure for the probability that the measured result could have arisen by chance if the null 
hypothesis is true. The null hypothesis is always: The means are the same. The degrees of 
freedom is the sample size minus the number of parameters estimated from the data [111]. 
For all continuous variables normal distribution and normal distribution of the residuals 
were assumed and a t-test was performed for comparison of means. A result was regarded 
as statistically significant, when p < 0.05. For count data, like from the transwell 
experiments, normal distribution of the residuals cannot be assumed [111]. Therefore, a 
rank based test, the Kruskal-Wallis test was performed that does not assume normal 
distribution of the residuals [112].   
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5. Results 
5.1 Cofilin and CIN expression in human glioma cells  
We tested which of the three cofilin family members, cofilin-1 (CFL1), cofilin-2 (CFL2) and 
actin depolymerizing factor (ADF), are expressed in GBM6840 cells. Among these, CFL1 was 
the most abundant member in GBM6840 cells (assuming that the PCR reactions for these 
different gene products were equally efficient). CFL2 and ADF were also expressed, but at 
rather low levels (see Fig. 13 A and B). Furthermore, the CIN protein expression level of 
selected human glioma cell lines was checked, given previous findings from our group that 
most cell lines from rat and human gliomas do not express CIN [48]. After normalization to 
GAPDH protein levels, it became apparent that DBTRG and GBM6840 cells expressed CIN at 
a level comparable to normal mouse astrocytes and were therefore suitable for shRNA 
mediated knockdown experiments (see Fig. 13 C). Interestingely, both the CIN and the 
GAPDH bands appeared at a lower molecular weight in the mouse sample than in the human 
samples. The murine CIN protein is 292 amino acids long and indeed shorter than the human 
protein with 296 amino acids, which resulted in a different behavior in the SDS-PAGE run. 
For the GAPDH protein, the molecular mass for the longest isoform in the human is 36.1 kDa. 
The longest isoform in the mouse has a molecular mass of 38.7 kDa, the shorter isoform 35.8 
kDa. If the mouse astrocytes expressed the shorter GAPDH isoform this might explain the 
lower apparent molecular weight of GAPDH in the murine samples. 
The DBTRG-05-MG cells were  newly transduced with a CIN targeting shRNA or a control 
shRNA, whereas GBM6840 cells were already available as transduced cell line previously 
generated in our laboratory [48]. U87 cells expressed only low levels of CIN, and were used 
for reexpression experiments with a full length hCIN. 
To examine the subcellular localization of CIN, one of the CIN expressing cell lines, 
GBM6840, was immunostained for CIN and F-actin. CIN localized to the nucleus and the 
cytoplasm in GBM6840 (see Fig. 13 D). Immunostainings of GBM6840 cells were visualized 
by confocal microscopy, shown is a single optical slize of 0.7 µm thickness.  
These experiments identified DBTRG-05-MG and GBM6840 cells as suitable cell lines for CIN 
knockdown experiments, and the cell line U87 as a good model for reexpression analyses.  
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Furthermore, as CFL1 was shown to be the most abundant ADF/cofilin family member in 
GBM6840, a rationale was created for the Phostag based analysis of the p-cofilin/total cofilin 
level with an antibody that recognizes CFL1 and CFL2, but not ADF. 
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Figure 13: Cofilin and CIN expression in human glioma cells. 
(A) Representative ethidium bromide stained agarose gel of a semiquantitative PCR showing PCR product 
abundance for the three cofilin/ADF family members in GBM6840. GAPDH was used as loading control. 
(B) Quantification of n=3 experiments as shown in (A). Shown is the mean GAPDH normalized fluorescence 
intensity of cofilin/ADF-transcripts + SEM.  
(C) Western blot with α-CIN antibody  in normal mouse astrocytes (NMA), and the human glioma cell lines 
GBM6840, U87 and DBTRG-05-MG. GBM6840 and DBTRG-05MG cells expressed CIN at levels comparable to 
NMAs. U87 cells expressed only very low amounts of CIN. GAPDH was used as loading control. 
(D) Immunocyctochemistry for CIN in GBM6840 cells. CIN localized to the nucleus and the cytoplasm. 
GBM6840 cells were stained for F-actin with Alexa Fluor 546 phalloidin, with α-CIN antibody and secondary 
Alexa Fluor 488 labeled anti-rabbit antibody and the nuclei were stained with DAPI. GBM6840 cells were 
visualized by confocal microscopy, shown is a single optical slize of 0.7 µm thickness. 
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5.2 Changes in cofilin phosphorylation after CIN  
deregulation 
As CFL1 was the most abundant transcript in GBM6840, we focused on CFL1 in the assays in 
which cofilin protein phosphorylation was analyzed. The ratio of Ser3-phosphocofilin to total 
(phosphorylated and unphosphorylated) cofilin was analyzed by western blot detection of 
cofilin after Phostag SDS-PAGE. 
The compound Phostag added to a SDS gel can lead to retardation of the phosphorylated 
protein as compared to non-phosphorylated protein [113,114]. For cofilin a pan-specific 
antibody is available that can detect both phosphorylated cofilin and the non-
phosphorylated form. 
This is especially interesting for cofilin proteins, as these proteins are regulated by 
phosphorylation on a single serine residue, serine 3 [41]. This modification regulates the 
actin binding of cofilin proteins, and is regulated, among other phosphatases, by CIN [74]. 
As controls, calf intestinal phosphatase (CIP) dephosphorylated lysates were loaded on the 
gels. After CIP treatment, the retarded phosphoprotein band was no longer present. Probing 
the membrane with a P-Ser3-cofilin specific antibody only yielded the retarded band in the 
non-dephosphorylated lysate, and no signal in the dephosphorylated lysate (see Fig. 14 A).  
When the lysates from GBM6840 control and CIN shRNA cells were probed with the total 
cofilin antibody after Phostag SDS-PAGE, a substantial increase in the p-cofilin/total cofilin 
ratio in GBM6840 after CIN knockdown was detectable (see Fig. 14 D). 
The p-cofilin/total cofilin ratio increased from 0.24 ± 0.04 in Ctl shRNA cells to 0.41 ± 0.03 in 
CIN shRNA cells, this difference was statistically significant (two-tailed t-test, p=0.0155, df=6, 
n=4). Whereas DMSO treatment did not change the p-cofilin content significantly (mean Ctl 
shRNA + DMSO= 0.23 ± 0.02, two-tailed t-test p=0.8816, df=5, n=3). To check if increased 
phosphorylation in CIN shRNA cells is dependent on ROCK activity, the cells were treated 
with the ROCK inhibitor Y-27632. At a concentration of 10 µM Y-27632, the p-cofilin content 
was reduced back to control levels. Therefore, CIN counteracts the ROCK and LIMK mediated 
cofilin phosphorylation, the regulatory pathway as shown in figure 4.  
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There was a significant difference in the p-cofilin/total cofilin ratio between Ctl shRNA and 
CIN shRNA cells after DMSO treatment (two-tailed t-test, p=0.0169, df=4, n=3), as well as 
between CIN shRNA cells treated with DMSO or Y-27632  (two-tailed t-test, p=0.0065, df=4). 
The cell lines U87 and DBTRG-05-MG contained a higher p-cofilin/total cofilin ratio than 
GBM6840 cells. In these cell lines, only minor changes of about 5 % of the p-cofilin/total 
cofilin ratio after CIN deregulation could be detected (see Fig. 14 F). 
Nonetheless, the difference was statistically significant in U87 cells (two-tailed t-test, p= 
0.0132, n=3, df=4), where the p-cofilin/total cofilin ratio dropped from 0.85 ± 0.009 in cells 
stably transfected with pIRESNeo2 empty vector to 0.81 ± 0.003 in hCIN expressing cells. 
In DBTRG-05-MG cells the p-cofilin/total cofilin ratio increased from 0.73 ± 0.04 in Ctl shRNA 
cells to  0.79 ± 0.02 in CIN shRNA cells. This difference was not statistically significant (two-
tailed t-test, p=0.2497, n=3, df=4). 
These experiments established the Phostag based separation of cofilin and p-cofilin as a 
valuable tool for the quantification of p-cofilin/total cofilin levels. 
Furthermore, it was verified that the p-cofilin/total cofilin ratio increased after CIN 
knockdown and decreased after CIN expression, although it has to be mentioned that the 
phenotype was rather mild in U87 and DBTRG-05-MG cells. 
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Figure 14: Analysis of cofilin phosphorylation in human glioma cells. 
(A) Western blot with α-cofilin antibody after separation of p-cofilin and cofilin by Phostag SDS-PAGE. After Phostag SDS -
PAGE and western blot there was a retarded band visible, that was well recognized by the P-Ser3 specific cofilin antibody. 
This band could be removed by treating the lysate with CIP. 
(B) Representative western blot with α-cofilin antibody after Phostag SDS-PAGE in DBTRG-05-MG. 
(C) Representative western blot with α-cofilin antibody after Phostag SDS-PAGE in U87. 
(D) Representative western blot with α-cofilin antibody after Phostag SDS-PAGE in GBM6840. 
(E) Representative western blot with α-cofilin antibody after Phostag SDS-PAGE in GBM6840 after treatment with 10 µM 
Y-27632 or DMSO (control). 
(F) Quantification of n=3 independently harvested lysates as shown in (B) and (C). The p-cofilin/total cofilin ratio 
decreased after CIN expression in U87 cells, and increased after CIN knockdown in DBTRG-05-MG. 
(G) Quantification of n=4 independently harvested lysates as shown in (D), and n=3 as shown in (E). The p-cofilin/total 
cofilin ratio increased after CIN knockdown. Whereas DMSO treatment had no effect on the p-cofilin/total cofilin ratio, Y-
27632 treatment reduced it back to control levels in CIN shRNA cells. 
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5.3 Regulation of cofilin phosphorylation in human glioma 
cells 
To test which upstream signaling events are able to increase p-cofilin levels as seen after CIN 
knockdown in glioma cells, substances were applied to GBM6840 cells which are supposed 
to activate Rac, CDC42 and RhoA respectively. The activation of the small GTPase Rac is well 
known to induce lamellipodia, CDC42 activation leads to induction of filopodia and RhoA 
activation induces stress fibers in other cell types [115]. For Rac, 50 ng/ml platelet-derived 
growth factor BB (PDGFBB) or 100 ng/ml epidermal growth factor (EGF) were used. RhoA 
activity was stimulated with 1 µM oleoyl-L-α-lysophosphatidic acid (LPA) and CDC42  
with 1 µM bradykinin.  
Stimulation with EGF and PDGFBB led to intense ruffling activity at the cell edge, indicative 
of increased Rac activity. After bradykinin stimulation, numerous filopodia were visible, 
which are well known to form in a CDC42 dependent manner. Finally, after incubation with 
LPA, an increase in actin stress fibers was observed. Stress fibers are known to form in a 
RhoA dependent fashion (see Fig. 16, n=3). In conclusion, after stimulation with these 
substances, the in the literature for fibroblasts reported actin phenotypes were observed  in 
the glioma cells, too [116]. 
Interestingly, only LPA stimulation, and therefore RhoA activation, was accompanied by a 
substantial and significant (two-tailed t-test, p=0.0251, df=2, n=2, see Fig. 15 H and I) 
increase in p-cofilin levels. 
To characterize the activity of signaling pathways regulating cofilin phosphorylation in 
glioma cells, RhoA and Rac 1/2/3 G-Lisa experiments were performed, to measure the levels 
of active RhoA and Rac 1/2/3. These proteins are, besides CDC42, important nodes in the 
signaling towards cofilin phosphorylation, and can activate kinases mediating cofilin 
phosphorylation [46].  
Whereas there was no significant difference in Rac 1/2/3 activity (two-tailed t-test, 
p=0.6321, n=3 df=4, see Fig. 15 A), there was an increase in RhoA activity in CIN shRNA cells 
as compared to Ctl shRNA cells in GBM6840 (see Fig. 15 B).  
Absorbance at 490 nm increased significantly (two-tailed t-test, p=0.0197, n=4, df=6) from 
0.34 ± 0.03 in Ctl shRNA cells to 0.44 ± 0.02 in CIN shRNA cells. 
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Expression of RhoA and Rac 1/2/3 was not significantly different on protein level (RhoA, two-
tailed t-test, p= 0.7907, df=6, n=4; Rac 1/2/3, two-tailed t-test, p= 0.5575, df=4; see Fig. 15 D, 
E, F).  
After stable hCIN expression in U87, there was no change in RhoA activity (two-tailed t-test, 
p=0.9112, df=6, n=4, see Fig. 15 C). In pIRESNeo2 empty vector transfected cells absorbance 
values were 1.72 ± 0.12 and in hCIN expressing cells 1.71 ± 0.04. The CIN expression was 
controlled via routine western blotting (see Fig. 15 G). 
These experiments suggested that Rac activities are not affected by CIN expression levels in 
glioma cells. In contrast, Rho activities were increased in GBM6840 after CIN knockdown. 
Moreover, RhoA activation via LPA stimulation, but not Rac or CDC42 activation, led to an 
increase in the p-cofilin/total cofilin ratio, emphasizing the importance of RhoA signaling for 
the regulation of the p-cofilin/total cofilin level in glioma cells. 
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Figure 16: The actin cytoskeleton after stimulation of different small GTPases. 
Shown are phalloidin stainings of the actin cytoskeleton in GBM6840. 
As compared to control cells, EGF and PDGFBB stimulated cells showed an increase in ruffling activity (arrow). LPA 
stimulation led to the build up of extensive stress fiber networks (arrow). Bradykinin induced numerous filopodia 
(arrow). Cells were visualized by confocal microscopy, at least 30 slices were imaged and 3D reconstructions (maximum 
projection) were calculated from the DAPI and Alexa Fluor 546 phalloidin stainings with the Leica LAS AF software.  
 
 
Figure 15: Regulation of cofilin phosphorylation in human glioma cells. 
(A) Quantification of n=3 Rac 1/2/3 G-Lisa experiments in GBM6840. Shown are means + SEM. 
(B) Quantification of n=4 RhoA G-Lisa experiments in GBM6840. Shown are means + SEM. There is a significant increase in 
RhoA activity in CIN shRNA cells. 
(C) Quantification of n=3 RhoA G-Lisa experiments in U87. Shown are means + SEM. 
(D) Representative western blot with α-RhoA and α-Rac 1/2/3 antibody in GBM6840. GAPDH was used as loading control. 
(E) Quantification of n=4 as shown in (D) for RhoA, the intensities were normalized to the GAPDH level. 
(F) Quantification of n=3 as shown in (D) for Rac 1/2/3, the intensities were normalized to the GAPDH level. 
(G) Representative western blot with α-CIN antibody in GBM6840 and U87, GAPDH or α-Tubulin were used as loading control. 
(H) Representative western blot with α-cofilin antibody after Phostag SDS-PAGE and differential stimulation of GBM6840 cells. 
Only LPA-treatment led to a substantial increase in p-cofilin levels, n=2.  
(I) Quantification of n=2 as shown in (H). 
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5.4 Quantification of F-actin levels via flow cytometry 
Phosphorylation on serine-3 inhibits the F-actin binding of cofilin, and phosphorylation is 
therefore a very important mechanism for regulation of its activity [41]. Reduction of cofilin 
protein levels lead to an increase in total F-actin in carcinoma cells [117]. 
Levels of total F-actin in glioma cells were determined by flow cytometry. U87 and GBM6840 
cells were trypsinized shortly, fixed and stained with fluorescently labeled phalloidin that 
specifically binds to F-actin. 
This technique has been used in adherent cells previously [93]. To test if the  
measured signals in the trypsinized cells correlated with  the F-actin content of the adherent 
glioma cells, different controls were performed to test if stimulus induced changes of the F-
actin content in adherent cells can be measured in the flow cytometry based assay.  
1 µM latrunculin A, 250 nM LPA or an equivalent volume of starving medium (unstimulated) 
were applied to the cells. Latrunculin A sequesters G-actin and inhibits F-actin assembly 
[118]. In contrast, LPA activates RhoA, and increases stress fiber bundling and the cellular F-
actin content [119]. As expected, LPA led to an increase in fluorescence labeling, whereas 
latrunculin A treatment led to a nearly complete extinction of the signal (see Fig. 17 A and 
D).  
In U87 cells, hCIN expression led to a significant reduction of the phalloidin staining, (two-
tailed t-test, p=0.0094, df=4, n=3) from 124.0 ± 6.02 arbitrary units (A.U.) in U87 cells stably 
transfected with the pIRESNeo2 empty vector to 95.57 ± 0.70 A.U. in cells stably transfected 
with the hCIN//pIRESNeo2 vector (see Fig. 17 B and E). In GBM6840, the labeling increased 
significantly after CIN knockdown (two-tailed t-test, p=0.0176, df=6, n=4), from 96.14 ± 6.02 
A.U. to 122.0 ± 5.23 A.U. (see Fig. 17 C and E). 
CIN expression was examined for every sample via routine western blotting (see Fig. 17 F). 
These experiments showed that the total F-actin content of U87 and GBM6840 cells is 
significantly modulated by the cellular CIN level. 
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Figure 17: Analysis of F-actin levels via FACS based measurement. 
(A) Representative histogram of Alexa Fluor 546 phalloidin stained GBM6840 cells after treatment with 1 
µM latrunculin A (LatA) or 250 nM LPA for 10´. Latrunculin A treatment drastically reduced the staining 
intensity, whereas LPA treatment lead to an increase in signal intensity. 
(B) Representative histogram of unstained or Alexa Fluor 546 phalloidin stained U87 cells stably 
transfected with pIRESNeo2 empty vector (referred to as empty vector) or hCIN//pIRESNeo2 (referred to 
as hCIN OE). hCIN expression led to a reduction in signal intensity. 
(C) Representative histogram of GBM6840 cells transduced with Ctl shRNA or CIN shRNA. CIN knockdown 
led to an increase in signal intensity as compared to Ctl shRNA cells. 
(D) Quantification of n=3 as shown in (A). 
(E) Quantification of n=3 as shown in (B) and n=4 as shown in (C). 
(F) Representative western blot with α-CIN antibody in GBM6840 and U87, GAPDH was used as loading 
control. 
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5.5 Analysis of F/G-actin ratios with the spin down assay 
The actin spin down assay is based on the separation of cellular G- and F-actin by 
ultracentrifugation [61]. The G-actin containing supernatant is collected, and the F-actin 
containing pellet is then resuspended in 8 M urea and the F-actin is depolymerized for 1 h. 
Afterwards both fractions are run on SDS-PAGE, and the actin content in the fractions and 
the F/G-actin ratio can be calculated. The advantage compared to the flow cytometry based 
assay as described in 5.4 is that there is no need for trypsinization.  The disadvantage is that 
the samples have to be centrifuged for 1 h and incubated at 37°C. This long term incubation 
at a physiological temperature can give rise to changes in the cytoskeletal components.  
In U87, hCIN expression led to a reduction in the F/G-actin ratio (two-tailed t-test, p=0.1376, 
df=4, see Fig. 18 A and C), and CIN knockdown in GBM6840 led to a significant increase in 
the F/G-actin ratio (two-tailed t-test, p=0.0014, df=4, see Fig. 18 B and D). In line with the 
results of the flow cytometry based assay, treatment of GBM6840 cells with 1µM LPA for 10´ 
led to an increase, whereas treatment with 1 µM latrunculin A for 10´ led to a strong 
reduction in the F/G-actin ratio (see Fig. 18 E and F). 
These experiments suggested that the F/G-actin ratio was regulated by the cellular CIN level 
in GBM6840 and U87, as had been shown for the total F-actin content in 5.4.  
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Figure 18: Analysis of F/G-actin ratios in glioma cells via actin spin down assay. 
(A) Representative western blot with α-ß-actin antibody for F-and G-actin containing fractions of U87 cells stably 
transfected with pIRESNeo2 or hCIN//pIRESNeo2. 
(B) Representative western blot with α-ß-actin antibody for F-and G-actin containing fractions of GBM6840 cells 
transduced with Ctl shRNA or CIN shRNA encoding plasmids. 
(C) Quantification of n=3 as shown in (A). 
(D) Quantification of n=3 as shown in (B). 
(E) Western blot with α-ß-actin antibody for F-and G-actin containing fractions of GBM6840 cells that were unstimulated 
or stimulated with LPA or latrunculin A (LatA). 
(F) Quantification of the western blot in (E). 
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5.6 Analysis of SRE reporter activity 
The serum response element (SRE) is regulated by the G-actin level in the cell, and SRE 
activity has been shown to be essential for invasion and experimental metastasis in breast 
carcinoma and melanoma cells [120]. LIMK activity has been shown to be important for both 
SRE activity and invasion [121]. Therefore, it was investigated if the knockdown of the 
functional LIMK antagonist CIN, which led to an altered cellular F/G-actin ratio, was also able 
to induce changes in SRE activity, possibly contributing to the invasive phenotype of CIN 
knockdown cells. G-actin binds the serum response factor (SRF) coactivator MAL, and 
thereby represses SRF activity, although the exact G-actin pool that regulates SRF is not 
known [122]. The SRE-activity was examined in GBM6840 cells. The assay is based on a 
firefly luciferase that is expressed from a reporter plasmid under control of a SRE, together 
with a renilla luciferase that is under control of a constitutively active promoter. 
Renilla normalized luminescence intensity in CIN siRNA transfected cells was 0.53 ± 0.09 and 
substantially lower than in Ctl siRNA transfected cells, which showed a mean intensity of 
0.71 ± 0.06 (two-tailed t-test, p=0.2583, df=2, n=2).  There was no major difference in Ctl 
siRNA transfected cells with a mean intensity of 0.07 ± 0.01 and 0.11 ± 0.06 in CIN siRNA 
transfected in the negative control (see Fig. 19, n=2). 
 
 
Figure 19: SRE-reporter activity assay in GBM6840.  
After transfection with a CIN siRNA reporter activity was reduced as compared to Ctl cells. Shown are means + SEM. 
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5.7 Changes in the actin cytoskeleton after CIN 
deregulation 
Cofilin is a central regulator of the dynamics of the actin cytoskeleton [36] that is regulated 
by CIN. In quantitative assays, a significant increase in total F-actin (see 5.4) and an increase 
in the F/G-actin ratio (see 5.5) were found after CIN knockdown. The opposite phenotype 
was observed after hCIN expression in U87, as expected. 
To investigate where the F-actin accumulates, standard immunocytochemistry with 
fluorescently labeled phalloidin was performed that selectively labels F-actin, to detect 
qualitative changes in the actin cytoskeleton. 
Interestingly, the hCIN overexpressing U87 cells showed a very dramatic phenotype. The 
cytoplasmic F-actin and the stress fibers, which were pronounced in control cells, were 
nearly completely dissolved. After CIN knockdown in GBM6840 cells, an increase in stress 
fibers could be detected. 
Furthermore, a loss of these F-actin structures was seen both after ROCK-inhibitor treatment 
as has been reported previously [68], and after expression of a RNAi resistant hCIN construct 
in GBM6840 CIN shRNA cells (see Fig. 20). However, no obvious shape change occurred after 
CIN deregulation.   
Taken together, through the use of immunocytochemistry a loss of stress fibers was 
correlated with higher CIN expression in GBM6840 and U87. Importantly, the increased 
stress fiber content after CIN knockdown was reduced after treatment with the ROCK 
inhibitor Y-27632. 
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Figure 20: The actin cytoskeleton after CIN deregulation or ROCK-inhibition.  
In U87 cells, a dramatic loss of cytoplasmic F-actin and stress fibers was present after expression of  
hCIN (upper panel). In GBM6840 cells, CIN knockdown led to an increase of these F-actin 
structures. The phenotype of GBM6840 cells could be reverted by expression of an RNAi resistant 
hCIN construct (hCINshRNA; middle panel) and by ROCK-inhibitor treatment (bottom panel). The 
pictures shown are maximum projections of at least 30 sections in the z-axis of slice thickness 0.7 
µm.  
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5.8 Analysis of the cofilin phosphorylation pathway in 
Rembrandt 
The cancer genome project provides a wealth of expression data for glioma, as well as 
information on copy number alterations and mutations [107]. 
This makes it possible to check the relative expression of the members of the cofilin 
phosphorylation pathway on mRNA level in normal brain and in GBM tissue. The Rembrandt 
database was accessed, and the pathway members CFL1, LIMK1, LIMK2, CIN, RhoA, RhoB, 
RhoC, ROCK1 and ROCK2, as well as the important RhoC effector FMNL3 were analyzed 
[123]. The downloaded data included 28 normal brain samples and 221 GBM samples. 
Upregulated (> 1.5 x) were LIMK2, ROCK1, RhoA and RhoC. Whereas there was no major 
change of the expression of CFL1, FMNL3, LIMK1 or ROCK2 and SSH genes, CIN was strongly 
downregulated (see table 6). 
Table 6: Gene expression analysis based on Rembrandt. 
Normal Brain Relative Expression in GBM Symbol Probe Set
1.00 1.11  CFL1  1555730_a_at
1.00 1.06  CFL1  200021_at
1.00 1,30  FMNL3  227844_at
1.00 1.45  FMNL3  231231_at
1.00 0.84  FMNL3  232249_at
1.00 1.19  FMNL3  238823_at
1.00 0.66  LIMK1  204356_at
1.00 2.27  LIMK2  202193_at
1.00 1.58 RhoA  1555814_a_at
1.00 0.85 RhoA  240337_at
1.00 0.88 RhoB  1553963_at
1.00 1.22 RhoB  212099_at
1.00 0.96 RhoB  226417_at
1.00 4.03 RhoC  200885_at
1.00 4.55 RhoC  235742_at
1.00 1.87  ROCK1  213044_at
1.00 0.80  ROCK1  230239_at
1.00 0.77  ROCK2  202762_at
1.00 1.24  SSH1  1554274_a_at
1.00 1.30  SSH1  1555624_a_at
1.00 0.90  SSH1  221752_at
1.00 0.93  SSH1  221753_at
1.00 1.10  SSH2  1555423_at
1.00 0.89  SSH2  226080_at
1.00 1.08  SSH3  51192_at
1.00 0.36 CIN  223290_at  
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5.9 Chemotaxis analysis on collagen IV 
Actin reorganization regulated by cofilin has been shown to be essential for chemotaxis in 
mammary carcinoma cells [59].  In metastatic mammary carcinoma cells, reorientation 
towards the chemoattractant is lost after increasing cofilin phosphorylation by LIMK 
overexpression [124]. Therefore, the chemotactic behavior of glioma cells after CIN 
knockdown was analyzed. GBM6840 cells were seeded on collagen IV coated µ-slide 
chemotaxis chambers. 10 % fetal calf serum (FCS) or 100 ng/ml EGF were then added as 
chemoattractant (n=1 and n=3, respectively). Both GBM6840 Ctl shRNA and CIN shRNA cells 
were able to chemotax towards FCS (see Fig. 21 A and B) and there was no obvious 
difference in their chemotactic behavior. In contrast to FCS, GBM6840 cells showed no major 
chemotactical response towards EGF (see Fig. 21 C and D). The calculated forward migration 
index was -0.02 ± 0.04 in CIN shRNA cells and 0.001 ± 0.035 in GBM6840 Ctl shRNA cells, and 
therefore not significantly different from zero in both cell lines. A forward migration index 
close to zero indicates that no chemotaxis has taken place. 
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Fig. 21: Analysis of the chemotactical behavior of GBM6840 cells. 
(A, B) Rose-plots of the individual tracks of 30 control (Ctl) or chronophin (CIN) shRNA cells 
in a gradient of FCS. 
(C, D) Representative rose-plots of the individual tracks of 30 control (Ctl) or chronophin 
(CIN) shRNA cells in a gradient of EGF. 
 
Ctl shRNA 
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5.10 Analysis of cell migration after CIN deregulation in 
2D environments 
As stated in 5.9, no chemotactic response was seen after application of a gradient of EGF in 
GBM6840 cells. However, the GBM6840 CIN shRNA cells seemed to migrate in a different, 
slower but more directional way, as can be seen in Fig. 21 C and D. We therefore quantified 
speed and directionality of glioma cells in a 2D environment. No chemotactical gradient was 
applied due to the technical limitations of the 8-well setup, but cellular integrins were 
stimulated with the collagen IV coating used in all assays. Due to the limited geometry of the 
chemotaxis chambers, only 30 randomly chosen cells could be analyzed on these chambers. 
For the quantifications of U87 cells, inhibitor-assays and GFP-expressing cells, at least 50 
randomly chosen cells were analyzed for each condition. Immotile (or non-motile) cells and 
cells that divided during the observation period were excluded from the analysis. Immotile 
cells were defined as cells that did not migrate more than one cell perimeter during the 
observation period. 
Indeed, quantification of the migratory parameters revealed that there was a significant 
drop in speed (two-tailed t-test, p=0.0285, n=3, df=4), but an increase in directionality (two-
tailed t-test, p=0.0161, n=3, df=4, see Fig. 22 A and B) in GBM6840 cells after CIN 
knockdown. 
In U87 cells, a significant increase in speed could be detected after expression of hCIN (two-
tailed t-test, p=0.0099, n=3, df=4), accompanied by a loss of directionality (two-tailed t-test, 
p=0.061, n=3, df=4, see Fig. 22 C and D). 
After treatment of the cell line GBM6840 with the ROCK-inhibitors fasudil and Y-27632 at a 
concentration of 10 µM, a significant increase in speed could be detected (two-tailed t-test, 
p=0.0062 and 0.0020 respectively, n=3, df=4), but directionality was decreased as compared 
to the DMSO treated control samples (two-tailed t-test, p=0.0232 and 0.03450 respectively, 
n=3, df=4, see Fig. 22 E and F).  
The phenotype that was measured in the chemotaxis setup as seen in Fig. 22, could be nicely 
reproduced with GFP-expressing Ctl shRNA and CIN shRNA GBM6840 cells (see Fig. 22 H and 
I).  
100 
 
Expression of a constitutively active, non-phosphorylatable CFL1 mutant (CFL1-S3A) [125] 
fused to GFP, was able to rescue the phenotype. Both an increase in speed and a decrease in 
directionality were seen after CFL1-S3A expression in GBM6840 CIN shRNA cells (see Fig. 22 
H and I). Expression levels of CIN and GFP were examined by routine western blotting for 
every experiment (see Fig. 22 G and J).  
These results pointed towards a specific involvement of CIN in 2D migration, which is 
mediated by its effect on cofilin phosphorylation. 
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Figure 22: Analysis of glioma cell migration in a 2D environment. 
(A) Quantification of the directionality on collagen IV coated µ-slide chemotaxis chambers in 
GBM6840, n=3, shown are means + SEM. 
(B) Quantification of the speed on collagen IV coated µ-slide chemotaxis chambers in GBM6840, n=3, 
shown are means + SEM. 
(C) Quantification of the directionality on collagen IV coated eight-well slides in U87 cells, n=3, shown 
are means + SEM. 
(D) Quantification of the speed on collagen IV coated eight-well slides in U87 cells, n=3, shown are 
means + SEM. 
(E) Quantification of the directionality on collagen IV coated eight-well slides in GBM6840 after DMSO 
(control) or ROCK-inhibitor treatment. 
(F) Quantification of the speed on collagen IV coated eight-well slides in GBM6840 after DMSO 
(control) or ROCK-inhibitor treatment. 
(G) Representative western blot with α-CIN antibody for 2D migration experiments, GAPDH was used 
as loading control. 
(H) Quantification of the directionality on collagen IV coated eight-well slides in Ctl shRNA + GFP, CIN 
shRNA + GFP and CIN shRNA + CFL1-S3A-GFP expressing GBM6840 cells, n=3. 
(I) Quantification of the directionality on collagen IV coated eight-well slides in Ctl shRNA + GFP, CIN 
shRNA + GFP and CIN shRNA + CFL1-S3A-GFP expressing GBM6840 cells, n=3. 
(J) Representative western blot with α-CIN and α-GFP antibody, GAPDH was used as loading control. 
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5.11 Analysis of cell invasion in the transwell setup 
The cell lines GBM6840, U87 and DBTRG-05-MG were tested for their invasive potential in a 
matrigel invasion assay after CIN deregulation. In this assay the cells migrate across a porous 
membrane in a gradient of EGF, and have to cross a barrier of ECM-molecules. The cells 
were incubated for 24 h after seeding onto the upper compartment of the transwell insert, 
and the concentration of EGF in the lower chamber was 100 ng/ml. 
Reduction of CIN levels via shRNA mediated knockdown increased the invasive capacity of 
DBTRG-05-MG cells significantly (Kruskal-Wallis test, p=0.02092, df=1, see Fig. 23 A and E). 
The invasiveness of GBM6840 cells was significantly higher after CIN knockdown (Kruskal-
Wallis test, p-value = 0.04953, df=1), whereas the difference between hCINΔshRNA 
expressing CIN shRNA cells and Ctl shRNA cells was not significant (Kruskal-Wallis test, p-
value = 0.2752, df=1, see Fig. 23 C and D). 
In U87 cells, expression of a human full length CIN led to a significant reduction of the 
number of invasive cells (Kruskal-Wallis test, p-value = 0.04953, df=1, see Fig. 23 B and F). 
Furthermore, it was tested if treatment with a ROCK-Inhibitor or expression of a 
constitutively active CFL1 mutant (CFL1-S3A-GFP) could rescue the pro-invasive phenotype in 
GBM6840 cells that was observed upon shRNA-mediated chronophin depletion.  Treatment 
with the ROCK-inhibitor Y-27632 at a concentration of 10 µM (see Fig. 23 H) as well as 
expression of the CFL1-S3A-GFP mutant (see Fig. 23 I) reduced the increased invasion of 
chronophin-depleted GBM6840 cells back to control levels. CIN and GFP expression were 
examined for each experiment via routine western blotting (see Fig. 23 G and K). Expression 
of CFL1-GFP, CFL1-S3A-GFP and CFL1-S3E-GFP alone in GBM6840 cells had no influence on 
the invasiveness (see Fig. 23 M). 
Taken together, these results suggested a strong and cell line independent effect of CIN 
expression on invasion. The increased invasiveness was dependent on active ROCK signaling 
and increased cofilin phosphorylation after CIN knockdown.  
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Figure 23: Analysis of glioma cell invasion in the transwell system. 
(A) Representative DAPI stained membranes of a matrigel invasion assay in DBTRG-05-MG. 
(B) Representative DAPI stained membranes of a matrigel invasion assay in U87. 
(C) Representative DAPI stained membranes of a matrigel invasion assay in GBM6840. 
(D) Quantification of n=3 as shown in (C). 
(E) Quantification of n=4 as shown in (A). 
(F) Quantification of n=3 as shown in (B). 
(G) Representative western blot with α-CIN antibody, GAPDH was used as loading control. 
(H) Representative DAPI stained membranes of a matrigel invasion assay in GBM6840 after Y-27632 
or DMSO (control) treatment. 
(I) Representative DAPI stained membranes of a matrigel invasion assay in GBM6840 cells expressing 
Ctl shRNA + GFP, CIN shRNA + GFP and CIN shRNA + CFL1-S3A-GFP. 
(J) Quantification of n=3 as shown in (H). 
(K) Quantification of n=4 as shown in (I). 
(L) Representative western blot with α-CIN and α-GFP antibody, GAPDH was used as loading control. 
(M) Quantification of transwell assays with GBM6840 cells expressing GFP, a CFL1 WT-GFP fusion 
construct, a CFL1-S3A constitutively active mutant and a CFL1-S3E inactive mutant fused to GFP, n=4. 
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5.12 Regulation of proteases on mRNA and protein level 
Different proteases increase glioma cell invasion by dissolving the ECM and releasing growth 
factors bound to the ECM. Well known to be involved in glioma invasion are MMP2,  
MMP9, MMP14, CathepsinB, and the uPA-uPAR system [126]. The expression of some of 
those proteases has already been linked to the phospho regulation of the cofilin protein. 
MMP2 downregulation has been found after treatment with the ROCK-inhibitor fasudil in 
glioma cells [67]. An increased expression of uPA and uPAR has been found after 
overexpression of catalytically active LIMK1 in breast cancer cells [127]. 
Therefore, GBM6840 cells were analyzed for expression of these proteases after CIN 
knockdown. However, the expression of MMP2, MMP9, MMP14 and uPA was not altered on 
the mRNA- and protein-level in Ctl shRNA and CIN shRNA cells (see Fig. 24 A, B, C and D). 
CatpepsinB could be examined only on mRNA level, but was not significantly altered, too 
(see Fig. 24 A and B). 
A mild but statistically significant uPAR overexpression was detectable on mRNA and protein 
level in GBM6840. However, this uPAR overexpression was not found in chronophin-
depleted DBTRG-05-MG cells, or in U87 cells compared to U87 cells reexpressing CIN (see 
Fig. 24 E). 
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Figure 24: Analysis of protease expression after CIN knockdown. 
(A) Representative ethidium bromide stained agarose gels for the PCR analysis of MMP2, MMP14, MMP9, uPA, uPAR, 
CathepsinB and CIN. GAPDH was used as loading control. 
(B) Quantification of n=3 as shown in (A). CIN is efficiently downregulated in CIN shRNA cells as compared to Ctl shRNA cells. 
There are no significant differences in the expression of MMP2, MMP14, MMP9, uPA und CathepsinB. uPAR is upregulated 
after CIN knockdown. Shown are means + SEM. 
(C) Western blots for MMP2, MMP14, MMP9, uPA and uPAR in GBM6840. In DBTRG-05-MG and U87 only uPAR expression 
was examined. GAPDH or α-Tubulin were used as loading control. 
(D) Quantification of n=3 as shown in (C) for MMP2, MMP14, MMP9, uPA and uPAR in GBM6840. The intensities of the 
bands were normalized to the GAPDH or α-Tubulin level, and the mean intensity in the three control samples was set to 
one. Shown are means + SEM. 
(E) Quantification of n=3 for uPAR in DBTRG-05-MG and U87 as shown in (C) U87 cells were transfected with pCDNA3 empty 
vector (EV) or a hCIN encoding plasmid.  Shown are means + SEM. 
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5.13 Live-analysis of proliferation after CIN deregulation 
using Hoechst 33342 
Differences in proliferation can impact the results of the transwell assay as shown in 5.11. 
LIMK1 overexpression can repress the growth of fibroblasts in cell culture [128]. 
Therefore, the cell lines GBM6840, DBTRG-05-MG and U87 were tested for their 
proliferation speed. For that purpose, cells were seeded at low density on 96-well plates, 
one well from every condition was stained with Hoechst 33342 every day and pictures were 
taken.   
Hoechst is a DNA binding dye that is suitable to stain the DNA of living cells in culture [129], 
and allows automatic counting of the cell numbers. Within the observation period of five 
days, all cell lines were proliferating robustly (see Fig. 25 A), although with different doubling 
time, as has already been reported in the literature [97,98]. However, deregulation of CIN 
did not affect the proliferation of any cell line (see Fig. 25 C). The knockdown and the 
expression of CIN were verified by routine western blotting (see Fig. 25 B) 
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Figure 25: Quantification of glioma cell proliferation after CIN deregulation. 
(A) Hoechst 33342 stained GBM6840 cells on day 1, day 3 and day 5 of a proliferation assay.  
(B) Representative western blot with α-CIN antibody, GAPDH was used as loading control. 
(C) Quantification of n=2 as shown in (A). There is no difference in proliferation in any of the three cell 
lines after CIN deregulation. 
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5.14 Analysis of cytokinesis after CIN deregulation 
Spatio-temporal control of cofilin phosphorylation is needed for a proper completion of the 
mitotic process [130], and deregulation of LIMK expression can lead to defects in it [131]. In 
HeLa cells, cytokinesis is disturbed after acute CIN downregulation [74]. Therefore, it was 
examined if the stable knockdown or expression of CIN affects the completion of cytokinesis 
in glioma cells. Cells were seeded in medium containing FCS, then starved to closely mimick 
the conditions of the transwell setup in 5.11. The number of successfully completed mitoses 
including a complete cytokinesis (see Fig. 26 A) were counted. There were no differences in 
the number of completed mitoses after CIN deregulation (see Fig. 26 A and B). At least 100 
cells were analyzed in each condition per replicate. These assays were performed in parallel 
with the transwell assays, and the routine western blotting from the transwell experiments 
also belongs to this assay. 
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Figure 26: Analysis of completed cytokineses after CIN deregulation. 
(A) Time-lapse movie of a GBM6840 cell that is first spread on the culture dish, then rounds up in mitosis and finally 
divides into two daughter cells (arrows). 
(B) Quantification of the number of completed mitoses in DBTRG-05-MG, U87 and GBM6840, n=3 as shown in (A). 
Shown is the mean + SEM. 
A 
B B 
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5.15 Analysis of cell roundness and area on collagen IV 
In GBM6840 CIN shRNA cells that are grown on a glass surface, cell area increases as 
compared to the Ctl shRNA cells [48]. Therefore, it was tested if the cells show any 
differences in area or roundness under the conditions of the migration setup as used in 5.10. 
Cells were stained with fluorescently labeled phalloidin and then photographed with a Nikon 
Ti eclipse epifluorescence microscope and analyzed via automatic image analysis with 
ImageProPlus 7.0 as shown in Fig. 27 A, followed by manual inspection and correction of 
every picture. There were no differences in area or roundness after CIN deregulation in 
GBM6840 and U87 (see Fig. 27). At least 100 cells were analyzed for each condition. 
 
 
 
 
 
 
 
 
 
Figure 27: Analysis of glioma cell roundness and area on collagen IV. 
(A) GBM6840 cells were stained with phalloidin and then photographed with a Nikon Ti eclipse 
epifluorescence microscope and analyzed via automatic image analysis (cell border detection) with 
ImageProPlus 7.0 as shown in the right panel.  Cell area, width and length were determined from these 
processed images and the roundness was calculated for each cell. 
(B) Quantification of n=2 as shown in (A), CIN deregulation did not influence area or roundness on collagen IV 
in U87 or GBM6840 cells. Shown are means + SEM. 
A 
B 
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5.16 Analysis of cell adhesion after CIN knockdown 
Changes in adhesion to extracellular matrix (ECM) molecules affect cell migration in 2D and 
3D differentially [132], and cofilin phosphorylation is regulated by integrin dependent 
adhesion [133].  Therefore, it was tested if there were any differences in adhesion to 
different ECM molecules after CIN knockdown. Cells were stained with calcein AM, allowed 
to adhere for different time points to an ECM-coated 96-well plate, and then the 
fluorescence intensities were measured for each condition. The adhesion between CIN 
shRNA cells and Ctl shRNA cells was not different on fibronectin, collagen IV, vitronectin or 
collagen I. Only on poly-L-lysine after 40 minutes, the measured signals were higher in CIN 
shRNA cells as compared to control cells. Under the assay conditions used, the cells adhered 
faster to the ECM molecules collagen IV and fibronectin than to cell culture plastic or poly-l-
lysine alone (see Fig. 28 A). Interestingly, the cells adhered only very weakly to the 
vitronectin coated surface. CIN knockdown was checked for every experiment via routine 
western blotting (see Fig. 28 B). 
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Figure 28: Analysis of cell adhesion after CIN knockdown. 
(A) Measurement of fluorescence intensities of calcein AM stained GBM6840 cells. Cell adhesion was 
increased on fibronectin, collagen I and collagen IV coating as compared to cell culture plastic alone. 
However, CIN knockdown induced no significant change in cell adhesion on these coatings. 
(B) Representative western blot with α-CIN antibody, GAPDH was used as loading control.  
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5.17 Analysis of tumor growth in vivo 
The brain ECM is highly hydrated, and difficult to mimic in an in vitro setup [134]. 
Therefore, it is important to monitor cell growth and invasion of the glioma cells in vivo. For 
that purpose, GBM6840 cells were transduced with a construct that encodes a GFP-
Luciferase fusion gene. Then clones were selected that possessed a high GFP and adequate 
CIN Expression (see Fig. 29 A, B and C). The clones Ctl shRNA + pIRESNeo2 16, hereafter 
named control, CIN shRNA + pIRESNeo2 16, hereafter named knockdown and CIN shRNA + 
hCINΔshRNA//pIRESNeo2 41, herafter named add-back were used for the following 
experiments. Luciferase activities in the GBM6840 cell lines were: Control, 6.2 × 103 
photons/cell/sec; knockdown, 2.4 × 103 photons/cell/sec; add-back 7.6 × 103 
photons/cell/sec. 
10,000 cells were injected orthotopically into the brains of immunocompromised NOD-SCID 
mice by Prof. Dr. A-L. Sirén, and the growth of the cells was monitored by Dr. S. Kraus and 
Prof. Dr. A-L. Sirén in the center for experimental biomedicine.  
Although comparable numbers of cells were injected in each case, as reflected by 
comparable luminescence intensities on day + 1 after the injection, analysis of the 
luminescence intensities over time revealed that control cells and chronophin add-back cells 
grew much faster than knockdown cells (see Fig. 30 A and B). Statistical analysis of the log 
transformed data with a linear model revealed that there was a highly significant difference 
between chronophin knockdown and control cells in cell growth (linear model: 
Luminescence intensity ~ day + shRNA, p=7.7 x 10-6, n=7). Luminescence intensity was 
modeled against the factors day and shRNA, but interactions between day and shRNA were 
not included. This means that it was assumed that the effects of the factors day and shRNA 
are simply additive and no parameters were included in the modeling which would account 
for interaction between the factors shRNA and day, due to the fact that the number of 
samples (mice) was not sufficient for estimating this amount of parameters. No significant 
difference between control and chronophin add-back cells (linear model: Luminescence 
intensity ~ day + shRNA, p=0.982, n=7) was found. 
Histology revealed that most brains injected with control cells contained intraparenchymatic 
lesions. All control cell injected brains also contained tumor masses that were superficially 
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positioned on the brain. Both chronophin knockdown and chronophin add-back injected 
brains did not contain intraparenchymatic lesions at all (see Fig. 31 und Table 7). 
 
 
 
 
 
 
 
Figure 29: Characterization of GBM6840 clones for in vivo assays. 
(A) Flow cytometric analysis of GFP expression of the three clones used. There were comparable GFP-expression 
levels in the three GBM6840 cell lines. Luciferase activities in the GBM6840 cell lines were: Control, 6.2 × 103 
photons/cell/sec; knockdown, 2.4 × 103 photons/cell/sec; chronophin add-back, 7.6 × 103 photons/cell/sec.  
(B) Western blot with α-CIN antibody, GAPDH was used as loading control. 
(C) Quantification of n=2 as shown in (B). 
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Figure 30: Analysis of GBM6840 cell growth in vivo using bioluminescence imaging. 
(A) Representative pictures of mice injected with GBM6840 control, knockdown or chronophin add-back  cells. Shown 
is the same mouse, one from each condition, on day 1, 7, 11, 15 and 20 after tumor cell implantation. The 
luminescence intensity is shown in emitted photons per second. 
(B) Quantification of n=7 mice per condition as shown in (A). 
Control cells and add-back cells, the chronophin expressing cells, grew much faster than cells with a low chronophin 
expression, chronophin knockdown cells, during the observation period of 21 days. 
Figure 31: Analysis of GBM6840 cells in vivo with immunohistochemistry. 
(A) α-COX IV DAB-staining of a mouse brain injected with control cells. Only a superficial lesion is 
present (arrow). The α-COX IV antibody used recognizes specifically only human cells. 
(B) α-COX IV DAB-staining of a mouse brain injected with control cells. Several 
intraparenchymatic lesions are present (arrow). 
B 
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Table 7: Histology based scoring of the tumor lesions in the in vivo assay. 
Every tenth slide from each brain was stained with an antibody specifically staining only 
human COX IV as indicated in 4.6.5 and 4.6.6. If tumor cells were present on one slide, Yes is 
indicated in the tumor cells present column. 
Animal Injected cell type Tumor cells present Superficial tumor Intraparenchymatic lesion
51 Control Yes Yes Yes
54 Control Yes Yes Yes
64 Control Yes Yes Yes
65 Control Yes Yes No
66 Control Yes Yes Yes
67 Control Yes Yes Yes
68 Control Yes Yes Yes
69 Knockdown No No No
70 Knockdown No No No
73 Knockdown No No No
74 Knockdown No No No
55 Knockdown No No No
58 Knockdown No No No
72 Knockdown No No No
59 Add-back Yes Yes No
60 Add-back No No No
75 Add-back No No No
76 Add-back No No No
77 Add-back No No No
78 Add-back Yes Yes No
80 Add-back NA NA NA
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5.18 Microarray analysis after CIN deregulation in 
GBM6840 
To study the impact of CIN deregulation on transcription in GBM cells, RNA was isolated 
from GBM6840 Ctl shRNA, CIN shRNA and CIN shRNA + hCIN ΔshRNA expressing cells 
(hereafter named Rescue). CIN expression was tested via western blot. Then, RNA quality 
was analyzed and a microarray experiment was performed and analyzed by the microarray 
core facility in Marburg. The chips used were Agilent Human Genome vers. 2.0 Chips.  
Then, all deregulated genes (probe sets) in the comparison Ctl shRNA versus CIN shRNA with 
a logFC ≥ 0.6 were extracted, resulting in 4944 deregulated transcripts. Afterwards, the 
genes (probe sets) regulated in the opposite direction in the CIN shRNA versus Rescue assay 
with a logFC ≥ 0.6 were filtered out, leading to 194 probe sets (see Table 8). As expected, CIN 
was among the top hits in the array, but was not included in the further analyses.  
Under the assumption that the most highly deregulated transcripts in the publicly available 
datasets from patient samples contain potentially important genes, it was tried to identify 
transcripts regulated specifically by CIN which are involved in progression from a benign to a 
very malignant tumor entity. 
Therefore, the 194 probe sets were filtered against data sets that are available in the GEO 
database [135].  
The first microarray experiment compared GBM to normal brain tissue (GEO Accession GSE 
4290, [108]). All genes (Symbols) from this experiment were extracted that showed a logFC ≥ 
0.5 at an adjusted p ≤ 0.05 and were also contained in the 194 probe sets identified for 
control versus chronophin shRNA cells, yielding 40 genes (Symbols) that are marked with (*) 
in table 8. Only those genes were extracted that were downregulated after chronophin 
knockdown in GBM6840 as compared to control cells and downregulated in GBM tissue as 
compared to control tissue or upregulated after chronophin knockdown in GBM6840 as 
compared to control cells and upregulated in GBM tissue as compared to control tissue. 
Genes that were downregulated after chronophin knockdown but upregulated in GBM tissue 
as compared to control tissue or upregulated after chronophin knockdown but 
downregulated in GBM tissue as compared to control tissue were excluded. 
These 40 were then compared to a pilocytic astrocytoma versus GBM dataset that is 
available in the GEO database (GSE12657, unpublished), and all significantly deregulated 
genes deregulated in the same direction were extracted leading to two genes (see Fig. 32).  
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The two genes identified by this approach were EDIL3 and MXI1.  
The functional annotation of the 194 probe sets with DAVID [109,110] revealed that the 
most significantly affected cellular functions were cell proliferation, cell adhesion and cell 
migration (see Table 9). All those have been examined in GBM6840 cells after CIN 
deregulation previously in 5.9, 5.13 and 5.16, respectively. 
Significantly affected transcription factors were identified through the use of IPA 
(Ingenuity®Systems, www.ingenuity.com). Identified transcription factors at a p-value ≤ 0.05 
that were regulating the highest number of genes were SP1, p53, STAT3 and c-myc (see Fig. 
34). As cells with deregulated c-myc activity may contain different levels of total RNA [83], 
total RNA levels in GBM6840 Ctl shRNA and CIN shRNA were compared. These were not 
significantly different between Ctl shRNA and CIN shRNA cells (see Fig. 33)   
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Figure 32: Analysis of the transcriptomic changes after CIN knockdown. 
Analysis of the transcriptomic changes induced after CIN knockdown in GBM6840 that are potentially involved in 
disease progression and invasion. MXI1 and EDIL3 are the most promising candidate genes that are regulated by CIN. 
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Table 8: List of all 194 genes (probe sets) specifically regulated by CIN. 
Shown is the logFC CIN shRNA versus Ctl shRNA, the average expression in the first 
experiment and the logFC Rescue versus CIN shRNA, n=2.  
ID SYMBOL logFC CIN shRNA vs Ctl shRNA AveExpr logFC Rescue vs CIN shRNA 
A_23_P345808 FAM133A  (*) -2.32 6.97 1.93 
A_23_P54144 BMP4 -2.14 6.5 0.86 
A_33_P3243554 SEPT6 -2.06 5.75 0.90 
A_24_P280029 PDXP -1.71 9.78 2.19 
A_33_P3263902 MXI1  (*) -1.36 6.24 0.87 
A_33_P3364240 PAEP -1.35 10.87 0.67 
A_33_P3399453 CAPZA1 -1.34 11.68 1.09 
A_33_P3323975 NA -1.3 4.27 0.65 
A_33_P3255647 HNRNPH2 -1.24 9.18 0.81 
A_33_P3224858 EIF2AK2 -1.22 7.48 0.65 
A_24_P142118 THBS1 -1.21 13.16 0.92 
A_23_P404481 S1PR1 (*) -1.18 4.78 0.69 
A_33_P3418833 FLRT3 (*) -1.17 7.25 1.04 
A_24_P179044 SNX9 -1.16 7.97 0.89 
A_32_P191895 NA -1.11 8.24 0.68 
A_24_P944991 SREK1IP1 -1.09 7.32 0.77 
A_23_P354151 ITK -1.08 3.32 0.62 
A_24_P283928 OBFC2B -1.07 9.96 0.70 
A_24_P76649 GPRIN3 -1.04 3.98 0.65 
A_33_P3371493 TOP1 -1.03 8.99 0.87 
A_33_P3317988 CMPK1 -1 9.2 0.95 
A_23_P55020 CD300LF -0.99 3.49 0.75 
A_23_P160934 ANP32E -0.99 9.82 0.75 
A_33_P3364864 NAMPT -0.97 8.45 0.63 
A_24_P59220 POTEF -0.97 13.87 0.65 
A_33_P3383233 NDRG2 (*) -0.97 6.38 0.65 
A_33_P3415820 THBS1 -0.97 8.42 1.26 
A_23_P401606 EDIL3 (*) -0.96 7.53 0.78 
A_33_P3397298 NA -0.95 10.51 0.69 
A_33_P3231277 HIF1A -0.95 10.14 0.72 
A_24_P870620 PTN -0.95 5.63 0.73 
A_33_P3421733 EIF3CL -0.95 10.54 1.17 
A_23_P217015 SET -0.93 11.65 0.73 
A_33_P3362891 HNRNPA2B1 -0.93 12.22 0.84 
A_33_P3314031 TMEM154 -0.92 4.46 0.61 
A_33_P3314466 NA -0.92 7.59 1.02 
A_24_P942481 GPR180 -0.9 8.85 0.62 
A_33_P3259902 NA -0.89 12.91 0.74 
A_33_P3407618 LOC80154 -0.89 7 1.01 
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ID SYMBOL logFC CIN shRNA vs Ctl shRNA AveExpr logFC Rescue vs CIN shRNA 
A_24_P333326 CTAGE5 -0.89 6.35 1.02 
A_24_P6903 ACTBL2 -0.88 13.06 0.62 
A_23_P153583 PPP5C -0.88 9.36 0.70 
A_33_P3232294 ITPR2 -0.88 8.18 0.88 
A_24_P33444 YWHAE -0.88 10.45 1.02 
A_33_P3338539 NA -0.87 4.94 0.98 
A_33_P3287760 RASGEF1A (*) -0.86 4.39 0.68 
A_24_P201153 TJP2 (*) -0.86 9.95 0.77 
A_32_P810645 FLJ40288 -0.86 4.37 0.86 
A_33_P3301394 NA -0.85 12.85 0.82 
A_23_P200772 ZNF644 -0.85 10.18 1.12 
A_33_P3283992 ZNF671 -0.84 6.72 0.71 
A_33_P3238976 TRMT5 -0.83 12.67 0.66 
A_24_P381136 PACSIN3 -0.83 9.39 0.69 
A_24_P391260 PTTG1IP -0.83 10.09 0.72 
A_24_P182494 DUSP10 -0.83 6.25 0.77 
A_33_P3234859 UTRN -0.83 6.71 0.79 
A_23_P28420 OLA1 (*) -0.82 12.91 0.75 
A_24_P190541 BRWD1 (*) -0.82 8.04 0.76 
A_32_P199252 HSP90AA1 -0.82 14.07 0.84 
A_33_P3270776 HTRA3 -0.81 7.06 0.71 
A_33_P3276455 KDM5B -0.8 8.04 0.90 
A_33_P3393456 LOC100131129 -0.79 4.82 0.71 
A_33_P3323520 KIAA1826 -0.79 7.52 0.72 
A_24_P169574 LOC649395 -0.79 10.44 1.05 
A_24_P65616 PVR -0.77 11.96 0.62 
A_23_P379550 YARS -0.77 12.64 0.66 
A_33_P3280003 HERC2 (*) -0.77 6.19 0.87 
A_33_P3233105 NA -0.75 5.58 0.75 
A_24_P8454 SPAG9 -0.75 8.26 1.00 
A_33_P3258223 MCM7 -0.75 10.63 1.27 
A_33_P3325131 CANX -0.74 9.34 0.64 
A_33_P3267948 SLC25A23 (*) -0.74 8.16 0.72 
A_24_P294821 SYNJ2 (*) -0.74 6.7 0.72 
A_23_P60286 EIF4B -0.74 11.57 0.85 
A_33_P3348782 CYP2S1 -0.73 6.28 0.63 
A_23_P200310 DEPDC1 -0.73 12.16 0.76 
A_23_P373799 CWC22 -0.72 9.71 0.62 
A_24_P111134 POMT2 -0.72 9.65 0.65 
A_23_P70398 VEGFA -0.72 9.39 0.65 
A_24_P374445 C17orf57 -0.72 4.03 0.78 
A_33_P3281816 CAP1 -0.72 10.31 0.81 
A_33_P3314468 IMMT -0.72 8.43 1.02 
A_23_P4909 SNRNP70 -0.72 12.38 1.28 
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ID SYMBOL logFC CIN shRNA vs Ctl shRNA AveExpr logFC Rescue vs CIN shRNA 
A_33_P3260605 CTNNAL1 -0.71 11.68 0.69 
A_24_P341187 GBA2 (*) -0.7 9 1.04 
A_33_P3369371 GPX3 -0.69 8.15 1.00 
A_24_P392690 ANP32BP1 -0.68 12.79 0.64 
A_33_P3311750 CCDC144A -0.68 6.15 0.81 
A_33_P3333507 SENP7 -0.68 6.27 1.00 
A_33_P3371381 ANKDD1B -0.67 4.81 0.61 
A_24_P14932 WDR52 (*) -0.67 5.39 0.64 
A_23_P92349 FGFRL1 -0.67 10.38 0.68 
A_24_P97825 CCDC69 -0.67 6.46 0.69 
A_24_P156267 SOX12 -0.67 5.71 0.80 
A_23_P42507 PPIL4 -0.67 9.19 0.82 
A_33_P3236267 REXO1L1 -0.67 12.66 0.98 
A_23_P426636 AHNAK -0.67 10.35 1.13 
A_24_P128145 ATF2 (*) -0.67 7.09 1.22 
A_33_P3211633 WDR3 -0.67 6.6 1.29 
A_23_P20615 ANP32B -0.66 13.15 0.60 
A_24_P415845 LIG4 (*) -0.66 6.01 0.61 
A_24_P81965 RAP2A (*) -0.66 10.09 0.63 
A_33_P3242493 PIBF1 -0.66 6.46 0.67 
A_23_P96087 H1FX -0.66 11.45 0.99 
A_33_P3299656 RPGR -0.65 7.85 0.60 
A_32_P144908 ZNF254 -0.65 11.07 0.65 
A_33_P3224595 OFD1 -0.65 6.81 0.69 
A_23_P411806 SLC44A1 (*) -0.65 7.73 0.70 
A_33_P3332860 STX16 -0.65 8.74 0.75 
A_23_P152768 TUBG1 -0.64 11.32 0.61 
A_23_P71146 POLD2 -0.64 10.74 0.63 
A_23_P371876 ALKBH8 -0.64 8.06 0.65 
A_23_P203658 PICALM (*) -0.64 9.18 0.79 
A_24_P106953 PTGES2 (*) -0.64 11.06 0.86 
A_32_P180210 FAM35A -0.64 7.44 1.07 
A_23_P252764 SMARCA2 (*) -0.64 8.07 1.14 
A_24_P345846 ANTXR2 -0.63 8.1 0.61 
A_32_P217390 SPATA8 -0.63 5.27 0.65 
A_24_P816384 UBE2Q2P1 -0.63 6.59 0.66 
A_24_P26177 VPRBP -0.63 7.92 0.70 
A_24_P106363 MARVELD2 -0.63 3.67 0.70 
A_23_P125639 ZFX -0.63 6.24 0.74 
A_33_P3288110 PKP4 (*) -0.63 8.26 0.84 
A_32_P83465 NBPF10 -0.63 12.25 1.35 
A_33_P3272412 FLJ45482 -0.62 7.72 0.63 
A_33_P3212640 NOTCH2NL -0.62 5.07 0.68 
A_24_P384755 NOL10 -0.62 8.72 0.73 
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ID SYMBOL logFC CIN shRNA vs Ctl shRNA AveExpr logFC Rescue vs CIN shRNA 
A_24_P358381 GTPBP6 -0.62 9.49 0.87 
A_33_P3412613 TMPO -0.62 6.59 1.25 
A_33_P3211854 NA -0.61 3.91 0.60 
A_33_P3320277 MFN2 (*) -0.61 7.82 0.65 
A_33_P3289996 USP45 -0.61 7.32 0.65 
A_24_P99090 CKAP2 -0.61 8.41 0.70 
A_23_P203665 ACER3 (*) -0.61 6.89 0.76 
A_33_P3404701 SEL1L (*) -0.61 7.98 0.77 
A_33_P3380932 ZNF800 -0.61 7.81 0.96 
A_33_P3300893 MADD  (*) -0.6 10.12 1.03 
A_33_P3411204 GCNT2  (*) 0.6 8.68 -0.60 
A_24_P583040 C17orf67 0.62 7.51 -0.64 
A_23_P76332 RFX4  (*) 0.63 4.07 -0.79 
A_33_P3247331 KCNQ1  (*) 0.64 4.15 -0.76 
A_23_P133236 PCDHB14 0.64 8.74 -0.63 
A_23_P347525 PATE1 0.65 4.75 -0.66 
A_33_P3382276 NA 0.67 4.22 -0.70 
A_23_P356717 ANKS1B 0.67 4.31 -0.67 
A_23_P42868 IGFBP1  (*) 0.67 9.83 -0.65 
A_23_P387585 NCRNA00246 0.68 4.75 -0.67 
A_23_P88767 PLA2G10 0.69 4.9 -0.76 
A_23_P76234 RPH3A 0.69 3.94 -0.63 
A_24_P349117 GPR158 0.7 4.29 -0.88 
A_33_P3256391 CRB3 0.71 5.49 -0.60 
A_33_P3351536 PTK2B 0.72 6.31 -0.63 
A_33_P3216694 HIVEP3  (*) 0.73 5.08 -0.75 
A_33_P3299915 NA 0.74 4.52 -0.77 
A_23_P7901 TTLL2 0.76 3.94 -0.67 
A_23_P42189 SLC17A1 0.76 4.26 -0.60 
A_33_P3361102 CAMTA1  (*) 0.77 4.63 -0.71 
A_23_P143247 TSHZ2 0.79 4.92 -0.88 
A_23_P421401 PDGFRB  (*) 0.79 9.18 -0.61 
A_33_P3278122 NA 0.82 4.33 -0.68 
A_33_P3320648 NA 0.83 4.99 -0.76 
A_33_P3342797 LOC401442 0.83 4.23 -0.72 
A_33_P3230995 NA 0.83 4.57 -0.61 
A_33_P3345678 NA 0.86 4.42 -0.62 
A_33_P3330911 BCAS1 0.9 4.16 -0.62 
A_24_P929388 TMEM169 0.9 3.71 -0.61 
A_24_P187056 LOC375010 (*) 0.91 4.41 -0.63 
A_33_P3263307 RANGAP1 0.92 16.39 -0.82 
A_24_P254506 PAGE4 0.92 4.6 -0.61 
A_33_P3324730 C20orf173 0.95 4.37 -0.73 
A_23_P218442 CEACAM6 0.97 3.91 -0.96 
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ID SYMBOL logFC CIN shRNA vs Ctl shRNA AveExpr logFC Rescue vs CIN shRNA 
A_23_P98580 FADS2  (*) 0.97 12.15 -0.63 
A_33_P3229107 LOC642587 1 3.64 -0.66 
A_23_P218549 EMR3 1.04 4.88 -0.77 
A_23_P205348 TCL6  (*) 1.11 4.41 -0.67 
A_33_P3404974 OPN5 1.13 4.02 -0.88 
A_32_P206479 ZNF831 1.18 4.31 -0.68 
A_23_P23829 CD34 (*) 1.19 4.63 -0.81 
A_24_P945096 CACNA1I 1.23 4.31 -0.88 
A_33_P3317336 NA 1.23 4.45 -0.67 
A_24_P15325 NA 1.28 3.78 -0.63 
A_23_P31626 ODF1 1.29 3.91 -0.62 
A_33_P3384695 NA 1.32 4.1 -0.75 
A_33_P3272957 NA 1.37 3.68 -0.73 
A_32_P480330 EYS 1.39 3.62 -0.63 
A_33_P3326427 OR4A16 1.48 4.82 -0.84 
A_33_P3290477 ZNF648 1.61 3.98 -0.68 
A_23_P131676 CXCR7  (*) 1.62 4.01 -0.66 
A_24_P935491 COL3A1 (*) 1.66 5.07 -0.98 
A_33_P3388192 GTSF1 1.71 4.23 -0.61 
A_23_P21120 NA 2.12 3.31 -0.83 
A_33_P3324114 NCRNA00295 2.22 4.25 -0.63 
A_32_P86578 LOC389023 2.56 3.65 -0.65 
A_23_P106405 NDN 2.98 8.44 -0.74 
 
 
 
Table 9: Functional Annotation of targets using DAVID. 
Term No. Genes % of all genes p-Value 
GO:0042127 regulation of cell proliferation 16 9.14 0.0035 
GO:0007155 cell adhesion 12 6.86 0.0419 
GO:0022610 biological adhesion 12 6.86 0.0423 
GO:0008285 negative regulation of cell proliferation 9 5.14 0.0137 
GO:0016477 cell migration 8 4.57 0.0105 
GO:0051674 localization of cell 8 4.57 0.0180 
GO:0048870 cell motility 8 4.57 0.0180 
GO:0008284 positive regulation of cell proliferation 8 4.57 0.0702 
 
 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Quantification of total RNA levels in GBM6840.  
RNA content did not differ significantly between GBM6840 Ctl shRNA and CIN shRNA cells. 
Figure 34: Potentially deregulated myc targets in GBM6840 CIN shRNA cells as compared to Ctl shRNA cells. 
Myc targets are shown as predicted by IPA (Ingenuity®Systems, www.ingenuity.com). 
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5.19 Real-time PCR validation of microarray hits 
Several hits from the microarray list in table 8 were reexamined via quantitative real-time 
PCR. The downregulation of THBS1, VEGFA, MXI1 and EDIL3 in CIN shRNA compared to Ctl 
shRNA cells could be confirmed. For THBS1, VEGFA and EDIL3 a complete rescue of the 
expression level was achieved in CIN shRNA cells reexpressing CIN. The expression of MXI1 
was 1.5 x higher in the rescue cells as compared to the CIN shRNA cells, but remained at 
about 60 % as compared to Ctl shRNA expressing cells (see Fig. 35, n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Real-time PCR of selected target genes.  
Selected target genes from table 8 were validated by real-time PCR in GBM6840, n=3.  The downregulation of 
THBS1, VEGFA, MXI1 and EDIL3 in CIN shRNA compared to Ctl shRNA could be confirmed.  
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5.20 Luciferase screening assay 
To examine the transcriptional activity of cancer relevant pathways, a Cignal Finder 10-
Pathway Reporter Array Cancer was used that monitors the activity of the transcription 
factors myc/max , E2F/DP1, HIF1A, NFκB, p53, RBP-Jκ , SMAD2/3/4, Elk-1/SRF and TCF/LEF in 
parallel including a negative and positive control [102]. This assay was performed in 
GBM6840 cells in a medium containing 0.5 % FCS. The myc/max reporter was the only one 
that showed reproducible differences in CIN siRNA transfected cells as compared to Ctl 
siRNA transfected cells (see Fig. 36). The cells were transfected with siRNAs to exclude any 
artifacts that are potentially introduced by different transfection efficiencies between the 
different stable cell lines. The myc/max activity was increased after CIN knockdown (two-
tailed t-test, p=0.0687, df=4, n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Measurement of the activity of cancer relevant transcription 
factors in GBM6840. 
The myc/max reporter showed a reproducible increase in activity after 
CIN knockdown (n=3, p=0.0687). 
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5.21 C-myc luciferase reporter activity in medium 
containing 5 % FCS 
Myc belongs to the immediate early response genes after serum stimulation [136]. Due to 
the fact that the signals from the myc/max reporter were rather low in the assay described 
in 5.20, the assay was performed in medium containing 5 % FCS again. Here, the increase of 
reporter activity after CIN knockdown could be nicely reproduced. The mean of the renilla 
normalized firefly intensity was 0.067 ± 0.005 in Ctl siRNA transfected GBM6840 cells and 
increased to 0.11 ± 0.02  in CIN siRNA treated cells (two-tailed t-test, p=0.0643, df=4, n=3). 
Moreover, expression of hCIN in U87 led to a reduction of the intensity from 0.25 ± 0.03 in 
pCDNA3 transfected cells to 0.16 ± 0.02 (p=0.0695, df=4, n=3, see Fig. 37). No major 
difference was observed in the negative control samples (n=3). Interestingly, the 
endogenous c-myc protein level was significantly reduced after CIN knockdown (see Fig. 37 B 
and C). Moreover, after transfection of a plasmid encoding full length human c-myc, the c-
myc level was much lower in GBM6840 CIN shRNA cells (see Fig. 37 E and F). The CIN 
knockdown was verified via routine western blotting for every sample. 
Alltogether, the results from the microarray study and from the c-myc reporter assay 
pointed towards a deregulation of c-myc activity after deregulation of CIN expression.  
Higher reporter activity was measured in cells with lower CIN levels in U87 and GBM6840. 
However, the c-myc protein level was reduced in GBM6840 after CIN knockdown. 
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Figure 37: Analysis of myc/max reporter activity in medium containing 5 % FCS. 
(A) Myc/max reporter activity was increased after CIN knockdown in GBM6840, but decreased after hCIN  
reexpression in U87. 
(B) Representative western blot with α-CIN and α-c-myc antibody, α-Tubulin was used as loading control. 
(C) Quantification of n=3 as shown in (B). 
(D) Quantification of n=3 as shown in (B). 
(E) Representative western blot with α-CIN and α-c-myc antibody, ß-Actin was used as loading control.  
(F) Quantification of n=2 as shown in (E). 
(G) Quantification of n=2 as shown in (E). 
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5.22 Semiquantitative PCR for transcription factors that 
are deregulated after CIN knockdown according to 
ingenuity pathway analysis (IPA) 
As mentioned in 5.18, the transcription factors p53, SP1, STAT3 and c-myc were identified as 
potentially altered after CIN deregulation by IPA. Therefore, the expression of these 
transcription factors and in addition the expression of c-JUN was examined via 
semiquantitative PCR (see Fig. 38 A). Quantification revealed that none of the transcription 
factors undergoes major changes after CIN knockdown in GBM6840 Ctl shRNA cells 
compared to CIN shRNA cells on mRNA level (see Fig. 38 B).  
 
 
 
 
 
 
Figure 38: Analysis of transcription factor expression after CIN knockdown.  
(A) Representative ethidium bromide stained agarose gels showing PCR product abundance of p53, SP1, STAT3, 
c-JUN, c-myc and CIN. GAPDH was used as loading  control. 
(B) Quantification of n=3 as shown in (A). CIN is efficiently downregulated in CIN shRNA cells as compared to 
Ctl shRNA cells. There are no significant differences in the RNA levels of p53, SP1, STAT3, c-JUN and c-myc. 
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5.23 Meta-analysis of studies dealing with glioma invasion 
In 5.21, it was shown that CIN knockdown increased the reporter activity of a c-myc reporter 
construct. To examine if deregulated c-myc transcriptional activity can contribute to the 
invasiveness of glioma cells, an in silico analysis of glioma invasion studies was performed. In 
the last years, a couple of papers have been published that aimed to identify genes involved 
in glioma invasion by high throughput approaches, including microarrays, 2D PAGE and 
suppression subtractive hybridization (SSH) [137-140]. However, the identified genes 
showed little, if any, overlap. This problem has been reported in many other systems and a 
variety of high throughput studies, e.g. in c-myc dependent transcription profiles [83,84]. 
Despite the lack of a common target gene, it is possible that (a) common deregulated 
transcription factor(s) can be identified from the datasets. Therefore, the data sets were 
reexamined for common, altered transcription factors through the use of IPA 
(Ingenuity®Systems, www.ingenuity.com). 
For that purpose, four datasets were reanalyzed that specifically compare invasive with non 
invasive cell populations [113-116] (see Table 10). Due to the fact that fold changes were not 
available in every study, the transcripts were only assigned to two categories (up- or 
downregulated) in the invasive cell population. A logFC of 2 was arbitrarily assigned to the 
genes in the category “upregulated”, and a logFC of -2 was assigned to the genes in the 
category “downregulated” for IPA analysis. 
Then, the datasets were analyzed for common transcription factors identified to be altered. 
The only two hits that were present in every study, and that were accounting for at least ten 
percent of the identified genes, were c-myc and p53 (see Table 10). However, it should be 
noted that proteins well known to be involved in glioma invasion, like MMPs and integrins, 
were not present in the identified gene lists in [113-116]. 
Table 10: Meta-analysis of studies dealing with glioma invasion. 
Reference Approach Genes identified Mapped by IPA % MYC % MYC and p53
[113] Microarray 25 21 33 48
[114] SSH 18 16 38 56
[115] 2D PAGE 18 17 24 41
[116] Microarray 118 92 15 33  
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6. Discussion 
6.1 Regulation of cofilin phosphorylation in GBM 
Receptor tyrosine kinases (RTKs) are frequently altered in GBM via mutation or 
overexpression [21]. Their signaling boosts cell proliferation and survival of cancer cells. In 
addition, RTKs influence actin dynamics and are therefore important initiators of cell 
migration and invasion [34]. In contrast to the RTKs and PI3K, for which a wealth of literature 
is available dealing with their involvement in glioma invasion, much less is known about their 
downstream effectors in the signaling to the actin cytoskeleton. 
The actin regulatory protein cofilin has been mainly examined in breast cancer cells for its 
contribution to cell migration, invasion and metastasis [46]. Some studies have found an 
association of increased cofilin phosphorylation levels with increased invasion in glioma cells 
[141,142]. In a previous thesis from our laboratory, it was shown that proteins that regulate 
cofilin phosphorylation are deregulated in gliomas. The kinases LIMK1 and LIMK2 that 
mediate cofilin phosphorylation are strongly upregulated, whereas the cofilin phosphatase 
CIN is strongly downregulated in GBM tissue on protein level as shown by western blotting 
[48].  
A concentration dependent motility response to cofilin in glioma cells has been described in 
a 2D in vitro setup. Here, U373 cell clones stably transfected with a cofilin encoding plasmid 
were examined for their motility and cofilin expression on protein level. Clones with 
intermediate cofilin expression levels, about 4.5 x above the wild type level, showed the 
highest motility. In clones expressing cofilin more than 7 x above the wild type level, the 
motility was only slightly higher than in the control cells [70]. A study that compared the 
transcriptional profiles of primary rat astrocytes and C6 rat glioma cells by serial analysis of 
gene expression, to identify markers for glioblastoma growth and motility, has found cofilin 
to be overexpressed in C6 cells [143]. 
Recently, it was shown that cofilin activity may be linked to glioma invasion in vitro and in 
vivo. In this study, the effects of overexpression of a constitutively active cofilin mutant on 
migration in 2D and invasion were analyzed [69]. In contrast, cofilin has not been found to 
be altered on mRNA or protein level in GBM [48]. Furthermore, the data available in the 
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Rembrandt database also did not show altered cofilin mRNA expression levels in glioma 
samples compared to normal brain tissue (this study). Fig. 39 summarizes the most 
important changes in the signaling towards cofilin as mapped by Rembrandt [107]. EGFR and 
PI3K are frequently mutated in GBMs, whereas for the other shown genes no mutations are 
known. EGFR and PI3K signaling are activated in a substantial amount of GBM samples [21]. 
The upregulated LIMK2 and ROCK1 have already been linked to increased invasion [41]. 
Interestingly, the highly upregulated RhoC has been found to be a driver for invasion and 
metastasis in breast cancer and melanoma [144-146], although the role of Rho family 
proteins in glioma invasion is controversially discussed [147]. ROCKs are predicted to bind 
especially efficiently to RhoC, which is also a potent ROCK activator [148]. The upregulation 
of cofilin kinases and the loss of CIN expression are commonly found in astrocytic tumors 
[48].   
Therefore, the consequences of a pathophysiological deregulation of cofilin phosphorylation, 
via altered CIN expression, was analyzed here.  
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Figure 39: Changes in proteins regulating cofilin phosphorylation as mapped by Rembrandt.  
EGFR and PI3K are frequently mutated in GBMs, whereas for the other genes shown no 
mutations are known. RhoC, ROCK1 and LIMK2 are strongly upregulated, whereas CIN is 
strongly downregulated on mRNA level. Shown are the logFC values for the comparison GBM 
tissue versus normal brain together with the gene symbols. 
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6.2 Actin and P-cofilin phenotypes 
Upon shRNA-mediated chronophin depletion, the p-cofilin level underwent major changes 
only in GBM6840 cells, whereas the phenotype in U87 and DBTRG-05-MG cells were rather 
mild. The cells were grown to high density and starved for these assays, to closely mimick 
the situation of the transwell setup, in which a strong phenotype was present in all cell lines 
after CIN deregulation.  
Consistent with decreased actin dynamics upon elevated cofilin phosphorylation due to CIN 
loss, total F-actin levels were increased after CIN knockdown in GBM6840. Conversely, total 
F-actin levels strongly decreased upon CIN reexpression in U87 cells, as determined by flow 
cytometry of phalloidin stained cells. In addition, the F/G-actin ratios increased after CIN 
knockdown in GBM6840, but decreased after CIN expression in U87 as determined in the 
spin down assay. As both assays showed a strong phenotype in GBM6840 and U87 (see Fig. 
17 and 18), it is likely that altered dynamics of the phosphocycling of cofilin are more 
important than absolute phosphocofilin levels for the regulation of the actin cytoskeleton. 
Among the growth factors tested, only activation of RhoA via LPA stimulation was able to 
increase phosphocofilin levels substantially (see Fig. 15 H and I). Or in other words, only 
stress fiber build up, but not induction of lamelliopdia or filopodia was associated with 
increased levels of phosphocofilin. That fits well to the observation that CIN knockdown 
induces F-actin accumulation in the cytoplasm and/or at the ventral membrane. 
Interestingly, the increased cofilin phosphorylation in GBM6840 was accompanied by an 
increase in RhoA activity in GBM6840 cells (see Fig. 14 and 15). There are two possibilities 
that can explain this phenomenon. First, in addition to its function as a cofilin phosphatase 
downstream of Rho-ROCK signaling, CIN may have a role in the upstream regulation of RhoA. 
Rho activity is tightly regulated by numerous GEFs and GAPs, which are in turn often 
regulated by phosphorylation [149]. Therefore, CIN dependent dephosphorylation of a GAP 
or GEF could be the reason for the difference in basal RhoA activity. 
It is also possible that there is a positive feedback loop between increased cofilin 
phosphorylation and/or changes in protrusive activity and RhoA activity. In PC-3 cells, 
inhibition of ROCK1 activity by siRNA mediated knockdown or chemical inhibition with 
fasudil leads to an increase in Rac-GTP levels but to a decrease in RhoA-GTP levels. The 
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fasudil induced decrease in RhoA activity is dependent on the presence of both Rac1 and 
Tiam1, a Rac GEF [150]. A positive feedback loop between RhoA and ROCK signaling might 
be present in glioma cells on the cellular level, although the molecular mechanism has to be 
different due to the fact that there was no change in Rac protein level and activity after CIN 
knockdown in GBM6840 cells. 
A feedback regulation between Rac and Rho proteins is also known from fibroblasts, where 
activation of Rac downregulates RhoA activity [151]. Until now it was not examined if 
changes in cofilin phosphorylation could also be part of the feedback between RhoA, Rac 
and ROCK, because cofilin is also a Rac signaling effector.  
Although primarily focusing on adhesion, it was reported that altered cytoskeletal tension 
can regulate RhoA activity [152]. CIN knockdown increased cofilin phosphorylation levels in 
GBM6840 (see Fig. 14). Cofilin competes with myosin for F-actin binding [153]. Therefore, 
increased cofilin phosphorylation potentially increases myosin association with actin and 
cytoskeletal tension, which could lead to elevated RhoA activity. 
In a study that examined ruffle formation and migratory behavior of human keratinocytes on 
different surfaces, it was found that differences in protrusive activity go hand in hand with 
changes in small GTPase activity. It was found that RhoA activity was highest under 
conditions that supported optimal cell substrate adhesion and lamellipodial persistence 
[154]. Although no obvious change in lamellipodia size or number occurred in CIN shRNA 
cells, it was not examined if protrusive persistence is altered. Protrusion persistence is the 
best indicator of 3D migratory behavior [155]. However, in epithelial cells the increase in 
RhoA activity is accompanied by changes in ruffle formation and Rac activity [154], and there 
were no global cellular changes in Rac activity measurable in GBM6840 cells after CIN 
knockdown (see Fig. 15 A). This suggests that the molecular mechanism for RhoA activation 
in GBM6840 cells is different from the one reported for keratinocytes. 
U87 cells overexpressing hCIN showed no reduction in RhoA-GTP levels (see Fig. 15 C). 
Therefore, the cellular background and the presence of other regulatory proteins might be 
important for CIN regulation of RhoA activity in U87 compared to GBM6840 cells. U87 cells 
were established from a grade IV astrocytoma that occurred in a male individual, whereas 
GBM6840 cells were established from a GBM that occurred in a young female individual. It is 
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not known to which molecular GBM subtype the original tumors belonged. Therefore, the 
molecular characteristics of the two cell lines can be quite different. 
That CIN downregulation leads to an accumulation of F-actin has been described previously 
[48].  This study has added a quantification of the observed phenotype via flow cytometry 
and actin spin down assays to the previous results (see Fig. 17 and 18). Moreover, through 
the use of the ROCK-inhibitor Y-27632 and hCIN overexpressing cells, important evidence for 
the CIN and phosphocofilin specificity of the observed phenotypes was collected.  
The observed phenotype on the actin level, the loss of stress fibers (see Fig. 20) , fits well to 
already published data after ROCK-inhibition in glioma cells [68]. 
An increased invasiveness after CIN knockdown has been described  in GBM6840 [48]. This 
study extends the finding to two other cell lines, U87 and DBTRG-05-MG. Through 
examination of U87 cells reexpressing CIN, and through expression of a RNAi-resistant CIN 
construct in GBM6840, further evidence in support of the specificity of the observed 
phenotype was generated (see Fig. 23 D, E and F). 
As both ROCK-inhibitor treatment and expression of a constitutively active cofilin mutant 
were able to normalize invasion back to control levels, at least in GBM6840, the migration 
and invasion phenotype depended on increased phosphorylation of cofilin (see Fig. 23 J and 
K). 
Changes in cofilin phosphorylation have a significant impact on actin dynamics, and can 
therefore change serum response factor activity [122]. The SRF is a widely expressed 
transcription factor that controls mitogen-activated genes, among them many cytoskeletal 
genes, and muscle specific target genes. Its activity is regulated, among other mechanisms, 
by cellular G-actin binding to its coactivator MAL [122]. SRF has already been published to be 
important for invasive behavior of glioma cells, in a study that showed that SRF knockdown 
in A172 cells reduces their invasive potential, and that SRF positively regulates the 
transcription of RTVP-1, which is a proinvasive gene [156].  
LIMK activity is needed both for SRF activity and for cellular invasion [121]. Therefore the 
hypothesis was tested if CIN induced cell invasion is also accompanied by an increase in SRF 
activity. 
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However, SRF activity was reduced after CIN knockdown (see Fig. 19). Lower levels of G-
actin, which were indeed observed after CIN depletion, are actually expected to increase SRF 
activity [122], as does LIMK expression [157] . However, the reporters used in the studies on 
LIMK are different from the reporter used in this study. The commercially available reporter 
used here contains a TRE of serum response elements, and is validated only for the serum 
and growth factor dependent MAPK/ELK-1 mediated stimulation of transcription that is an 
alternative activation mechanism in contrast to MAL activation of SRF. The reporter used in 
the LIMK study contains the 3D.ACAT promoter as described in [158], and has been 
extensively used in the study of actin dependent regulation of SRF activity [157]. It is 
possible that an increase in MAL dependent activation leads to a decrease in activity in the 
MAPK dependent transcriptional element, what might explain the observed results.  
Furthermore, the exact nature of the actin pool mediating the SRF regulation is not known. It 
would be interesting to examine the nuclear actin concentrations in CIN shRNA cells 
compared to Ctl shRNA cells. 
Therefore, due to the technical differences in the methods used, the involvement of SRF 
activity in the invasive process needs further investigation. 
 
6.3 Migration and invasion 
Cofilin [46,117] as well as the LIMKs [127,159,160] have been shown to be important 
regulators of migration and invasion in 3D culture systems and in vivo models. 
In 2D culture conditions, some cells show no migratiory phenotype after altered cofilin 
phosphorylation as has been reported for immune cells [161] as well as fibroblasts [51]. In 
contrast, in these studies strong phenotypes in 3D culture conditions, like the matrigel 
system, were observed. 
It was also reported that actin itself plays only a minor role in the 2D motility of glioma cells 
[118]. Although the treatments applied in this study were rather drastic, it is important to 
note that 2D motility in glioma cells might be less dependent on F-actin than in other 
systems, which would nicely explain the rather mild phenotypes found in this study. 
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Other studies have found a significant impact of cofilin expression levels on the 2D migratory 
behavior of cancer cells.  More specifically, a cofilin knockdown increases speed and 
directionality in metastatic breast cancer cells, the Mtln3 cells. [117]  In the same cells, 
expression of the kinase domain of LIMK1 abolishes protrusion and reactivity towards EGF 
[124].  
For CIN, this is the first study that describes a migratory phenotype after CIN deregulation 
under 2D culture conditions. This phenotype nicely fits to the results of the transwell system. 
In contrast to other studies dealing with glioma cell invasion [162,163] a decrease in the 
speed under 2D migration conditions was correlated with an increase in matrigel invasion in 
transwell assays (see Fig. 22 and 23).  One explanation for this observation is that the 
different conditions examined in these reports [162,163], malignancy grade and response to 
growth factor stimulation, are different from the actin regulatory pathway affected in CIN 
depleted glioma cells. Importantly, a recent report has also found a decrease in 2D motility 
and an increase in invasiveness after manipulation of actin regulatory proteins. It was found 
that knockdown of the SCAR/WAVE complex in A431 squamous carcinoma cells strongly 
decreases their migration in a wound healing assay, but promotes their invasion into 
matrigel via N-WASP activation. This leads to the conclusion that the actin machinery is 
utilized differently in 2D and 3D migration [164].  
Increased invasion in 3D but a decreased speed in 2D can also be explained by increased 
force build up through cancer cells by a more stable actin cytoskeleton. 
Increased actomyosin contractility is present after ROCK overexpression in melanoma cells 
[65], and ROCK also plays a role in cancer initiation and progression [165]. A decrease in 
actomyosin contractility after the treatment of GBM6840 cells with Y-27632 could be 
responsible for the decrease in invasion observed. 
In line with an elevated ROCK activity, increased cofilin phosphorylation can lead to an 
increase in actomyosin assembly, and force build up [153]. This mechanism could be of 
crucial importance in the brain, as the brain ECM is highly hydrated, and may be more 
susceptible to deformation by cancer cells than other tissue barriers [134].  
Importantly, inhibitors for both ROCKs and LIMKs are available [166,167], and LIMK 
inhibitors have been shown to inhibit glioma cell invasion in vitro recently [168]. 
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6.4 In vivo studies 
In the orthotopic implantation model that was used here, a significant growth delay could be 
detected after CIN downregulation in GBM6840 in vivo (see Fig. 30).  
Slower growth is associated with increased invasion in glioma [169,170]. It is possible that in 
addition to that a reduction of angiogenesis through transcriptional silencing of VEGFA and 
the loss of c-myc protein expression (see Fig. 35 D and 37 F) contributed to the growth 
reduction in vivo.  
However, no intraparenchymatic lesions could be detected in CIN knockdown or rescue cell 
injected animals (see Fig. 31 and Table 7), and neither angiogenesis nor stem cell properties 
could be examined in the xenografts in CIN knockdown and rescue cells. It is possible that 
the numbers of the injected cells were too low to allow observation of invasiveness during 
the observation period, as cell numbers can greatly influence the outcome in an 
implantation experiment [171]. 
It is also possible that the cells have lost their potential to form invasive lesions in vivo by an 
off target or integration effect of the shRNA construct used. It would be very interesting to 
create other CIN shRNA knockdown cell lines with different shRNAs and to analyze them in 
vivo and to inject higher cell numbers. It would be also very interesting to see if other CIN 
knockdown lines show a specific growth retardation in vivo, as in vitro assays under 2D 
culture conditions did not yield any evidence for differences in proliferation after CIN 
deregulation. However, the cells might proliferate differentially under 3D culture conditions 
and not under 2D conditions in vitro, as has been reported in other systems [172,173].  
 
 
6.5 Transcription 
The analysis of the glioma cell transcriptome has identified two CIN specific regulated 
transcripts, EDIL3 and MXI1, which are potentially involved in disease progression and 
invasion (see Table 8 and Fig. 32). The hits from the microarray analysis could be nicely 
verified in an independently harvested set of RNAs via real-time quantitative PCR (see Fig. 
35). Interestingly, a negative regulator of c-myc dependent transcription, MXI1, is 
downregulated upon CIN depletion in GBM6840. MXI1 is known to be a regulator of 
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differentiation and tumorigenesis [174]. On the other hand, c-myc protein levels were 
reduced after CIN depletion (see Fig. 37), suggesting a complex relationship between CIN 
expression and c-myc activity. Overall, the measured activity of the c-myc reporter construct 
was higher after CIN depletion, which might indicate that the effect of the loss of MXI1 
expression overrides the effect of c-myc protein reduction in vitro (see Fig. 37). 
The phenotypes in the c-myc reporter assays in GBM6840 and U87 were rather mild, but 
seemed to be CIN specific. Moreover, c-myc was identified by IPA as one of the significantly 
altered regulators of transcription (see Fig. 34). MXI1 has been reported to act as a tumor 
suppressor in glioma cells [92], and influences the growth of glioma cells in vitro and in vivo 
[175,176]. Therefore, despite the rather small differences in reporter activity, these 
phenotypes might be highly relevant for glioma initiation and progression induced by CIN. It 
has to be taken into consideration that promoters containing E-Boxes, like the ß-Thymosin 
promoter, can also have overlapping binding sites for other transcription factors like AP2 and 
it is possible that the E-Box reporter used is not completely c-myc specific [177]. 
As myc/max activity could be reduced by expression of CIN in U87 cells (see Fig. 37), it would 
be very interesting to check if MXI1 is upregulated by CIN expression in this cell line. 
Additionally, detailed studies of mRNA- and protein-levels of MXI1 and c-myc are needed in 
GBM6840 and U87, to clarify the role of chronophin in myc regulation in glioma. As 
phosphorylation on Threonin 58 and Serine 62 influences myc stability and regulates myc 
dependent transcription, it would be interesting to quantifiy the levels of these 
phosphoproteins in the two cell lines.  
A possible functional role for MXI1 in glioma initiation is its impact on mitochondrial 
biogenesis, which is mediated via HIF-1 signaling [178]. It would be promising to 
reinvestigate the observed phenotypes under hypoxia, due to the fact that CIN has also been 
reported to be regulated by cellular ATP levels [80], and to measure mitochondrial 
biogenesis after CIN deregulation. 
It would also be possible to measure myc-reporter activity after treatment of cells with 
ROCK- and LIMK-inhibitors, to determine if the observed phenotypes are cofilin specific. 
A meta-analysis of different studies on glioma invasion identified c-myc and p53 as 
significantly altered transcription factors in all studies analyzed (see Table 6). There were 
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some contradictionary results regarding the question if c-myc activity is enhanced or 
inhibited. A reason for this discrepancy could be the small number of genes identified in 
some studies. 
Recently, the upregulation of p53 and downregulation of c-myc activity have been reported 
to be correlated with motility in glioma cells. In addition, it was shown that c-myc 
downregulation by siRNA knockdown increases migration and slows down growth of GBM 
cells in vitro [179]. 
Until now there is only limited information on the impact of c-myc on glioma invasion. Myc 
has been reported to be overexpressed in glioma [89], and has a significant impact on tumor 
initiation [91,180] and stem cell renewal in this tumor [90].  
However, there are numerous studies on the pro-and anti-invasive roles of c-myc in other 
cancers [181,182]. 
In medulloblastoma, silencing of THBS1 is important for the c-myc mediated invasion [183].  
THBS1 was downregulated in CIN knockdown cells in the microarray experiment, too. 
CIN has previously been linked to c-myc regulation [75]. It was identified together with PP1 
and PP2A in a screen for phosphatases that regulate nuclear receptor coactivator / steroid 
receptor coactivator 3 (NCOA3/SRC-3) activity. HEK293T cells expressing NCOA3 and 
estrogen receptor were transfected with a phosphatase library and screened for differences 
in NCOA3 phosphorylation. CIN was identified as important negative regulator of NCOA3 
activity, and found to influence the hormone dependent expression of NCOA3 target genes 
[75]. However, the mechanism of CIN dependent myc regulation in this published report and 
in the present study has to be different. In the previous study c-myc is upregulated after CIN 
knockdown and estrogen stimulation. C-myc is a known target gene of estrogen receptor 
signaling and NCOA3. In the system examined, CIN, and other phosphatases, function as 
negative regulators of NCOA3 coactivation by dephosphorylation. Therefore, the induction 
of c-myc mRNA after estrogen stimulation is increased after CIN knockdown. In GBM6840, 
there was no alteration in c-myc expression on mRNA level after CIN knockdown, but a 
decrease on protein level. 
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P-cofilin might be the mediator of c-myc regulation, as RhoA induced cytoskeletal 
rearrangements have been shown to be connected to c-myc activity in NIH3T3 fibroblasts. 
Here, overexpression of c-myc was able to reduce the F-actin content in NIH3T3 fibroblasts 
that were transformed with the oncogenic RhoAQ63L mutant [93]. 
It has been reported that increases in LIMK expression, and therefore cofilin 
phosphorylation, can alter STAT3 activity and c-myc expression. LIMK1 overexpression in 
keratinocytes leads to a reduction in c-myc protein levels. Moreover, expression of a cofilin-
S3A construct together with LIMK1 is able to rescue the c-myc protein level, and chemical 
inhibition of ROCK by Y-27632 treatment results in an increase in c-myc protein. Both Y-
27632 and expression of S3A cofilin are able to increase STAT3 phosphorylation on tyrosine 
705 [94]. The reduction of c-myc protein following increased cofilin phosphorylation is in line 
with the finding that c-myc levels were reduced on protein level in GBM6840 after CIN 
depletion.  
Another possible mechanism by which cofilin phosphorylation could influence c-myc activity 
is via MYCBP. MYCBP has been found in a yeast two hybrid screen as interaction partner of 
cofilin, as reported in the STRING database. It is possible that altered cofilin phosphorylation 
via CIN impacts cofilins interaction with MYCBP and influences transcription. 
 
A kinase that can induce both c-myc degradation and cofilin phosphorylation is GSK3ß. 
In neutrophils, GSK3ß increases cofilin phosphorylation via inhibition of SSH2 [184] and 
GSK3ß is well known to phosphorylate c-myc on Threonin 58, targeting it for degradation 
[185]. 
Interestingly, the transcription of GSK3ß is upregulated in mice fed with a vitamin B deficient 
diet, linking CIN that is a phosphatase for active vitamin B6, to the transcriptional regulation 
of GSK3ß [186]. Therefore, study of GSK3ß mRNA and protein levels might provide a 
mechanistic insight into the regulation of both molecules. However, it has to be mentioned 
that CIN depletion should lead to an increase in active vitamin B6, and therefore to a 
reduction of GSK3ß activity, if the regulation is according to [186]. 
Due to the fact that MMP2 and uPA/uPAR expression have already been linked to altered 
cofilin phosphorylation, it was examined if these proteins are deregulated after CIN 
knockdown. In GBM6840, only a mild upregulation of uPAR was detected. This upregulation 
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was not present in DBTRG-05-MG and U87 cells. It is possible that the upregulation of uPAR 
contributed to the invasive phenotype of GBM6840 CIN shRNA cells. However, because 
DBTRG-05-MG and U87 cells had a strong phenotype in the transwell assay, uPAR 
upregulation was not the only factor that contributed to increased invasiveness after CIN 
knockdown. 
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7. Summary 
Glioblastomas, primary brain tumors, represent a tumor entity with a dismal prognosis and a 
median survival of only about one year. Invasion into the healthy brain parenchyma 
contributes substantially to the malignancy of this type of brain tumor. Therefore, a better 
understanding of the mechanisms promoting the invasive behavior of these brain tumors is 
needed to identify new therapeutic targets.  
Cofilin, an actin regulatory protein, has been shown to be an important regulator of the 
invasive behavior of tumor cells in other types of cancer and the actin cytoskeleton is 
involved in the formation of a variety of cellular structures important for cell migration and 
invasion. Cofilin is regulated by phosphorylation on a single residue, serine 3. The aim of this 
thesis was to examine the role of the cofilin regulatory phosphatase chronophin for glioma 
cell migration and invasion.  
First, it was established that chronophin depletion in the cell line GBM6840 leads to an 
increase in the ratio of phosphorylated cofilin to total cofilin. Higher chronophin levels were 
correlated with a decrease in F-actin in the cell lines GBM6840 and U87 as measured in an 
actin spin down assay and in a flow cytometry based assay. 
Furthermore, it was shown that knockdown of chronophin in two different cell lines, 
GBM6840 and DBTRG-05-MG, strongly increased their invasiveness in vitro. Expression of 
human chronophin in the cell line U87 decreased its invasiveness substantially. There was no 
difference in cell proliferation between GBM6840 and DBTRG-05-MG cells expressing a 
chronophin targeting shRNA or a control shRNA and U87 cells transfected with an empty 
vector or a human chronophin encoding plasmid. The increase in invasiveness after 
chronophin depletion could be correlated with an increase in directionality in cell migration 
under 2D culture conditions in the cell lines U87 and GBM6840. Moreover, treatment with 
the ROCK inhibitor Y-27632 decreased directionality in GBM6840 cells under 2D culture 
conditions and reduced the invasiveness of GBM6840 chronophin shRNA cells back to 
control levels. 
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Expression of a non-phosphorylatable cofilin mutant, the S3A mutant, was able to reduce 
invasiveness and to reduce directionality under 2D culture conditions back to control levels 
in GBM6840 chronophin shRNA cells. 
This provides important evidence for the involvement of cofilin phosphoregulation in the 
phenotypes described above.  
In vivo, when injected into NOD-SCID mice, chronophin depleted cells showed a dramatic 
growth reduction as compared to control and rescue cells.  
Transciptomic characterization of GBM6840 cells by microarray analysis and subsequent 
comparison of the data with microarray profiles of normal brain tissues and different glioma 
entities identified two specifically chronophin regulated transcripts potentially involved in 
tumor progression and invasion, MXI1 and EDIL3. Moreover, c-myc was identified as a 
significantly altered transcription factor after chronophin deregulation based on the number 
of c-myc target molecules in the microarray dataset. 
MXI1 is a potential negative regulator of c-myc dependent transcription, and was strongly 
downregulated after chronophin knockdown in GBM6840. In line with this, the activity of a 
c-myc reporter plasmid was increased after chronophin depletion in GBM6840 and reduced 
after chronophin expression in U87 cells.  
However, the protein level of the c-myc protein was reduced after chronophin depletion in 
GBM6840.  
Finally, anaylsis of the expression of proteases known to be important for glioblastoma 
pathogenesis revealed no major changes in protease expression between chronophin 
depleted and control cells. 
Therefore, a comprehensive analysis of chronophin in the context of glioma pathogenesis 
has been performed in this thesis. It has been shown that chronophin depletion strongly 
enhanced invasiveness of glioma cells and that it induced transcriptomic changes potentially 
involved in tumor progression. The proteins regulating cofilin phosphorylation are therefore 
valuable therapeutic targets for anti-invasive therapy in glioblastomas. Inhibitors for kinases 
upstream of cofilin, e.g. LIMKs and ROCKs, are available, and might be promising agents for 
anti-invasive therapy.  
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8. Zusammenfassung 
Glioblastome sind primäre Gehirntumore, die eine besonders schlechte Prognose besitzen 
und bei denen die mediane Überlebenszeit nur ca. ein Jahr beträgt. Zur Malignität dieses 
Tumortyps trägt entscheidend das Eindringen der Tumorzellen in das gesunde 
Hirnparenchym bei. Daher ist es notwendig die molekularen Mechanismen zu verstehen, die 
diesem Phänomen zu Grunde liegen, um neue therapeutische Zielmoleküle zu identifizieren.  
Cofilin, ein Protein das das Aktinzytoskellet reguliert, ist in anderen Krebsarten als wichtiger 
Regulator des invasiven Verhaltens von Zellen bekannt und das Aktinzytoskellet ist an der 
Bildung einer Vielzahl von zellulären Strukturen beteiligt, die wichtig für die Zellmigration 
und –invasion sind. Cofilin wird über die Phosphorylierung einer einzigen Aminosäure, des 
Serin 3, reguliert. Das Ziel dieser Arbeit war es, die Rolle der Cofilin regulatorischen 
Phosphatase Chronophin für Zellmigration und -invasion zu untersuchen.  
Zuerst konnte gezeigt werden, dass eine Chronophin Depletion in der Zelllinie GBM6840 zu 
einer Zunahme des Anteils von P-Cofilin am Gesamtcofilin führt. Ebenso war ein hohes 
Chronophin Level in den Zelllinien GBM6840 und U87 mit einer Abnahme des F-Actin Levels 
korreliert, was in einem Aktin spin down Assay als auch mittels Durchflusszytrometrie 
gemessen werden konnte.  
Es konnte weiter gezeigt werden, dass eine shRNA vermittelte Depletion des Chronphin zu 
einer starken Zunahme der Invasivität in den Zelllinien GBM6840 und DBTRG-05-MG in vitro 
führt. Chronophin Expression in der Zelllinie U87 führte zu einer starken Abnahme der 
Invasivität. Es gab hingegen keinen Chronophin abhängigen Unterschied in der Proliferation 
von GBM6840 und DBTRG-05-MG Zellen, die entweder eine Kontroll- oder eine Chronophin 
gerichtete shRNA exprimierten, sowie keinen zwischen U87 Zellen, die mit einem Leervektor 
oder einem Chronophin codierenden Konstrukt transfiziert worden waren. Die Zunahme der 
Invasion nach Chronophin Depletion konnte mit einer Zunahme der Direktionalität der Zellen 
bei der Migration in einer 2D Umgebung korreliert werden. Desweiteren konnte durch 
Behandlung mit dem ROCK-Inhibitor Y-27632 in GBM6840 Zellen eine Erniedrigung der 
Direktionalität bei der Migration in 2D Kultur ebenso erreicht werden, wie eine Reduktion 
der Invasivität von Chronophin shRNA exprimierenden GBM6840 Zellen auf Kontrollniveau. 
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Die Expression einer nicht-phosphorylierbaren Cofilin Mutante, der S3A Mutante, 
erniedrigte sowohl die Direktionalität in der 2D Migration als auch die Invasivität von 
GBM6840 Chronophin shRNA exprimierenden Zellen zurück auf Kontrollniveau. 
Diese Experimente lieferten wichtige Hinweise darauf, dass die Phosphoregulation von 
Cofilin ursächlich an der Entstehung der Phänotypen beteiligt war, die nach Chronophin 
Knockdown beobachtet wurden.  
In vivo konnte nach Injektion in NOD-SCID Mäuse eine dramatische Wachstumsreduktion der 
Chronophin depletierten Zellen gemessen werden.  
Durch Charakterisierung des Transkriptoms der Zelllinie GBM6840 mittels Microarrays und 
nachfolgender Vergleich der Ergebnisse mit Microarray-Profilen von Normalhirngewebe und 
verschiedenen Gliomentitäten konnten zwei spezifisch Chronophin abhängig regulierte 
Transkripte identifiziert werden, MXI1 und EDIL3, die potentiell mit der Progression und 
Invasivität von Gliomen verknüpft sind.  
MXI1, ein potentieller negativer Regulator der c-myc abhängigen Transkription, war nach 
Chronophin Herunterregulation in GBM6840 stark herunterreguliert. In Übereinstimmung 
mit diesem Befund war die Aktiviät eines c-myc Reporterplasmids nach Chronophin 
Herunterregulation in GBM6840 erhöht, nach Chronophin Expression in U87 jedoch 
erniedrigt. Das c-myc Protein selbst wies eine deutliche Reduktion nach Chronophin 
Depletion in GBM6840 auf.  
Abschließend wurde die Expression von Proteasen untersucht, für die eine Rolle in der 
Gliominvasion bekannt ist. Hier wurden jedoch keine größeren Chronophin abhängigen 
Expressionsunterschiede gefunden. 
Zusammenfassend gesagt konnte eine umfassende Charakterisierung der Rolle des 
Chronophin in der Gliompathogenese erreicht werden. Zum einen konnte gezeigt werden, 
dass Chronophin ein äußerst wichtiger Regulator der Invasion ist, zum anderen dass es zu 
Chronophin abhängigen transkriptomischen Veränderungen kommt, die potentiell zur 
Malignisierung des Tumors beitragen.  
Daher sind die Proteine die die Cofilinphosphorylierung regulieren potentielle 
therapeutische Zielmoleküle für eine anti-invasive Therapie im Glioblastom. Inhibitoren für 
die Kinasen, die Regulatoren des Cofilin sind, die ROCK- und LIM-Kinasen, sind verfügbar und 
stellen möglicherweise vielversprechende Substanzen für die anti-invasive Therapie dar.  
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